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It is now a matter of routine for the forensic scientist to obtain the genetic profile 
of an individual from DNA recovered from a biological stain deposited at a crime scene. 
Potential contributors of the stain must either be known to investigators (i.e. a developed 
suspect) or the questioned profile must be searched against a database of DNA profiles 
such as those maintained in the CODIS National DNA database. However, in those 
instances where there is no developed suspect and no match is obtained after 
interrogation of appropriate DNA databases, the DNA profile per se presently provides 
no meaningful information to investigators, with the notable exception of gender 
determination. In these situations it would be advantageous to the investigation, if 
additional probative information could be obtained from the biological stain. A useful 
biometric that could provide important probative information, and one that may be 
amenable to molecular genetic analysis, is the biological age of an individual. The ability 
to provide investigators with information as to whether a DNA donor is a newborn, 
infant, toddler, child, adolescent, adult, middle-aged or elderly individual could be useful 
in certain cases, particularly those involving young children such as kidnappings or in 
providing additional intelligence during terrorist investigations. Currently no validated 
molecular assays exist for age determination. 
Biological human ageing can be defined by two distinct processes, degenerative 
and developmental ageing. The degenerative process of ageing is based on theories which 
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identify an increase or decrease in physiological conditions with increasing age. In 
contrast, the developmental process of ageing is based on the theory that as individuals 
increase in chronological age, there will be subtle corresponding molecular based 
biological changes, each requiring genes to be expressed or silenced, indicative of that 
particular stage of life. 
We investigated the degenerative process of chromosomal telomere shortening, as 
well as the developmental process of gene expression profiling analysis, in an attempt to 
identify biomarkers of biological age in a self-renewing tissue such as blood. While 
telomere length analysis was an ineffective method for age determination; gene 
expression analysis revealed three gene transcripts expressed in an age-dependent 
physiological manner. These species namely- COL1A2, HBE1 and IGFBP3, were found 
to be expressed at elevated levels in younger individuals, newborns, or post-pubertal 
individuals, respectively. 
The biological process of hemoglobin switching was also investigated for the 
possibility of determining human age. While experimenting with the potential of using 
the gamma-hemoglobin chains, as newborn specific gene candidates, we serendipitously 
discovered four novel truncated transcripts, which we have termed HBG1n1, HBG1n2, 
HBG2n2 and HBG2n3; whose expression was restricted to whole-blood newborn 
samples and specific fetal tissues. The molecular origin of these transcripts appears to be 
at the RNA level, being produced by specific rearrangement events occurring in the 
standard gamma hemoglobin transcripts (HBG1 and HBG2), which yield these new 
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 CHAPTER ONE: INTRODUCTION 
It is now a matter of routine for the forensic scientist to obtain the genetic profile 
of an individual from DNA recovered from a biological stain deposited at a crime scene. 
Potential contributors of the stain must either be known to investigators (i.e. a developed 
suspect) or the questioned profile must be searched against a database of DNA profiles 
such as those maintained in the CODIS National DNA database [1]. However, in those 
instances where there is no developed suspect and no match is obtained after 
interrogation of appropriate DNA databases, the DNA profile per se presently provides 
no meaningful information to investigators, with the notable exception of gender 
determination [2]. In these situations it would be advantageous to the investigation, if 
additional probative information could be obtained from the biological stain. Additional 
investigative parameters could include determining the physical characteristics of the 
individual depositing the biological stain. A number of physically recognizable 
characteristics of an individual are at least partly inherited and these include skin-, hair- 
and eye- color, stature (height and weight) and facial morphology [3-7]. Theoretically, 
and given sufficient knowledge of the genetics of complex polygenic traits, DNA 
analysis on a crime scene sample could provide investigators with information akin to 
eyewitness identification. Since, with few exceptions, our understanding of the genetics 
of these complex traits is somewhat rudimentary, development of significant forensic 
applications awaits further advances in our knowledge in this area. One exception may be 
skin and hair pigmentation since to a large degree the genetics of pigmentation has 
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proved to be amenable to molecular genetic analysis [3, 4, 8].  An additional useful 
biometric that could provide important probative information, and one that may be 
amenable to molecular genetic analysis, is the biological age of an individual. The ability 
to provide investigators with information as to whether a DNA donor is a newborn, 
infant, toddler, child, adolescent, adult, middle-aged or elderly individual [9] could be 
useful in certain cases, particularly those involving young children such as kidnappings 
or in providing additional intelligence during terrorist investigations. Currently no 
validated molecular assays exist for age determination. Two approaches have been 
evaluated for their ability to identify biomarkers associated with biological age; 
messenger RNA profiling and telomere length analysis. 
Biological human ageing can be defined by two distinct processes, degenerative 
and developmental ageing. The degenerative process of ageing is based on theories which 
identify an increase or decrease in physiological conditions with increasing age. 
Postulated molecular mechanisms of the degenerative ageing process include, inter alia, 
progressive damage to DNA, including mitochondrial DNA mutations, deletions, and 
insertions [10-13], the shortening of telomeric regions on the ends of chromosomes [14, 
15], long-lived protein glycation [16], and reactive oxygen species (ROS)-mediated 
oxidative damage to macromolecules [17-19]. These degenerative studies attempt to 
correlate specific molecular damage with increases in age, particularly in post-
reproductive individuals [20].  From a forensic standpoint however, and in contrast to the 
degenerative process of ageing, it would be useful to be able to distinguish between 
individuals of all age groups, but this may require the detection of more subtle molecular 
changes. Thus we have considered an alternative approach to age determination that is 
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based upon the epigenetic and developmental control of gene expression that occurs 
during all stages of human development [9]. 
The developmental process of ageing is based on the theory that as individuals 
increase in chronological age, there will be subtle corresponding molecular based 
biological changes, each requiring genes to be expressed or silenced indicative of that 
particular stage of life. Using this approach to biological age determination, every stage 
of the human lifecycle (birth through death) [9] can be defined by identifying sub-sets of 
the 20-25 thousand human genes [21] that will be differentially expressed in correlation 
with a specific developmental stage [22]. Theoretically, a comparison of the gene 
expression profile from individuals of different ages could reveal constellations of 
candidate genes whose expression is correlated with a specific age. A number of recent 
reports have described age-associated differential gene expression profiles in skeletal 
muscle [23, 24], liver [25], brain [26], teeth [27, 28] and skin [29, 30].  
Determining the biological age of an individual depositing a body fluid at a crime 
scene was evaluated by differential gene expression analysis using the Affymetrix 
GeneChip® as well as PubMed literature searches of age related gene expression 
differences. Candidate genes were generated from the Affymetrix array by performing 
three two-group comparisons between newborn, juvenile and elderly male individuals. A 
clear example of developmental age related differential gene expression, is that of 
hemoglobin gene switching [31, 32]. The human β-hemoglobin locus is located on the 
short arm of chromosome 11 (11p15.5), and encodes five functional β-like globin genes, 
ε, Gγ, Aγ, δ, and β, and a non-functional β-pseudogene (βψ) [33, 34]. The expression of 
embryonic hemoglobin (ε-globin) commences in the yolk sac in the early stages of 
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gestational development, approximately during week two and continues until six weeks 
(37 days) postconception [35]. During the next six weeks of gestation (days 37-79), the 
newly developed fetal liver and fetal spleen begin to produce the fetal specific gamma 
globin chains (Aγ and Gγ) of fetal hemoglobin [35]. This increased production of γ-globin 
is accompanied by a shutdown of ε-globin synthesis. Beginning at approximately 20 
weeks gestation and continuing throughout life, adult β-globin gene expression 
commences in the bone marrow and γ-globin expression is down regulated [35]. This 
biological process of hemoglobin switching was investigated for the possibility that the 
detection of gamma (γ)-globin messenger RNA (mRNA) in a bloodstain would be 
indicative of a newborn baby. While experimenting with the potential of using the 
gamma-hemoglobin chains as newborn specific gene candidates, we serendipitously 
discovered four truncated mRNA transcripts, which we have termed HBG1n1, HBG1n2, 
HBG2n2 and HBG2n3. These novel isoforms exhibit a highly regulated expression 
pattern, only be formed in newborn blood, fetal liver and spleen, and to a lesser extent 
fetal heart, thymus and kidney. The molecular origin of these transcripts appears to be at 
the RNA level, being produced by specific rearrangement events occurring between 
direct repeat sequences located exons two and three of the standard gamma hemoglobin 
mRNA transcripts (HBG1 or HBG2).  
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CHAPTER TWO: RESEARCH DESIGN AND METHODOLOGY 
Messenger RNA Profiling Analysis for Biological Age Determination 
Affymetrix GeneChip® Whole Blood RNA Isolation and Sample Preparation 
Human blood samples were obtained from donors from Florida Hospital 
(Orlando, FL) after receiving exemption from the Hospital’s Institutional Review Board 
and in accordance with procedures approved by the University of Central Florida’s 
Institutional Review Board (APPENDIX H: UCF IRB FORM). Whole blood samples 
from three male newborns (all <24-hours old), three male juveniles (14-, 15- and 18-
years old) and three male elderly (74-, and 79- (x2), years old), were transferred from 
sterile EDTA collection tubes into PAXgeneTM Blood RNA Tubes (QIAGEN Inc., 
PreAnalytiX, Valencia, CA), which concentrate and stabilize cellular RNA, protect 
degradation by RNases and prevent induction of gene expression [36-38]. PAXgeneTM 
Blood RNA tubes were incubated at room temperature overnight, and processed by the 
manufactures instructions [36-38]. Extracted RNA was shipped overnight to Expression 
Analysis (Durham, NC) for hybridization to the GeneChip® Human Genome U133 Plus 
2.0 Array (HG-U133+2), which analyzes the expression levels of over 47,000 transcripts 
and variants, including 38,500 well-characterized human genes derived from GenBank®, 
dbEST, and RefSeq [39].  
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Expression Analysis Processing of Total RNA for Affymetrix GeneChip® 
Hybridization 
The ribosomal subunit 28S/18S peak ratio was assessed for quality control of the 
submitted total RNA samples via the Agilent 2100 Bioanalyzer [40]. For low quantity 
(10-100 ng) samples, total RNA undergoes to a two-cycle target labeling procedure, 
before GeneChip® hybridization [41]. Briefly, total RNA is submitted to a first cycle, 
first strand cDNA synthesis reaction with T7-Oligo(dT) primers, followed by a first 
cycle, second strand cDNA synthesis reaction to produce double-stranded T7-labeled 
cDNA. A first cycle in vitro transcription (IVT) reaction containing unlabeled 
ribonucleotides is performed; and the newly synthesized unlabeled cRNA is reverse 
transcribed, using random primers, in the second cycle, first strand cDNA synthesis step. 
In the second cycle, second strand cDNA synthesis reaction the T7-Oligo(dT) promoter 
primer is used to generate a double-stranded cDNA template containing T7 promoter 
sequences. A second IVT reaction is then performed with biotinylated ribonucleotides to 
label the antisense cRNA. The labeled cRNA is then cleaned, fragmented, and hybridized 
to the AFFYMETRIX GeneChip® expression array (Figure 1) [41]. 
Statistical Evaluation of Hybridization Intensities on the Affymetrix GeneChip®  
GeneChip algorithms are a set of rules and calculations used to derive biologically 
meaningful results from hybridization intensities measured on GeneChip expression 
probe arrays. A particular transcript is represented by a probe set with 15-20 probe pairs, 
containing perfect match (PM) and mismatch (MM) probe cells, which are used to 
generate discrimination scores followed by detection p-values. The discrimination score 
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(R) is determined by the ability of a probe pair to detect its intended target, by measuring 
the target-specific intensity difference of the probe pair (PM-MM) relative to its overall 
hybridization intensity (PM+MM) (Figure 2) [42]. Discrimination score values are then 
compared to the threshold Tau (default value = 0.015) and the detection p-value is 
determined by One-sided Wilcoxon’s Signed Rank test, which assigns each probe pair a 
value based on how far the R-score is from Tau [42]. Once detection p-values are 
calculated, the algorithm for comparison analysis is used [43] to determine the relative 
change in abundance for each transcript between a baseline and an experimental sample 
set. Comparison analysis generates two transcript expression estimates between different 
data arrays: change significance and change quantity metrics. Change significance values 
calculate an increase, decrease or no change in gene expression, while change quantity 
estimates the magnitude and direction of transcript change [42].  
Blood Sample Preparation 
Human blood samples were obtained from donors from Florida Hospital 
(Orlando, FL) after receiving exemption from the Hospital’s Institutional Review Board 
and in accordance with procedures approved by the University of Central Florida’s 
Institutional Review Board (APPENDIX H: UCF IRB FORM). Bloodstains were made 




A guanidine isothiocyanate-phenol:chloroform extraction method was used [44]. 
Briefly, 500-μL denaturing solution (4M guanidine isothiocyanate, 0.02M sodium citrate, 
0.5% sarkosyl, 0.1M β-mercaptoethanol) was preheated in a Spin-EaseTM extraction tube 
(Gibco BRL, Life Technologies, Inc., Gaithersburg, MD) at 56ºC for 10 minutes. 
Prepared stains were then added and incubated at 56ºC for 30 minutes. The stain was 
removed into a Spin-EaseTM extraction tube filter insert, placed back inside the extraction 
tube and centrifuged for 5 min at 16,000g, after which the filter and the fabric remnants 
were discarded.  Fifty microliters of 2 M sodium acetate and 600-μL of acid 
phenol:chloroform 5:1, pH 4.5 (Ambion Inc., Austin, TX) were added to the extract, and 
incubated at 4ºC until two phases were resolved (~20 minutes), then centrifuged at 
16,000g for 20 minutes. The RNA-containing aqueous phase was transferred to a sterile 
microcentrifuge tube, along with 30-μg GlycoBlueTM glycogen carrier (Ambion Inc., 
Austin, TX) and precipitated with 500-μL isopropanol overnight, at -20ºC. Samples were 
then centrifuged at 16,000g for 20 minutes to pellet the RNA.  The supernatant was 
carefully removed and the pellet washed once with 1-mL 75% ethanol/25% 
DEPC-treated water and re-centrifuged at 16,000g for 10 minutes. The supernatant was 
discarded, the pellet dried in a vacuum centrifuge for 3-5 minutes and re-solubilized in 
17-μL of RNAsecure Resuspension Solution (Ambion Inc., Austin, TX) at 60ºC for 10 
minutes. RNA samples were treated with DNase I immediately or stored at -20ºC. 
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DNase I Digestion 
Total RNA was treated with six units of TURBOTM DNase (RNase-Free) (2 
U/μL) (Ambion Inc., Austin, TX) at 37ºC for 1-2 hours.  The TURBOTM DNase was 
inactivated at 75ºC for 10 minutes, the samples chilled on ice and then stored at -20ºC 
until needed [45, 46]. 
Quantification of Nucleic Acids 
RNA was quantified using a sensitive fluorescence assay based upon the binding 
of the unsymmetrical cyanine dye RiboGreen® (Molecular Probes, Eugene, OR) [47]. 
The manufacturer’s instructions were followed for the high-range assay, which detects 
from 20-ng/mL to 1-μg/mL.  Briefly, 200-μL assays comprised of 2-μL TURBOTM 
DNase treated RNA extract, 98-μL TE buffer (10 mM Tris–HCl, 1 mM EDTA, pH 7.5, 
in nuclease-free water), and 100-μL 750 nM RiboGreen® reagent in a 96-well plate 
format. After RiboGreen® addition and a three minute incubation at room temperature 
protected from light, fluorescence emission at 535 nm (excited at 485 nm) was 
determined using a Wallac Victor2 microplate reader (Perkin Elmer Life Sciences, 
Boston, MA).  RNA concentration was calculated using an appropriate standard curve as 
described by the manufacturer [47]. All RNA samples were diluted to 5ng/uL with 
nuclease-free water (Ambion Inc., Austin, TX). 
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Reverse Transcription (cDNA Synthesis) 
For all samples 6-μL of RNA (30-ng), was heated at 75ºC for 3 minutes and 
combined with 4-μL of a 10 mM dNTP mix (Applied Biosystems, Foster City, CA), 2-μL 
of 10X first-strand buffer (500 mM Tris–HCl pH 8.3, 750 mM KCl, 30 mM MgCl2, 50 
mM DTT), 2-μL Random Decamer primers (50-μM), 20-units SUPERase-InTM RNase 
Inhibitor (20 U/μL) (Ambion Inc., Austin, TX), 100-units Moloney Murine Leukemia 
Virus-Reverse Transcriptase (100 U/μL) (Ambion Inc., Austin, TX) and nuclease-free 
water (Ambion Inc., Austin, TX) were added to yield a final reaction volume of 20-μL. 
Reaction mixtures were incubated at 42ºC for 1 hour and 95ºC for 10 minutes to 
inactivate the reverse transcriptase [48, 49].  
Polymerase Chain Reaction 
All single gene amplification reactions were conducted in a total volume of 25-
μL. Three nanograms of cDNA was amplified with a standard reaction mix containing 1x 
PCR buffer (10 mM Tris–HCl, pH 8.3, 50 mM KCl), 1.5 mM MgCl2, 0.125 mM each 
dNTP, 0.4 μM primers (APPENDIX E: CANDIDATE GENE PRIMER 
SEQUENCES FOR RT-PCR) and 1.25-units AmpliTaq GoldTM DNA polymerase (5 
U/μL) (Applied Biosystems, Foster City, CA). Nuclease-free water (Ambion Inc., Austin, 
TX) was added to yield the final reaction volume. 
Standard PCR conditions consisted of an 11 minute denaturing step at 95ºC 
followed by 35 cycles at (1) 94ºC; 0:20 (2) 55ºC or 60ºC; 0:30 (3) 72ºC; 0:40 and a final 
extension step (72ºC; 10:00) [50, 51]. 
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Post RT-PCR Electrophoresis 
RT-PCR amplified products were visualized on 4% NuSieve® GTG® Agarose gels 
(Cambrex Bio Science Rockland, Inc., Rockland, ME). Electrophoresis was carried out at 
100V for 1.25 hours in TAE (0.04 M Tris-acetate, 0.001 M EDTA) buffer. Gels were 
stained with SYBR® Gold nucleic acid stain (Molecular Probes, Eugene, OR), visualized 
on the Omega10 Chemiluminescence Imaging System (ΜLTRA-LUM, Inc., Claremont, 
CA) and analyzed with ONE-Dscan 2.05, 1-D Gel Analysis Software for Windows 
(Scanalytics, Inc., Fairfax, VA). 
Real-Time PCR 
All singleplex qRT-PCR assays were performed in a 25-μL total reaction volume 
consisting of a standard reaction mix containing: three nanograms of cDNA, 12.5-μL 2x 
Taqman® Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 0.40-μM 
each forward and reverse primer, 0.25-μM of each probe and nuclease-free water 
(Ambion Inc., Austin, TX). Primer and probe sequences are listed in APPENDIX G: 
CANDIDATE GENE PRIMER SEQUENCES FOR qRT-PCR. 
Three optimized duplex real-time PCR reactions consisted of the following 
changes to the standard reaction mix: COL1A2 0.9-μM primers to S15 0.025-μM 
primers; HBE1 0.2-μM primers to S15 0.4-μM primers, and IGFBP3 1.2-μM primers to 
S15 0.05-μM primers. 
Real-Time PCR reactions were carried out on a 7500 Real Time PCR System 
(Applied Biosystems, Foster City, CA). Amplification conditions consisted of: (1) 1 cycle 
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of 50˚C; 2:00 (2) 1 cycle of 95˚C; 10:00 (3) 50 cycles of 95˚C; 0:15 and 60˚C; 1:00. Data 
was collected at stage 3, step 2 (60˚C; 1:00). Delta cycle threshold (dCt) values were 
calculated by subtracting the Ct value generated from the age specific gene of interest 
(GOI) from the Ct value of the housekeeping gene (i.e. dCt = Ct (S15) – Ct (GOI)) [52].  
Samples which fail to amplify the GOI are given a default Ct value of 40.000 or 50.00 
(the amount of qPCR cycles used). 
Fetal Specific Isoforms of Gamma Hemoglobin as Biomarkers for Biological Age 
Determination 
Sample Preparation 
Human blood samples were obtained from donors from Florida Hospital 
(Orlando, FL) after receiving exemption from the Hospital’s Institutional Review Board 
and in accordance with procedures approved by the University of Central Florida’s 
Institutional Review Board (APPENDIX H: UCF IRB FORM). Bloodstains were made 
by dispensing 50-μL aliquots onto sterile cotton gauze and air-dried overnight at room 
temperature. Other body fluid samples were collected from volunteers in accordance with 
guidelines approved by the UCFIRB. Saliva and semen samples were obtained from 
healthy individuals and 50-µL stains prepared. Buccal swabs, vaginal secretion swabs 
and menstrual blood swabs were obtained from healthy individuals and allowed to air-dry 
overnight at room temperature. Venous blood, saliva and vaginal secretion swabs 
obtained from an expectant mother at various time points throughout the pregnancy and 
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breast milk swabs (1-month post delivery) were air dried overnight. All stains were stored 
at -45ºC until needed. 
For stability studies, venous blood (50-μL) was prepared on sterile cotton gauze 
and allowed to sit at room temperature (~25ºC) for one, three, six, nine, twelve and 
fifteen months. Animal blood (with biological age, if known) for species specificity 
testing was collected from two Pigtailed Macaques (22-days and 5-years), two Rhesus 
Macaques (24-days and 12-years) (Yerkes National Primate Research Center, Atlanta, 
GA); calf (10-months), sheep (3-years), lamb (4-months) (Innovative Research, 
Southfield, MI); cat, dog (Tuscawilla Oaks Animal Hospital, Oviedo, FL); cow, horse 
(HemoStat Laboratories, Dixon, CA); deer (Charles R. Daniels, DeLand, FL); spider 
monkey (Coriell Cell Repository, Camden, NJ); African crown cranes (2- and 3-years), 
gopher tortoise (20-years), and patagonian cavy (1-year) (Wuesthoff Reference 
Laboratory, Melbourne, FL). One buccal swab from a Chinese Muntjac (12-years) 
(Wuesthoff Reference Laboratory, Melbourne, FL) was also tested for specificity. All 
stains were stored at -45ºC until needed.  
Fetal tissue (brain, heart, kidney, liver, spleen, thymus) and adult tissue (adipose, 
bone marrow, brain, kidney, liver, lung, skeletal muscle, skin, salivary gland, spleen, 
thymus, testis, uterus) total RNA was obtained from BD Biosciences Clontech (Palo 
Alto, CA). Fetal liver, fetal spleen, adult adipose and adult bone marrow DNA was 
obtained from BioChain Institute, Inc. (Hayward, CA). 
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RNA Isolation 
A guanidine isothiocyanate-phenol:chloroform extraction method was used [22, 
44, 53]. Briefly, 500-μL denaturing solution (4M guanidine isothiocyanate, 0.02M 
sodium citrate, 0.5% sarkosyl, 0.1M β-mercaptoethanol) was preheated in a Spin-EaseTM 
extraction tube (Gibco BRL, Life Technologies, Inc., Gaithersburg, MD) at 56ºC for 10 
minutes. Prepared stains were then added and incubated at 56ºC for 30 minutes. The stain 
was removed into a Spin-EaseTM extraction tube filter insert, placed back inside the 
extraction tube and centrifuged for 5 min at 16,000g, after which the filter and the fabric 
remnants were discarded.  Fifty microliters of 2 M sodium acetate and 600-μL of acid 
phenol:chloroform 5:1, pH 4.5 (Ambion Inc., Austin, TX) were added to the extract, and 
incubated at 4ºC until two phases were resolved (~20 minutes), then centrifuged at 
16,000g for 20 minutes. The RNA-containing aqueous phase was transferred to a sterile 
microcentrifuge tube, along with 30-μg GlycoBlueTM glycogen carrier (Ambion Inc., 
Austin, TX) and precipitated with 500-μL isopropanol overnight, at -20ºC. Samples were 
then centrifuged at 16,000g for 20 minutes to pellet the RNA.  The supernatant was 
carefully removed and the pellet washed once with 1-mL 75% ethanol/25% 
DEPC-treated water and re-centrifuged at 16,000g for 10 minutes. The supernatant was 
discarded, the pellet dried in a vacuum centrifuge for 3-5 minutes and re-solubilized in 
12-17-μL of RNAsecure Resuspension Solution (Ambion Inc., Austin, TX) at 60ºC for 
10 minutes. RNA samples were treated with DNase I immediately or subsequent to 
storage at -20ºC. 
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DNA Isolation 
Genomic DNA was extracted from 50-μL bloodstains by an organic solvent 
extraction method [54]. Briefly, samples were incubated overnight at 56ºC in stain 
extraction buffer (0.1M NaCl, 10mM Tris–HCl pH 8.0, 25mM EDTA pH 8.0, 20mM 
SDS) supplemented with 0.5 mg/ml proteinase K. An equal volume of 
phenol/chloroform/isoamyl alcohol (25:24:1, pH 6.6) was added to the extract, mixed 
gently by inversion and centrifuged for 5 min at 16,000g to separate the phases. The 
DNA containing aqueous layer was transferred to a sterile microcentrifuge tube, 
precipitated with 1-mL of ice-cold 100% ethanol overnight, centrifuged at 16,000g for 15 
minutes, washed once with 1-mL 70% ethanol and solubilized in 100-μL TE-4 (10 mM 
Tris, 0.1 mM EDTA) at 56ºC overnight.  
DNase I Digestion 
Extracted total RNA was treated with two units of TURBOTM DNase 
(RNase-Free) (2 U/μL) (Ambion Inc., Austin, TX) at 37ºC for 1-2 hours.  The TURBOTM 
DNase was inactivated at 75ºC for 10 minutes, the samples chilled on ice and then stored 
at -20ºC until needed [45, 46]. 
Quantification of Nucleic Acids 
RNA was quantified using a sensitive fluorescence assay based upon the binding 
of the unsymmetrical cyanine dye RiboGreen® (Molecular Probes, Eugene, OR) [47]. 
The manufacturer’s instructions were followed for the high-range assay, which detects 
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from 20-ng/mL to 1-μg/mL.  Briefly, 200-μL assays comprised of 2-μL TURBOTM 
DNase treated RNA extract, 98-μL TE buffer (10 mM Tris–HCl, 1 mM EDTA, pH 7.5, 
in nuclease-free water), and 100-μL 750 nM RiboGreen® reagent in a 96-well plate 
format. After RiboGreen® addition and a three minute incubation at room temperature 
protected from light, fluorescence emission at 535 nm (excited at 485 nm) was 
determined using a Wallac Victor2 microplate reader (Perkin Elmer Life Sciences, 
Boston, MA).  RNA concentration was calculated using an appropriate standard curve as 
described by the manufacturer [47]. All RNA samples were diluted to 5ng/uL (saliva and 
buccal swabs were diluted to 10ng/uL) with nuclease-free water (Ambion Inc., Austin, 
TX). 
DNA was quantified by electrophoresis on 1% agarose gels stained with ethidium 
bromide and compared to known reference standards. All DNA samples were diluted to 1 
ng/μL with TE-4 (10 mM Tris, 0.1 mM EDTA). 
Reverse Transcription (cDNA Synthesis) 
For all blood and tissue RNA samples 6-μL of RNA (30-ng), and for saliva/buccal 
6-μL of RNA (60-ng), was heated at 75ºC for 3 minutes, snap cooled. For the mixture 
study total RNA from three newborns (<24-hours) and three juvenile/adult females (16-, 
22-, and 31-years) were combined in different ratio combinations (1:1, 1:5, 5:1, 1:10 and 
10:1) to yield the 6-uL (30-ng) necessary for the amplification. To the RNA, 4-μL of a 10 
mM dNTP mix (Applied Biosystems, Foster City, CA), 2-μL of 10X first-strand buffer 
(500 mM Tris–HCl pH 8.3, 750 mM KCl, 30 mM MgCl2, 50 mM DTT), 2-μL Random 
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Decamer primers (50-μM), 20-units SUPERase-InTM RNase Inhibitor (20 U/μL) 
(Ambion Inc., Austin, TX), 100-units Moloney Murine Leukemia Virus-Reverse 
Transcriptase (100 U/μL) (Ambion Inc., Austin, TX) and nuclease-free water (Ambion 
Inc., Austin, TX) were added to yield a final reaction volume of 20-μL. For the (–RT) 
reaction tubes the Moloney Murine Leukemia Virus-Reverse Transcriptase was replaced 
with Nuclease-free water. Reaction mixtures were incubated at 42ºC for 1 hour and 95ºC 
for 10 minutes to inactivate the reverse transcriptase [48, 49].  
Polymerase Chain Reaction  
Amplimer sizes for all genes tested are included in Table 16. All amplification 
reactions were conducted in a total volume of 25-μL containing genomic DNA (2-ng) or 
mRNA/cDNA (3-ng) (except for HBG1 and HBG2 singleplex reactions which contained 
5-ng mRNA/cDNA). A standard reaction mix containing 1x PCR buffer (10 mM Tris–
HCl, pH 8.3, 50 mM KCl), 1.5 mM MgCl2, 0.125 mM each dNTP, 0.4 μM primers and 
1.25-units AmpliTaq GoldTM DNA polymerase (5 U/μL) (Applied Biosystems, Foster 
City, CA). Nuclease-free water (Ambion Inc., Austin, TX) was added to yield the final 
reaction volume. 
 For the newborn mRNA duplex HBG1n1-S15 and HBG2n3-S15 RT-PCR 
reactions, 3ng of cDNA was amplified with the following changes to the standard 
reaction mix: 0.6 μM S15 primers and 0.05 μM HBG1n1 or 0.05 μM HBG2n3 primers. 
The ribosomal protein gene transcript, S15, was included as an internal positive control 
for the reverse-transcription and amplification reactions.  
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For the fetal and adult tissue amplifications as well as the recombination 
experiment all single-gene reactions contained 400nM each primer and duplex reactions 
were as follows: HBG1n1-GNAS and HBG1n2-GNAS consisted of 400nM-100nM 
primers, and HBG2n2-GNAS and HBG2n3-GNAS consisted of 200nM-400nM primers.  
Standard PCR conditions were used for all amplifications and consisted of an 
initial incubation step (95ºC; 11:00) followed by repeating cycles of [denaturation (94ºC; 
0:20), annealing (60ºC; 0:30), and extention (72ºC; 0:40)] with a final incubation of 
(72ºC; 10:00) [50, 51]. Amplification cycle numbers are as follows: singleplex HBG, 
HBG1 and HBG2 (32 cycles; 55ºC annealing); HBG1n1 and HBG2n3 (28 cycles); 
singleplex HBG1-GNAS and HBG2-GNAS (35 cycles), duplexes HBG1n1-GNAS2 and 
HBG1n2-GNAS2 (30 cycles) and duplexes HBG2n2-GNAS2 and HBG2n3-GNAS2 (28 
cycles). 
Cloning and Sequencing 
Newly identified hemoglobin products were excised from agarose gels and 
purified using MERmaid® SPIN columns, which specifically isolate low molecular 
weight DNA products (10-200 bp) (Q-BIOgene, Carlsbad, CA). Purified products were 
cloned into TOP10F’ One Shot® chemically competent cells using the TOPO TA 
Cloning® Kit (pCR®2.1-TOPO®) (Invitrogen, Carlsbad, CA). Positive colonies were 
isolated and plasmids purified using the RapidPURETM Plasmid Mini Kit (Q-BIOgene, 
Carlsbad, CA). Plasmids which contained the inserted product were sent to Lark 
Technologies for sequencing analysis (Lark Technologies, Inc., Houston, TX). 
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Post Amplification Electrophoresis 
PCR and RT-PCR amplified products were visualized on 4% NuSieve® GTG® 
Agarose gels (Cambrex Bio Science Rockland, Inc., Rockland, ME).  Electrophoresis 
was carried out at 100V for 1.25 hours in TAE (0.04 M Tris-acetate, 0.001 M EDTA) 
buffer. Gels were stained with SYBR® Gold nucleic acid stain (Molecular Probes, 
Eugene, OR), visualized on the Omega10 Chemiluminescence Imaging System 
(ΜLTRA-LUM, Inc., Claremont, CA) and analyzed with ONE-Dscan 2.05, 1-D Gel 
Analysis Software for Windows (Scanalytics, Inc., Fairfax, VA). 
Duplex Real-Time PCR (qPCR)  
All primer and probe sequences are listed in Table 17. All qPCR assays were 
performed in a 25-μL total reaction volume consisting of a standard reaction mix 
containing: three nanograms of cDNA (blood, semen, vaginal secretions, menstrual blood 
and breast milk) or six nanograms of cDNA (saliva/buccal), 12.5-μL Taqman® Universal 
PCR Master Mix (Applied Biosystems, Foster City, CA), 0.25-μM of each probe and 
nuclease-free water (Ambion Inc., Austin, TX). 
For the newborn assays (≤4 months old), 0.6-μM (S15), and 0.1-μM (HBG1n1) or 
0.05-μM (HBG2n3) primers were added to the standard reaction mix. For the newborn 
assays (<24 hours old), 0.9-μM S15 primer and 0.05-μM HBG1n1 primer or 0.05-μM 
HBG2n3 primer were added to the standard reaction mix. 
Real-Time PCR reactions were carried out on a 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA). Amplification conditions consisted of: (1) 1 cycle 
 19
of 50˚C; 2:00 (2) 1 cycle of 95˚C; 10:00 (3) 40 cycles of 95˚C; 0:15 and 60˚C; 1:00. Data 
was collected at stage 3, step 2 (60˚C; 1:00). Delta cycle threshold (dCt) values were 
calculated by subtracting the Ct value generated from the newborn specific gene from the 
Ct value of the housekeeping gene (i.e. dCt = Ct (S15) – Ct (HBG1n1 or HBG2n3) [52].  
Samples which fail to amplify the newborn genes are given a default HBG1n1 or 
HBG2n3 Ct value of 40.00 (the amount of qPCR cycles used). 
Recombination Experiment 
Tissue DNA (43-ng) and blood DNA (64-ng) was treated with five units of 
TURBOTM DNase (RNase-Free) (2 U/μL) (Ambion Inc., Austin, TX) or tissue DNA (50-
ng) and blood DNA (75-ng) was treated with 100-units of RNase I (100 U/μL) (Ambion 
Inc., Austin, TX) at 37ºC for 30 minutes. The DNase I enzyme was inactivated by 
incubation at 75ºC for 10 minutes.[45, 46] The RNase I enzyme was inactivated by the 
addition of 50-μL phenol/chloroform/isoamyl alcohol (25:24:1, pH 6.6). RNase I treated 
DNA samples were then centrifuged at 16,000g (5-min) and the aqueous phase 
transferred to a new tube. Only 1-μL of these DNA samples (untreated, +DNase I, + 
RNase I) was added to the PCR reaction. 
Blood and tissue total RNA (250-ng) was treated with 250-units of RNase I (100 
U/μL) (Ambion Inc., Austin, TX) at 37°C for 30 minutes and inactivated with 60-μL acid 
phenol:chloroform 5:1, pH 4.5 (Ambion Inc., Austin, TX). The samples were centrifuged 
(10 minutes at 16,000g) and the aqueous phase precipitated at -20ºC overnight, with 15-
μg GlycoBlueTM glycogen carrier (Ambion Inc., Austin, TX) and 50-μL isopropanol. 
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Samples were then centrifuged at 16,000g (20-min), the supernatant removed and the 
pellet washed once with 200-μL 75% ethanol/25% DEPC-treated water, re-centrifuged at 
16,000g (10-min), the pellet was dried in a vacuum centrifuge, and finally re-solubilized 
in 10-μL of RNAsecure Resuspension Solution (Ambion Inc., Austin, TX) at 60ºC for 10 
minutes. The RNA samples were then reverse transcribed (see above) and 2-μL added to 
PCR. 
Telomere Length Analysis for Biological Age Determination 
Sample Preparation 
Human blood samples were collected from Florida Hospital (Orlando, FL) only 
after exemption from the Hospitals Institutional Review Board and in accordance with 
procedures approved by our University’s Institutional Review Board (APPENDIX H: 
UCF IRB FORM). Bloodstains were made by dispensing 50-μL aliquots onto sterile 
cotton gauze, allowed to air-dry overnight at room temperature and stored at -45ºC until 
needed. 
DNA Extraction 
Genomic DNA was extracted from 50-μL bloodstains by an organic solvent 
extraction method [54] followed by Centricon Filter Purification (Millipore Corp., 
Bedford, MA). Briefly, samples were incubated overnight at 56ºC in stain extraction 
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buffer (0.1M NaCl, 10mM Tris–HCl pH 8.0, 25mM EDTA pH 8.0, 20mM SDS) 
supplemented with 0.5 mg/ml proteinase K. An equal volume of 
phenol/chloroform/isoamyl alcohol (25:24:1, pH 6.6) was added to the extract, mixed 
gently by inversion and centrifuged for 5 min at 16,000g to separate the phases. The 
DNA containing aqueous layer was transferred to a prewet Centricon filter and purified 
by washing with 2-mL TE-4 (10 mM Tris, 0.1 mM EDTA) and centrifugation at 2000g. 
Finally, DNA was removed by inverted centrifugation at 1000g with 100-µL TE-4. 
DNA Quantification 
The real-time PCR Human QuantifilerTM Kit (Applied Biosystems, Foster City, 
CA) was used for quantification. Extracted DNA was diluted to a final working 
concentration of 10ng/uL with TE-4, after comparison to a standard curve which was 
generated by running DNA samples of known concentrations from 25 to 0.63 ng/uL [55]. 
Delta Cycle Threshold Determination by Real-Time PCR – SYBR Green I Assay 
Primer sequences are listed in Table 21. All qPCR assays were performed with a 
standard reaction mix containing: 17.5 nanograms of DNA, 1x SYBR® Green I PCR 
Buffer containing Passive Reference 1, 25-mM MgCl2, 12.5-mM dNTPs, and 1.25-U 
AmpliTaq Gold DNA Polymerase (5U/µL) (Applied Biosystems, Foster City, CA). 
T10E0.1 (1M Tris-HCl pH 8.0, 0.5M Na2EDTA) was used to bring the final volume to 25-
μL. Primer concentrations for the telomere amplification were 270-nM tel 1 and 900-nM 
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tel 2, while the single copy gene (36B4) amplification required 300-nM 36B4u and 500-
nM 36B4d [56]. 
Real-Time PCR reactions were carried out on a 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA). Real-time PCR amplification conditions 
consisted of: (1) 1 cycle of 95˚C; 10:00 and either (2T) 22 cycles of 95˚C; 0:15 and 54˚C; 
2:00 or (2S) 30 cycles of 95˚C; 0:15 and 58˚C; 1:00, for the telomere (2T) and single-
gene (2S) amplifications, respectively. Data was collected at stage 2, step 2 (54˚C; 2:00 
or 58˚C; 1:00). Each standard or DNA extract was performed in duplicate and average 
cycle threshold values were determined. The delta Ct calculation was determined by the 
difference in amplification rates of the single-gene, 36B4, to the telomere repeats, dCt = 
SCt - TCt. 
Real-Time PCR Amplification of Telomeres – TaqMan Assay 
Primer and probe sequences are listed in Table 21. Genomic DNA (10.0 
nanograms) was amplified in a standard reaction containing: 1x Taqman Universal PCR 
Master Mix (Applied Biosystems, Foster City, CA), 250-nM probe (tel 3 or tel 6), 500-
nM primers (tel 1 and tel 2 or tel 4 and tel 5), and an additional 5.0-U AmpliTaq Gold 
DNA Polymerase (5U/µL) (Applied Biosystems, Foster City, CA). Nuclease-free water 
was used to yield the final reaction volume of 25-µL. 
Real-Time PCR reactions were carried out on a 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA). Real-time PCR amplification conditions 
consisted of: (1) 1 cycle of 95˚C; 10:00 and (2) 40 cycles of 95˚C; 0:15 and 50˚C; 2:00. 
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Data was collected at stage 2, step 2 (50˚C; 2:00). The cycle number at which the 
amplification curve reaches a pre-set threshold, the cycle threshold (Ct) value, was 
plotted against the biological age of each individual tested.  
STELA Telorette Ligation Reaction 
Genomic DNA (200ng) was ligated with 0.9uM each telorette linker (Table 21) 
in six separate reactions containing 1x manufacturers ligation buffer and 10-units T4 
DNA Ligase (USB Corp., Cleveland, OH) for 12-hours at 35°C [57]. The T4 ligase was 
inactivated by heating at 65°C for 15 minutes. Ligated DNA was re-purified using 
Centricon Filters and re-quantified using the Human Quantifiler Kit as described in the 
DNA Extraction and Quantification sections, respectively, and diluted to a final 
concentration of 1 ng/uL with TE-4.  
STELA PCR Amplification  
Forward (XpYpE2) and reverse (teltail) primer sequences are listed in Table 21. 
Telorette ligated genomic DNA (3-ng) was amplified in a 25-μL reaction volume 
containing 1x PCR buffer (10 mM Tris–HCl, pH 8.3, 50 mM KCl), 1.5 mM MgCl2, 0.3 
mM each dNTP, 0.5uM telomere primer XpYpE2, 0.5uM teltail primer, 2.5-units 
AmpliTaq GoldTM DNA polymerase (5 U/μL) (Applied Biosystems, Foster City, CA) 
and nuclease-free water (Ambion Inc., Austin, TX) [57]. PCR conditions for all six 
telorette amplifications consisted of an initial incubation step (95ºC; 11:00) followed by 
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35 cycles of [denaturation (94ºC; 0:15), annealing (65ºC; 0:30), and extention (68ºC; 
10:00)] and a final incubation of (68ºC; 10:00) [50, 51, 57]. 
STELA Post-Amplification Electrophoresis 
PCR amplified products were visualized on 1% Agarose gels. Electrophoresis was 
carried out at 170V for 1.5 hours in TAE (0.04 M Tris-acetate, 0.001 M EDTA) buffer. 
Gels were stained with SYBR® Gold nucleic acid stain (Molecular Probes, Eugene, OR), 
visualized on the Omega10 Chemiluminescence Imaging System (ΜLTRA-LUM, Inc., 
Claremont, CA) and analyzed with ONE-Dscan 2.05, 1-D Gel Analysis Software for 
Windows (Scanalytics, Inc., Fairfax, VA). 
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CHAPTER THREE: RESULTS AND DISCUSSION 
Messenger RNA Profiling Analysis for Biological Age Determination 
Generating a Candidate Gene List from the Hybridization Intensities on the 
Affymetrix GeneChip® by Two-Group Comparison Analysis 
Human venous blood was obtained from nine different individuals; three newborn 
babies (<24-hours old), three adolescent teenagers (14 – 18-years old) and three elderly 
males (74 – 79-years old). Total RNA from each individual sample was extracted and 
sent to Expression Analysis (Durham, NC) for hybridization to the GeneChip® Human 
Genome U133 Plus 2.0 Array (HG-U133+2). Three two-group comparisons were 
performed; newborns vs. juveniles, newborns vs. elderly, and juveniles vs. elderly, to 
provide gene expression fold changes between developmentally extreme age groups. The 
initial list of 54,675 probe sets was screened and all two-group comparisons which 
exhibited detection p-values >0.05 were eliminated. In general, the lower the p-value the 
more likely the transcript will truly be present in the sample, and vice versa. The 1,627 
remaining probe sets (all statistically significant with p-values ≤0.05) were narrowed by 
eliminating all probe sets with absolute adjusted fold changes less than 2.0. The absolute 
adjusted fold change is the calculated fold change from the control to the experimental 
group. This measurement eliminates all probe sets with “Absent” detection calls in both 
the baseline and experimental comparison groups [58]. The remaining 1,241 probe sets 
from the Affymetrix GeneChip® two-group comparison results are shown in 
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APPENDIX C: AFFYMETRIX COMPARISONS. Included in the comparison 
summaries are the control and experimental group signals, which provide an overall 
estimate of individual transcript abundances for each group, the absolute adjusted fold 
change, the p-value and the gene symbols.  
Generating Candidate Genes from Our Knowledge in Biochemistry and Physiology, 
as well as Published Literature Searches 
Potential age dependent areas of molecular based developmental changes were 
searched in the NCBI PubMed literature database. In theory, an investigation of basic, 
highly characterized developmental changes should produce a battery of genes, whose 
expression patterns and relative levels have been examined in specific tissues, under 
specific conditions. Candidate genes for newborns (birth – 3-months) and infants (4-
months – 9-months) included identifying proteins which were specific to fetuses or fetal 
tissues [59-62], including fetal specific protein isoforms [59, 60] and cellular immune 
responses [63]. Pre-pubertal developmental changes were examined to develop candidate 
genes for toddlers (10-months – 3-years) and children (4-years – 12-years) [62]. One 
example is the N-methyl-D-aspartate receptor gene (GRIN1, with transcripts NR1-1, 
NR1-2 and NR1-3, GRIN2A and GRIN2B) whose expression is increased in pre-pubertal 
mammals [64]. All juvenile or adolescent (13-years – 18-years) candidates were derived 
from pubertal developmental changes, mainly hormones which regulate sexual 
maturation. Female and male hormones, receptors, and activators are known to be 
upregulated in this age group and include estrogen [65], testosterone [66], and various 
sex steroids or endorphins [65-78]. Adults or post-pubertal (19-years – 45-years) 
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individuals were thought to also express hormones, however the relative levels of 
expression was thought to be less then that of juvenile individuals, and quantitative gene 
expression analysis would allow these age groups to be differentiated. Potential adult 
specific candidates were derived from known protein isoforms including the p45 adult 
specific form of the AUF1/hnRNP D (AU-rich element RNA binding protein-
1/heterogeneous nuclear ribonucleoprotein D) gene [60]. The amount of research that has 
been conducted on generalized human ageing and the majority of our tested literature 
candidate genes ~69% (143/208) were targeted towards the middle-aged (46-years – 64-
years) and elderly (>65-years) age groups. Major research areas have shown that specific 
molecular changes are increased in older individuals. These areas include an increase in 
the production of DNA damage machinery [79, 80] and other factors which are induced 
upon increased oxidative stress [81] and generalized DNA damage [23, 82].  At the 
present time it is unclear how apoptosis affects ageing, however apoptosis has been 
implicated in numerous diseases, which have been shown to correlate with increased 
biological age [83, 84]. Additionally, it has been illustrated that increased bone loss is 
evident in older ages [85]. Finally, a large number of age related gene candidates were 
obtained by published literature which illustrated an alteration in gene expression 
patterns. Examples include increases in cyclins D1 and E [59], the insulin growth factor 
binding proteins [86-88],  various pro-inflammatory mediators [89], the tumor suppressor 
genes p53 and p21 [59, 90, 91], regulators of telomere length [92], and other various 
factors regulating transcription and gene expression [59, 90, 93]. A list of all candidate 
genes tested, along with the NCBI gene description, Nucleotide Accession number, and 
target age group is included in APPENDIX D: CANDIDATE GENE DATABASE. 
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Initial Screening of 319 Potential Candidate Genes by RT-PCR Gel Based Gene 
Expression Profiling Analysis 
To determine the expression profiles of the potential candidate age related genes, 
PCR primers were designed using Primer3 design software (http://frodo.wi.mit.edu/). The 
input DNA sequence was obtained from the NCBI Nucleotide database and all mRNA 
sequences were BLASTed against the human genome to identify precise exon/intron 
boundaries. Primers were then designed to land in separate exons for facile separation of 
DNA and mRNA species (Figure 3). APPENDIX E: CANDIDATE GENE PRIMER 
SEQUENCES FOR RT-PCR lists all individual candidate primer sequences. 
Potential age correlated candidate genes are tested by a series of RT-PCR 
amplifications with an array of biological ages (n=4-10), ranging from 1-hour old 
newborns to elderly individuals. All available extracted mRNA blood samples (n=147) 
for candidate testing are shown in Table 1. Genomic DNA is amplified with every 
candidate gene, as an amplification control for RNA specific detection (Figure 3). 
Figure 4 illustrates the basic protocol of candidate gene testing by RT-PCR analysis. 
Initially, a first-round 35-cycle PCR amplification reaction is performed and based on the 
obtained results; a candidate gene is either rejected outright or is passed into a second 
round of PCR amplification. After this first-round amplification reaction candidates can 
be rejected for two reasons. First, candidates that have no amplified mRNA/cDNA 
product, yet show amplification of the genomic DNA control are rejected, mainly 
because if more than 35-cycles are required for visual product amplification, it is inferred 
that the transcript is present at extremely low levels and for the main goal of forensic 
assay development, these genes would not be ideal. Second, candidates that amplify an 
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mRNA/cDNA and genomic DNA control product of the same size are rejected, due to the 
fact that mRNA specific detection cannot be verified. Candidates can successfully pass 
this initial round of testing by generating one of two possible expression profiles. First, a 
candidate can exhibit amplification which shows a pattern of differential expression, 
termed sporadic expression or secondly, a candidate gene can amplify product in all ages 
tested. Candidates which are amplified in all ages tested are passed onto the next round 
but the amount of PCR cycles is decreased. PCR is an end-point analysis method and at 
35-cycles, some high abundance transcripts appear saturated in all samples, but may 
actually be present in different copy numbers in varying ages. Therefore, a decrease in 
the amount of PCR cycles may illustrate a subtle sporadic expression pattern between 
different ages. Based on the results obtained in the first-round of testing the second-round 
of screening consists of either amplification at 35-cycles or at a decreased cycle number, 
usually 30, and regardless of cycle number, all candidates are assayed with a new array of 
biological ages (n=8). Combined analysis of rounds-one and -two determine if a 
candidate has passed onto the third and final round of screening. To pass into the third-
round of amplification a candidate must exhibit a pattern of expression which is 
differentially expressed between ages and consistently expressed within an age group. 
The final amplification reaction is performed with a wide array of mRNA samples 
(n>30), with the purposed of verifying that amplification of the target age groups is 
consistent and that there is no amplification in the non-target age groups or there is a 
measurable amount of differential expression between age groups. At this juncture 
candidates are either accepted and taken to the quantitative RT-PCR analysis platform or 
rejected due to sporadic amplification of the target age group, specifically, if an amplicon 
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is present in only some of the target samples, or if non-differential expression is observed 
throughout all biological ages.  
Using the Affymetrix GeneChip® and PubMed literature searches, 319 potential 
candidate genes were tested using the protocol described above and illustrated in Figure 
4. A summary of the RT-PCR expression results is listed in Table 2, where the amount 
and percentage of accepted and rejected candidate genes is arranged by target age group, 
either newborns, juveniles, adults, or elderly, and by their source of acquirement, either 
the Affymetrix GeneChip® or literature searches. Of the 319 initial candidates, a total of 
26 (8.15%) were accepted as potential biomarkers of biological age determination. Of 
these candidates; nine were from newborns, seven from juveniles and ten were from the 
elderly age group. These genes and their expression profiles are: AFP (fetal liver), 
COL1A2 (5-year), FLJ20344a (1-hour and 86-years), HBE1 (<3-months), and 
LOC151194 (1-hour and >68-years) for newborns (Figure 5). Additionally, four 
hemoglobin transcripts, HBG1n1, HBG1n2, HBG2n2 and HBG2n3 were determined to 
be specific to newborn blood and are shown in Figure 29. Juvenile candidates: ASL 
(>84-years), PPOX (sporadic), PRL (7-months), SPTRX-1 (3-years), SPTRX-2 (7-
months – 3-years), TBC1 (14-years – 15-years), and TEKT2 (7-months – 3-years) are 
shown in Figure 6; while the elderly candidates: AGGF1 (<15-years), CDC2 (5-year), 
IGFBP3 (>29-years), LOH11CR2A (>79-years), MAD1L1 (<5-years), PDCD6 (5-years 
– 41-years), POLM (<13-years), POLQ (<5-years and 91-years), PPARD (<5-years), and 
SRC (<45-years) can be seen in Figure 7 (see APPENDIX D: CANDIDATE GENE 
DATABASE for individual gene descriptions). These candidate genes were then 
transferred to the real-time PCR platform, which is described in the next section. 
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Alternatively, of the original 319 candidates, 105 (32.92%) which originated from the 
Affymetrix GeneChip® and 188 (58.93%) of the literature candidates, were rejected for a 
total of 293 (91.85%) rejected candidates. Rejected Affymetrix and literature candidates 
are categorized in Table 3A and 3B, respectively. After the first-round of RT-PCR 
analysis 6.0% (19/319) and 15.4% (49/319) of the Affymetrix and literature candidates, 
respectively, were rejected because no amplified mRNA/cDNA product was detected 
(Figure 8), whilst 8.5% (27/319) and 0.9% (3/319) of Affymetrix and literature 
candidates, respectively, were rejected due to the mRNA/cDNA and genomic DNA 
product amplifying at the same molecular size (Figure 9). The majority of rejected 
candidates (40.1%) from amplification rounds-two and -three consisted of those, which, 
even after decreased cycle number, amplified an mRNA/cDNA product in all biological 
ages tested, with no apparent difference in expression levels, specifically, 11.6% (37/319) 
of Affymetrix, and 28.5% (91/319) of literature candidates (Figure 10). The final group 
of rejected candidates, 6.9% (22/319) Affymetrix and 14.1% (45/319) literature, were 
those which exhibited sporadic expression when multiple samples of the target age range 
were amplified (Figure 11). APPENDIX F: CANDIDATE GENE RT-PCR 
RESULTS lists all candidates with their corresponding accepted age groups or rejection 
categories. 
Quantitative Real-Time RT-PCR Gene Expression Profiling Analysis for 23 
Potential Age Specific Biomarkers 
Only after a candidate gene has passed numerous gel based screening 
amplifications, with various aged RNA samples, was it taken to quantitative real-time 
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PCR analysis. Real-time PCR provides numerous advantages over the conventional PCR 
technique, including increased sensitivity, decreased processing time and decreased 
sample consumption, which is a major advantage in forensic assay development; 
additionally, the ability of biomarker multiplexing with the inclusion of an internal 
positive control (IPC) is possible. Real-time PCR primers are designed, along with a 
sequence specific minor groove binding (MGB) probe, using ABI Primer Express 
software (version 2.0.0). To inhibit signal fluorescence from genomic DNA, primers are 
designed to land in separate exons, while the sequence specific probe is targeted to bind 
directly on the exon/exon boundary (Figure 12). All candidate gene probes are 5′ 6-FAM 
labeled, while the housekeeping gene, S15, is 5′ VIC labeled, and all probes are 3′ labeled 
with a non-fluorescent quencher (NFQ). All qPCR primers and probes are listed in 
APPENDIX G: CANDIDATE GENE PRIMER SEQUENCES FOR qRT-PCR.  
Only 23 of the 26 potential candidates were taken to real-time PCR. The newborn 
biomarkers, HBG1n2 and HBG2n2 were omitted from real-time assay development 
because two hemoglobin derived newborn candidates (HBG1n1 and HBG2n3) had 
previously been discovered and assays had already been developed (see the Fetal 
Specific Isoforms section). The alpha-fetoprotein (AFP) gene was not persued at the 
qPCR level, because, although it is specific for the fetal liver, it was not detected in 
newborn blood (Figure 5).  
In connection with the RT-PCR screening method, a real-time PCR protocol is 
followed for candidate gene testing. Initially, all genes are amplified with a range of 
biological ages (n>10), from 1-hour old newborns to elderly individuals, along with a 
genomic DNA control and a non-template control (NTC); one that has nuclease-free 
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water substituted for the nucleic acid. This first reaction verifies if the primer and probe 
set are mRNA/cDNA specific, and if there is any primer/probe interaction, based on 
amplification results of the genomic DNA and NTC, respectively. Amplification of a 
variety of biological ages is important for two reasons; first, differential amplification of 
the target age group must be verified by examining the cycle threshold (Ct) values 
generated against the non-target ages and second, the cycle threshold baseline of the 
target age group must be determined. 
Results from the initial round of qPCR rejected 14 of the 23 candidates. First, the 
polymerase mu subunit gene, POLM, was the only candidate rejected due to the threshold 
never being crossed in any biological sample (Figure 13). The other 13 candidates were 
rejected because of non-differential expression, specifically, there was no amplifiable 
difference between target and non-target age ranges. These rejected genes include CDC2, 
POLQ, SRC, LOH11CR2A, ASL, FLJ20344a, LOC151194, SPTRX-1, SPTRX-2, 
PPOX, TBC1, TEKT2, and PRL. The Ct values for the biological ages tested, for each 
candidate gene, are shown in Table 4, along with data charts graphing the generated Ct 
values against their corresponding biological ages Figure 14. 
Four of the original 23 candidates that were taken to real-time PCR produced 
differential Ct values in the first-round of screening which allowed them to be pursued 
further. These genes AGGF1, MAD1L1, PDCD6, and PPARD, along with their first-
round amplification results and Ct values are shown in Figure 15 and Table 5. As 
illustrated in these figures and tables, the younger aged individuals generated lower Ct 
values in the AGGF1 and PPARD amplifications, and increasing biological age, yielded 
increased Ct values. With the MAD1L1 and PDCD6 candidates, lower Ct values were 
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also generated with younger individuals, however the results were ununiform, whereby 
some younger ages exhibited Ct values that were consistent with older aged individuals, 
>50-years.  
Second-round qPCR screening consists of designing and developing duplex 
reactions, incorporating the IPC and subsequent testing of a wide array of biological ages 
(n=96). Analysis of duplex reactions is conducted by calculating delta cycle threshold 
(dCt) values for each biological age, where the difference in amplification efficiency is 
determined by subtracting the Ct value of the GOI from the Ct value of S15, (dCt = Ct 
S15 – Ct GOI). This dCt metric signifies the amount of GOI transcript number in 
differing ages. To explain, all ages will have similar copies of the housekeeping gene and 
therefore should generate relatively similar Ct values for S15, acting as the IPC. In 
contrast, amplification of the GOI is dependent on the initial amount of transcript copy 
number, whereby target and non-target biological ages will have more and less copies of 
the GOI, thereby generating lower and higher Ct values, respectively. We can then 
compare the dCt values of unknown samples to those generated from known ages to 
determine biological age. 
All four candidate genes, although producing differential amplification results in 
singleplex reactions, yielded blanket dCt values in duplex reactions. As illustrated in 
Figure 16 and Table 6 the results for AGGF1, MAD1L1, PDCD6, and PPARD, showed 
positive dCt values in all biological ages tested, from 1-hour to 102-years. These 
candidates were then rejected because of non-differential amplification of the GOI in the 
qPCR duplex reactions. 
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Discussed in the following sections are three candidate genes namely- COL1A2, 
HBE1 and IGFBP3, which showed target age specificity and were optimized into duplex 
reactions with the IPC housekeeping gene, S15. Additionally, two newborn candidates, 
HBG1n1 and HBG2n3, have been optimized into duplexes with the S15 housekeeping 
gene and validation studies have been completed (see the Fetal Specific Isoforms 
section). 
COL1A2, A Biomarker for Age Determination of Younger Aged Individuals  
When searching for literature candidate genes, an article by K. Kerschan-Schindl 
et al., reveled that the c-terminal telopeptide of type I collagen, had been increased in 
elderly subjects [85]. This lead to an investigation of all genes known to be associated 
with bone development; where the Homo sapiens collagen, type I, alpha 2 (COL1A2) 
gene, was identified as a potential biomarker of ageing. First-round singleplex 
amplification results illustrated that COL1A2 expression was increased in younger 
individuals, 1-hour to 12-years old, and all other ages >12-years, generated undetermined 
Ct values (default value of 50.000, the amount of qPCR cycles used) (Figure 17 and 
Table 7). A duplex reaction was then optimized and amplification results with all 
biological ages (n=96) is illustrated in Figure 18 and Table 8. The dCt values 
demonstrate that the amplification of the GOI is at a higher level in younger biological 
ages (1-hour – 5-months), when compared to other individuals (>5-months in biological 
age) due to the production of positive and negative dCt values, respectively. These results 
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established the development of a forensic tool for biological age estimation of younger 
aged individuals. 
Initial validation specificity results, where 109 different blood samples were 
amplified in triplicate, are shown in Table 9, where each sample is listed with its 
corresponding average COL1A2 (GOI) and S15 Ct value and their standard deviations, as 
well as the calculated dCt values (±SD). Figure 19, gives a summary of the target age 
group (newborns and infants), in comparison to the non-target ages: toddlers, children, 
juveniles, adults, middle-age, and elderly individuals. Additionally, the overall average 
COL1A2 and S15 Ct values ±SD, and average dCt values are illustrated; specifically, the 
newborn and infant age group dCt value was +6.748 (±4.185 SD), compared to –2.980 
(±5.020) in toddlers and children, and –4.830 (±3.681) in juveniles, adults, mid-age and 
elderly individuals. 
HBE1, A Biomarker for Age Determination of Newborns 
The Homo sapiens hemoglobin, epsilon 1 gene (HBE1), was selected as a 
potential newborn specific gene, due to its restricted expression to embryonic blood and 
select embryonic organs. First-round singleplex amplification results illustrated that 
HBE1 expression was increased in younger individuals, specifically 1-hour old 
newborns, and all other ages >17-days, generated at a minimum a 4 cycle higher Ct value 
(Figure 20 and Table 10). A duplex reaction was then optimized and amplification 
results with all biological ages (n=96) is illustrated in Figure 21 and Table 11. The dCt 
values demonstrate that the amplification of the GOI is at a higher level in younger 
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biological ages (1-hour – 3-months), when compared to older individuals (>3-months in 
biological age) due to the production of positive and negative dCt values, respectively. 
Although, some of the biological ages from 21-years to 92-years also positive dCt values, 
there is a detectable difference in the magnitude of positive dCt values, between the 
younger and older age groups. 
Initial validation specificity results, where 139 different blood samples were 
amplified in triplicate, are shown in Table 12 and Figure 22. Each sample is listed with 
its corresponding average HBE1 (GOI) and S15 Ct value and their standard deviations, as 
well as the calculated dCt values (±SD). Figure 22 gives a summary of the target age 
group (newborns), in comparison to the non-target ages: infants, toddlers, children, 
juveniles, adults, middle-age, and elderly individuals. Additionally, the overall average 
HBE1 and S15 Ct values ±SD, and average dCt values are illustrated; specifically, the 
newborn age group dCt value was +3.088 (±2.523 SD), compared to –2.978 (±0.302) in 
infants, toddlers, children, juveniles, and adults; and –1.348 (±0.330) in mid-age and 
elderly individuals. 
IGFBP3, A Biomarker for Age Determination of Post-Pubertal Individuals 
The Homo sapiens insulin-like growth factor binding protein 3 gene, was 
identified when literature searches of human ageing reveled that mutations in Lamin A 
were responsible for prematureing ageing and that the levels of IGFBP3, decreased with 
lamin A splicing inhibition [82]. Additionally, a separate publication by Wang et al., 
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listed IGFBP3, in addition to numerous others, as a gene with increased expression in 
senescent cells [59]. 
First-round singleplex amplification results of IGFBP3 illustrated that Ct values 
were obtained with all samples in the post-pubertal (>15-years old) age range (19/19), 
while IGFBP3 was unamplifiable in 71% (5/7) of samples aged 1-hour to 12-years old 
Table 13. Figure 23 shows this initial round of amplification results, where 
undetermined +RT Ct values are given a default value of 40.000, the amount of qPCR 
cycles used. 
 After the favorable singleplex amplification results, a duplex reaction was 
optimized and amplification results with all biological ages (n=96) is illustrated in Figure 
24 and Table 14. The dCt values demonstrate that amplification of IGFBP3 (the GOI) is 
at a higher level in older biological ages, due to the production of positive dCt values in 
ages greater than 35-years old. More importantly, 96% (44/46) of the younger biological 
ages, those from 1-hour to 34-years old, produced negative dCt values. Only two samples 
a 14- and a 24-year old, produced positive dCt results of +2.126 and +2.054, respectively. 
These results established the development of a forensic tool for biological age estimation 
of post-pubertal individuals, aged 35-years and older. Initial validation specificity results, 
where 123 different blood samples were amplified in triplicate, are shown in Table 15. 
Each sample is listed with its corresponding average IGFBP3 (GOI) and S15 Ct values 
and their standard deviations, as well as the calculated dCt values (±SD). Figure 25 gives 
a summary of the target age group (adults, middle-aged and elderly), in comparison to the 
non-target ages: newborns, infants, toddlers, children and to a lesser extent juveniles. The 
overall average IGFBP3 and S15 individual Ct values ±SD, are listed for each age group 
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and the calculated average dCt values are illustrated. Individual results from the IGFBP3-
S15 duplex amplification yielded an average dCt value of –0.725 (±2.637), in the target 
age groups, compared to –9.914 (±5.402) in newborns, infants, and toddlers, and –4.208 
(±4.260) in the children and juvenile age range. 
Fetal Specific Isoforms of Gamma Hemoglobin as Biomarkers for Biological Age 
Determination 
Expression Analysis of the Standard Hemoglobin Gamma Transcripts, HBG1 and 
HBG2  
The tetrameric fetal and adult hemoglobin protein complexes are composed of 
two alpha and either two gamma (α2γ2) or two beta (α2β2) hemoglobin chains, 
respectively. This well characterized variation in fetal versus adult hemoglobin was the 
basis for the initial design of a newborn specific assay. The gamma hemoglobin locus 
was analyzed by a reverse transcription-polymerase chain reaction (RT-PCR) using three 
different sets of primers. The universal set amplifies both gamma hemoglobin genes 
simultaneously (HBG), while two sets of gene specific primers amplify either the HBG1 
(A-gamma) or HBG2 (G-gamma) genes individually (Figure 26). All forward and 
reverse primers were designed to land in exons two and three (flanking intron two), 
respectively, for separation of cDNA and genomic DNA amplified products in agarose 
gels. To test the expression of the gamma hemoglobin transcripts over different 
biological ages, total RNA was extracted from venous bloodstain samples donated from 
individuals aged 1-hour to 91-years. Messenger RNA was reverse-transcribed and the 
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corresponding cDNA, along with a genomic DNA control, was amplified using primers 
designed to specifically recognize total hemoglobin (HBG) or the individual HBG1 or 
HBG2 gene transcripts (Figure 27).  
Contrary to the initial hypothesis, a gamma hemoglobin messenger RNA 
amplified product corresponding to total HBG (154 bp) (Figure 27A) or individual 
HBG1 (277 bp) (Figure 27B) or HBG2 (274 bp) (Figure 27C) genes was amplified in all 
ages tested. Detection of these fetal hemoglobin chains (Aγ and Gγ) in non-newborn blood 
samples was unexpected, based on our knowledge that expression of the fetal hemoglobin 
protein falls to ~3% within five months after birth and is completely replaced by adult 
hemoglobin after two years of biological age [35, 94]. These results demonstrate that, in 
contrast to the expression pattern for the fetal hemoglobin protein, HBG mRNA 
production is not solely restricted to the fetal and newborn stages of development. While 
evaluating the results from the standard hemoglobin amplification reactions in Figure 27, 
we serendipitously detected additional lower molecular weight bands in only the younger 
aged individuals aged 1-hour, 13-days and 3-months (+RT) (illustrated with asterisks) at 
approximately 65bp and 100bp, for the HBG1 (Figure 27B) and HBG2 (Figure 27C) 
amplifications, respectively. 
Sequence Determination and Alignment of the Newborn Specific Gamma 
Hemoglobin Isoforms 
To determine the molecular sequence of the newly identified low molecular 
weight amplimers; amplified products were excised from agarose gels, purified, cloned 
into chemically competent cells and sequenced (see Cloning and Sequencing). The 
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sequencing results for the HBG1 and HBG2 low molecular weight products revealed that 
each band was actually composed of two separate amplimers, which seemed to be of the 
same size or only slightly different. Once all four low molecular weight amplimers had 
been sequenced, we utilized the (NCBI) human genome BLAST alignment tool to 
determine the origin of the amplified products. Alignment results illustrated that both low 
molecular weight sequences obtained from the HBG1 reaction and both low molecular 
weight sequences from the HBG2 reaction, only aligned with regions of the original 
HBG1 and HBG2 transcripts, and did not exhibit sequence similarity to any other part of 
the human genome. The specificity of the forward and reverse primers for both 
hemoglobin genes was also tested using the NCBI nucleotide BLAST (search for short, 
nearly exact matches). The results illustrated that although the primers are not human 
specific, they are specific for the HBG1 and HBG2 transcripts, within the human 
transcriptome. 
After determining that these amplimers originated from the standard hemoglobin 
gamma genes, MegAlign software from DNAstar Lasergene was used to align the lower 
molecular weight sequences to the corresponding standard hemoglobin sequences. This 
was necessary in order to determine the regions of similarity and dissimilarity within the 
transcripts. Alignment analysis showed that all four of the low molecular weight 
amplimers contained identical sequences to the standard hemoglobin sequences, 
beginning with the forward primer binding site (located in exon two) and extending to the 
reverse primer binding site (located in exon three). More importantly, alignment analysis 
illustrated that the middle of the amplified sequence was deleted in all four low molecular 
weight products, specifically, the 3′ end of exon two and the 5′ end of exon three, was 
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missing from all four of the sequences. Further evaluation of each specific deleted region 
(all four transcripts had a deleted region, however the size of the deleted region as well as 
the first and last nucleotides in the deletion was different) exhibited the presence of either 
a penta- or octanucleotide direct repeat sequence at the beginning and the end of each 
deletion. These direct repeat sequences were located in both exons two and three of each 
transcript and seemed to be the breakpoints between the aligned regions within the 
standard hemoglobin sequences and each of the four low molecular weight sequences. 
Figure 28 illustrates the exact locations of these direct repeat breakpoints for the HBG1 
and HBG2 genes and their low molecular weight products. Direct repeat sequences and 
their locations within the gene for HBG1 [Genbank: NM_000559] are ATGAT (292-296, 
509-513) and AGATGCCA (272-279, 486-493), and the corresponding low molecular 
weight amplimers have been named HBG1n1 and HBG1n2, respectively. The direct 
repeats for the HBG2 [Genbank: NM_000184] gene are TGCCC (311-315, 473-477) and 
CACTG (330-334, 492-496) and the corresponding low molecular weight amplimers 
have been named HBG2n2 and HBG2n3, respectively. After the sequencing and 
alignment results were interpreted, the deleted regions and amplicon sizes for each of 
these transcripts was determined. For HBG1n1, HBG1n2, HBG2n2 and HBG2n3 the 
number of deleted bases was 217, 214, 162, and 162 bp, which produced amplicons of 
60, 63, 112 and 112 bp, respectively. It should also be noted that although the sequence 
of the breakpoints is known, the actual position within the direct repeat where the break 
occurs is unknown. 
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RT-PCR Amplification of the Individual Newborn Gamma Hemoglobin Isoforms 
Based on the sequencing results for the four newborn transcripts, gel based RT-
PCR assays were developed for amplification of the individual transcripts. Forward 
primers for the HBG1n1, HBG1n2, HBG2n2 and HBG2n3 assays were designed to span 
the breakpoints in each of the two isoforms, therefore precluding the amplification of the 
standard HBG genes (Table 16, underlined sequences). Total RNA from bloodstains 
from three individuals aged 8-days, 15-years and 84-years were tested, along with a 
genomic DNA control. As expected an amplified product consistent with the detection of 
the four transcripts was detected only in the 8-day old newborn (Figure 29). 
An internal positive control (IPC), the ribosomal protein, S15, was incorporated 
into two of the newborn assays resulting in two duplex RT-PCR reactions. S15 was 
chosen as the IPC instead of either of the commonly-used housekeeping genes, GAPDH 
or Beta-Actin, since S15 exhibited significantly fewer processed pseudogene derived 
artifacts in RNA isolates containing trace quantities of genomic DNA (data not shown). 
Each duplex reaction contained primers for the housekeeping gene, S15 [51], and one of 
the two newborn gamma isoforms, either HBG1n1 and HBG2n3. The S15-HBG1n1 
(Figure 30A) and S15-HBG2n3 (Figure 30B) duplexes demonstrated the presence of 
S15 mRNA in all ages tested, while the newborn gamma hemoglobin gene transcripts 
were only found in individuals aged 1 hour to 3- and 4-months, respectively. 
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Quantitative Real-Time PCR Analysis of the HBG1n1 and HBG2n3 Newborn 
Specific Gamma Isoforms 
The two gel-based duplex RT-PCR assays for the identification of HBG1n1 and 
HBG2n3 were re-configured for analysis using a real-time, quantitative PCR (qPCR) 
platform. The resulting prototype qRT-PCR assays as formulated, should detect the 
HBG1n1 and HBG2n3–derived amplicons at a significantly higher level in newborn 
individuals (≤4 months) compared to those of older age groups (>4 months). In order to 
accomplish this, the amount of HBG1n1 and HBG2n3 expression in different age groups 
was characterized by a dCt metric [Ct (S15) – Ct (HBG1n1 or HBG2n3)] which measures 
the expression of HBG1n1 and HBG2n3 isoforms in relation to the S15 internal positive 
control. Samples from newborns (≤4 months) typically generated Ct (HBG1n1 and 
HBG2n3) values less than that of S15, indicating the relatively high level of expression 
of HBG1n1 and HBG2n3 in newborns compared to the S15 housekeeping gene (Figure 
31A and Figure 31B, left panels). In contrast, Ct (HBG1n1 and HBG2n3) values from 
non-newborns (>4 months old) were greater than generated S15 Ct values (Figure 31A 
and Figure 31B, right panels). In some non-newborn individuals (>4 months old) the 
HBG1n1 and HBG2n3 transcripts were present in insufficient quantity to reach the Ct 
threshold (Figure 31B2). In these instances the Ct (HBG1n1 and HBG2n3 was given a 
default value of 40.00 which represents the total number of PCR cycles used (i.e. 40). 
Therefore, the qRT-PCR assays, as configured, should produce positive dCt results for 
newborn blood samples whereas all other age groups should produce negative dCt 
results. For example, the dCt values of the newborns illustrated in Figure 31A and 
 45
Figure 31B were +1.60 (HBG1n1) and +5.60 (HBG2n3) whereas the non-newborns were 
–2.61 (HBG1n1, 72-years old) and –8.03 (HBG2n3, 15-years old). 
In certain circumstances (e.g. newborns whom have been illegally removed from 
the hospital) it would be useful to determine whether an individual was <24 hours old.  It 
was possible (see below), by altering the primer concentrations, to modify the two duplex 
qRT-PCR assays described above such that they were predictive (i.e. based upon a 
positive dCt metric) of blood from a child <24 hours old (Figure 31C and Figure 31D). 
Examples of the results from the <24 hours newborn assays are provided in Figure 31C 
(HBG1n1) and Figure 31D (HBG2n3). The corresponding dCt values for a 1-hour 
newborn were +3.75 (HBG1n1) and +5.89 (HBG2n3), whereas an 8-day old newborn 
produced values of –1.40 and –1.66, respectively. 
The precise Ct that an amplified gene product attains is dependent on two factors, 
the amount of target gene present in the sample and the concentration of primer and 
probe used in the PCR reaction. The two newborn duplex real-time PCR assays (≤4 
months and <24 hours) illustrate the effect these two factors have in real-time PCR 
amplification (Figure 32). Ubiquitously expressed genes (i.e. housekeeping genes) are 
expressed at relatively the same levels in all cell types. Differentially expressed genes 
have regulated expression patterns and are either turned on/off (i.e. present/not-present) 
or are expressed at different levels (i.e. increased/decreased) in a tissue or developmental 
stage specific manner. In both newborn assays the concentration of the newborn gamma 
hemoglobin isoform primers is similar (HBG1n1= 100nM (≤4 month) and 50nM (<24 
hour); HBG2n3= 50nM (≤4 month) and 50nM (<24 hour)). Therefore, since the 
primer/probe concentrations are the same in both assays amplification of these 
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hemoglobin isoforms is dependent on the initial gene copy number. Figure 32, illustrates 
that a sample amplified with all four duplex reactions from both assays should produce a 
relatively constant HBG1n1 and HBG2n3 Ct value. Since the S15 housekeeping gene 
exhibits a constant level of expression (constant initial copy number), all samples should 
reach the threshold at relatively the same cycle number. Thus, increasing or decreasing 
the S15 primer/probe concentration will shift all amplification response plots to the left or 
right, respectively. The S15 primer concentrations vary significantly between the two 
newborn assays. In the ≤4 month assay 600nM is used, compared to 900nM in the <24 
hour assay. Therefore, by increasing the S15 primer concentration all amplification plots 
(Ct values) are leftward shifted in the <24 hour assay when compared to the ≤4 month 
assay, and with the hemoglobin genes remaining constant, this allows older newborns to 
now produce negative dCt values (more S15 product than HBG1n1 and HBG2n3) when 
compared to younger newborns (more HBG1n1 and HBG2n3 product than S15) (Figure 
32). 
Biological Age Specificity of the qPCR Newborn Hemoglobin Biomarkers 
The ability of the qRT-PCR assays to identify newborn individuals (≤4 months or 
<24 hours) was tested by analyzing 132 blood samples from multiple donors varying in 
biological age from 1-hour to 92-years (<24h (n=10); 1 day-1 month (n=19); 2-4 months 
(n=22); 5 months-3 years (n=37); 4-18 years (n=20); 19-92 years (n=24)).  The results are 
summarized in the form of two-dimensional scatter plots in which each sample’s dCt 
(S15-HBG1n1) and dCt (S15-HBG2n3) are displayed (Figure 33). Positive results from 
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newborns are expected to be confined to the upper right quadrant (positive dCt HBG1n1 
and dCt HBG2n3) whereas negative results from non-newborns would be found in the 
lower left quadrant (negative dCt HBG1n1 and dCt HBG2n3). 
In the ≤4 month assay, 98% (i.e. 50) of the 51 newborn (≤4 month old) samples 
yielded at least one positive dCt value, while 96% (i.e. 78) of the 81 non-newborns 
yielded two negative dCt values (Figure 33A and Table 18). Indeed the vast majority of 
≤4 month old newborn samples (90% (46/51)), gave two positive dCt values (upper right 
quadrant). The one non-newborn sample that appears in the upper right quadrant in 
Figure 33A originates from a 7-month old infant.  Subsequent repeat analysis (x2) places 
it in the lower right quadrant (i.e. one positive and one negative dCt). Of the samples that 
generated one positive and one negative dCt value, four of the six individuals were 4-
months old.  This is consistent with the occurrence of a transitional developmental state 
that occurs about 4-months after birth in which transcription of the HBG1n1 and 
HBG2n3 isoforms is curtailed. 
For the <24 hour assay, all newborn samples aged from 1-hour to 24-hours 
generated positive dCt values (10/10) for each duplex (Figure 33B and Table 18). 
Ninety-seven percent (100/103) of individuals biologically aged greater than one-month 
generated two negative dCt values as expected.  
No sex-specific differences were observed with either the <24 hour or ≤4 month 
assays (data not shown). 
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Body Fluid Specificity of the qPCR Newborn Hemoglobin Biomarkers 
Saliva (n=18), semen (n=2), vaginal secretions (n=2) and menstrual blood (n=7) 
from healthy donors; as well as venous blood, saliva, vaginal secretions from a pregnant 
female and breast milk (1-month post delivery) were assayed with the ≤4 month and <24 
hour duplexes. HBG1n1 and HBG2n3 Ct values were undetermined for all body fluids 
tested, illustrating that the two duplexes are specific for venous newborn blood (Figure 
34). 
Human Specificity of the qPCR Newborn Hemoglobin Biomarkers 
RNA was extracted from bloodstains from a variety of animal species including 
two Pigtailed Macaques (one newborn and one adult), two Rhesus Macaques (one 
newborn and one adult), calf (newborn), cow (adult), lamb (newborn), sheep (adult), cat, 
dog, horse, deer, spider monkey, two African crown cranes, gopher tortoise, and a 
patagonian cavy, and tested with the newborn qPCR assays. One buccal swab from a 
Chinese Muntjac was also tested. HBG1n1 and HBG2n3 cycle threshold (Ct) values were 
undetermined for all animal samples tested, illustrating that the two duplexes are specific 
for human newborn blood (Figure 35). 
Mixture Study of the qPCR Newborn Hemoglobin Biomarkers 
The newborn assays are expected to be of use in the investigation of criminal 
abortion cases. In such instances putative products of conception are sometimes 
recovered and expected to comprise mixed samples, typically the newborn (or fetus) and 
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that of an adult.  Therefore, to ensure the detectability of newborn blood in the presence 
of adult blood, controlled mixture studies were carried out. Total RNA from the blood of 
newborns (<24-hours old) and either juvenile (16-years) or adult (22- or 31-years) 
individuals was combined to simulate mixtures from criminal abortion cases. Three 
separate newborn/non-newborn admixed pairs were studied with each pair comprising a 
sample set of the same admixture ratios (1:1, 1:5, 5:1, 1:10 and 10:1). The 15 mixed 
RNAs were reverse-transcribed and amplified with both newborn duplexes, using the ≤4 
month and <24 hours assay formats.  
In the ≤4 month assay all 15 mixtures generated two positive dCt values, except 
for one of the 1:10 mixtures (24-hour newborn: 31-year adult) (Figure 36A). This latter 
sample generated one positive (S15-HBG1n1) and one negative (S15-HBG2n3) dCt 
value. In the <24 hour assay all of the 1:1, 5:1 and 10:1 mixtures generated two positive 
dCt values (Figure 36B). The three 1:5 mixtures and two of the three 1:10 mixtures 
generated one positive and one negative dCt value in the S15-HBG2n3 and S15-HBG1n1 
assays, respectively. The other 1:10 mixture (24-hour newborn to 31-year adult) 
generated two negative dCt values (Figure 36B). 
The above results indicate that the assays can detect newborn/non-newborn 
admixed samples and are likely to be of use to demonstrate the presence of newborn 
blood in putative products of conception. 
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Real-Time PCR Sensitivity of the Newborn Hemoglobin Biomarkers 
The sensitivities of the qRT-PCR newborn assays were determined by varying the 
amount of total RNA input into the assays using RNA isolated from bloodstains from two 
newborns (both 1-hour old) and two non newborns (a 13-year old and a 53-year old). The 
average dCt values from both newborns and both adults are shown for each duplex 
reaction (Figure 37, Table 19, and Table 20). The ≤4 month newborn assay generated 
positive dCt values with ≥ 5 pg RNA with the newborn samples while the adult samples 
generated negative dCt values with ≥ 50 pg RNA (Figure 37A and Table 19).  Input 
RNA less than these concentrations did not produce detectable housekeeping gene or 
newborn gene products that reached the Ct threshold. With the <24 hour newborn assay, 
the S15-HBG1n1 duplex generated the expected positive and negative dCt values 
(newborns and adults, respectively) with ≥ 25 pg RNA input. (Figure 37B1 and Table 
20). With the S15-HBG2n3 assay, newborns generated positive dCt values with ≥ 5 pg of 
input RNA, while the adult samples generated negative dCt values with ≥ 50 pg input 
RNA (Figure 37B2 and Table 20).  
Based upon these sensitivity studies, a minimum input of 50-pg RNA is 
recommended for the qRT-PCR newborn assays. 
Stability of HBG1n1 and HBG2n3 Transcripts in Aged Bloodstains 
In order to be useful in forensic casework, the HBG1n1 and HBG2n3 transcripts 
should be stable over time in dried stains. In order to assess the stability of the newborn 
transcripts in the dried state, blood from two newborns (1-hour and 2-months old), two 
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juveniles (14- and 15-years old) and two elderly individuals (84- and 86-years old) were 
deposited on cloth, allowed to air dry and stored at room temperature (~25˚C) for various 
time points (1, 3, 6, 9, 12 and 15 months).  Total RNA was isolated from the bloodstains 
and then assayed for HBG1n and HBG2n transcripts by qRT-PCR.  The results are 
displayed in a two dimensional scatter plot as before (Figure 38).  In both newborn 
assays (i.e. ≤4 months and <24 hours), the one-hour old newborn individual generated 
two positive dCt values in all aged samples, while the juvenile and elderly individuals 
generated two negative dCt values at all time points tested.   
Despite the excellent specificity exhibited by the assays with 15-month aged 
bloodstains (i.e. aged newborn bloodstains cluster separately from aged bloodstains from 
other developmental age groups), caution must be exercised in aged samples from older 
newborns.  While the two-month old newborn sample produced two positive dCt values 
when stored at room temperature up to one month with the ≤4 month assay, it produced 
one positive and one negative dCt value for the S15-HBG2n and S15-HBG1n duplexes 
respectively with stains aged 3-15 months (Figure 38A). In the <24 hour assay, the same 
two-month old newborn produced one positive and one negative dCt value when aged for 
1, 3, 6 and 9 months but two negative dCts after 12 and 15 months of storage (Figure 
38B).  
Expression Profiles of the Standard and Newborn Hemoglobin Gamma Transcripts 
in Six Fetal Tissues 
With the discovery of four novel hemoglobin derived transcripts, each exhibiting 
regulated expression to only newborn blood, we next evaluated the expression patterns of 
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each of the hemoglobin genes (HBG1, HBG1n1, HBG1n2, HBG2, HBG2n2, and 
HBG2n3 (primer sequences are located in Table 16)) in total RNA obtained from six 
fetal tissues: brain, heart, kidney, liver, spleen, and thymus. Additionally, total RNA was 
extracted from three blood samples, donated by different biologically aged individuals 
and assayed as amplification positive (1-hour old) or negative (45- and 79-years old) 
controls. To correctly determine the expression patterns of the novel transcripts, RT-PCR 
duplex reactions were created by integrating the housekeeping gene, GNAS (guanine 
nucleotide binding protein, alpha stimulating), into amplification reactions with each of 
the individual hemoglobin transcripts. Incorporating the housekeeping gene as an internal 
positive control (IPC), allowed us to conclude if the hemoglobin transcripts were truly 
present or truly absent in each particular tissue sample. By visualizing the positive 
amplification of the GNAS transcript, the quality and quantity of our RNA/cDNA 
sample, along with the reverse transcription and PCR reactions, were verified.  
Figure 39 illustrates the expression profiles obtained from the duplex hemoglobin 
amplification reactions. Consistent amplification of the IPC (GNAS), in all blood and 
fetal tissue samples, allowed us to directly compare the expression patterns of the 
hemoglobin genes. Results obtained from amplification of the standard hemoglobin 
HBG1 and HBG2 transcripts (Figure 39A and Figure 39D), illustrate that all blood and 
tissue samples showed nearly identical amplification products, with no age related 
differences in gene expression. These results confirm our previous experiment of 
analyzing (and rejecting) the standard hemoglobin genes as potential newborn specific 
mRNA candidates (Figure 27). Although the expression of the HBG1 and HBG2 mRNA 
transcripts in non-newborn blood samples seem to contradict our current knowledge of 
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the expression of the fetal hemoglobin protein (i.e. HbF is found at levels <2% in normal 
adult blood) [95-97], the results do stimulate the possibility of a post-transcriptional 
regulation mechanism, triggered shortly after birth, which inhibits fetal hemoglobin 
protein synthesis. 
In contrast to the uniform expression patterns obtained from the standard 
hemoglobin genes in blood and fetal tissue samples, the four novel hemoglobin 
transcripts seemed to have tightly regulated and individualistic expression patterns 
(Figure 39). All four transcripts were detected in the 1-hour old blood donor (+RT only), 
but were not amplified in either the 45- or the 79-year old donors, confirming their 
specificity to newborn blood. Amplification of the HBG1n1 and HBG2n3 genes was 
detected at high levels in fetal liver and fetal spleen and lower expression was seen in the 
fetal heart, kidney and thymus tissue, however neither gene was detected in fetal brain 
(Figure 39B and Figure 39F). The HBG1n2 transcript exhibited relatively low 
expression levels in fetal heart, liver and spleen tissues, and was not detected in fetal 
brain, kidney or thymus samples (Figure 39C). In contrast to the other three novel 
hemoglobin genes, the expression of the HBG2n2 transcript was restricted to the 
newborn blood sample, and was not detected in any of the fetal tissues (Figure 39E). The 
expression of the standard and novel gamma hemoglobin transcripts at higher levels in 
fetal liver and spleen was expected, due to the fact that the liver and to a lesser extent the 
spleen are the major sites for hematopoiesis, after the transition from vitelline to placental 
circulation and disappearance of the embryonic yolk sac [35]. 
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Expression Profiles of the Standard and Newborn Hemoglobin Gamma Transcripts 
in Thirteen Adult Tissues 
After determining the expression patterns of the newborn hemoglobin transcripts 
in fetal tissues, we next evaluated their expression in adult derived tissues. Total RNA 
from adult adipose, bone marrow, brain, kidney, liver, lung, skeletal muscle, skin, 
salivary gland, spleen, thymus, testis, and uterus was amplified, along with newborn 
blood (1-hour) as a positive control and two negative controls, an adult (45-years old) and 
an elderly (79-years old). Duplex RT-PCR reactions, containing the GNAS housekeeping 
gene and a newborn transcript of interest, were performed and the results were evaluated 
by agarose gel electrophoresis (Figure 40). All samples successfully amplified the GNAS 
control, which allowed us to directly compare the hemoglobin amplification expression 
patterns. All three blood samples, along with adult adipose and bone marrow exhibited 
high transcript levels when assayed for the standard HBG1 and HBG2 genes, Figure 40A 
and Figure 40D, respectively. In contrast, only the newborn blood (1-hour) positive 
control was amplified with any of the newborn specific hemoglobin gene duplexes, the 
two blood negative controls and all thirteen adult tissues failed to amplify with the 
HBG1n1, HBG1n2, HBG2n2 and HBG2n3 genes in Figure 40B, Figure 40C, Figure 
40E, Figure 40F, respectively.  
The four novel hemoglobin transcripts showed restricted expression, only being 
detected in newborn blood, which coincides with our knowledge of fetal hemoglobin 
protein expression. The presence of the fetal hemoglobin transcripts was expected in 
adult bone marrow, due to it being the primary site of hematopoiesis, taking over for the 
fetal liver at approximately 20 weeks gestation [35]. The presence of the HBG1 and 
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HBG2 transcripts in human adult adipose tissue was unexpected, due to its lack of direct 
association with erythropoiesis. A literature search identified a single report of the 
gamma hemoglobin promoter being active in adipose tissue. This study was conducted 
using transgenic mice which linked the human fetal HBG2 promoter to the viral simian 
virus 40 T antigen [98]. After transfection, the presence of brown adipose tumors was 
detected in the subcutaneous interscapular neck and shoulder areas; illustrating the ability 
of the gamma hemoglobin promoter to be transcribed in adult mouse adipose tissue [98].  
Molecular Origin of the Four Newborn Gamma Hemoglobin Isoforms 
Sequencing results from the four novel hemoglobin transcripts illustrated that an 
octanucleotide (HBG1n2) and varying pentanucleotide (HBG1n1, HBG2n2, HBG2n3) 
repeats were the initiation sites for the partial gene deletions (Figure 28). At the 
molecular level it appears that the newborn transcripts are formed by rearrangement 
events, which excise the intervening regions of exons two and three, between the 
repeated segments. Figure 41A illustrates a potential rearrangement event occurring at 
the genomic DNA level, while Figure 41B illustrates an interaction at the RNA level and 
although intermolecular interactions are illustrated, the potential for intramolecular 
rearrangements is inferred. A recent paper by Lutay et al, illustrated the ability of RNA, 
in nonenzymatic recombination reactions, to successfully create novel RNA molecules 
from two oligonucleotides, in vitro [99]. Because our four transcripts were detected at the 
RNA level, the possibility of an RNA based origin was evaluated, in addition to the 
recombination event originating at the genomic DNA level [22]. These two possibilities 
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were evaluated by extracting total genomic DNA and RNA from newborn (1-hour), adult 
(31-years) and elderly (86-years) bloodstains or purchasing genomic DNA and total RNA 
from fetal liver and spleen and adult adipose and bone marrow (BM) (See Materials and 
Methods). The extracts were treated with DNase I or RNase I digestions, followed by 
amplification with the previously described duplex PCR reactions containing the GNAS 
housekeeping gene and one of the four newborn specific isoforms (Figure 42). In all 
eight blood samples (Figure 42A), and fetal and adult tissues (Figure 42B), the genomic 
DNA extracts solely produced amplicons of the expected GNAS product size (855 bp) in 
the untreated and RNase I treated samples, lanes 1 and 3, respectively, with no 
amplification detected in the DNase I treated samples, lane 2. Additionally, none of the 
blood or tissue DNA samples, lanes 1-3, amplified a newborn hemoglobin isoform. For 
the RNA extracts, all samples were DNase I digested to eliminate any contaminating 
DNA before analysis. Lanes 4, 5 and 6, 7 represent total RNA treated or untreated with 
the RNase I enzyme, respectively. Following ±RNase I treatment, the RNA samples were 
reverse transcribed with or without the reverse transcriptase enzyme (±RT) and amplified 
with the duplex PCR reactions. The amplification results illustrate that all reverse 
transcribed RNA samples failed to amplify a GNAS or a hemoglobin product after 
treatment with both the DNase I and RNase I enzymes (lanes 4 and 5). In contrast, when 
total RNA was treated with the DNase I and RT enzymes (no RNase I digestion) we were 
able to detect an mRNA/cDNA product corresponding to the GNAS gene (371 bp, lane 
6) in all samples tested, while only the newborn blood samples, fetal liver and fetal 
spleen amplified the newborn hemoglobin isoforms. The HBG2n2 gene did not amplify 
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in the fetal liver sample, which was expected due to it only being expressed in newborn 
blood (Figure 39E). 
If the recombination event which leads to the generation of these four novel 
isoforms was occurring at the genomic DNA level we would expect to amplify a product 
for these transcripts in our untreated and RNase I treated DNA samples, in tandem with 
the GNAS positive control. Our results indicate that the hemoglobin transcripts are not 
found at the genomic DNA level. In RNA samples treated with DNase I and the RT 
enzyme, successful amplification of GNAS and the newborn hemoglobin isoforms is 
detected in newborn blood donors and fetal tissue origins. These results allow us to 
conclude that the recombination event which creates these novel transcripts is occurring 
at the molecular RNA level.  
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Telomere Length Analysis for Biological Age Determination 
One highly studied molecular based degenerative process is the shortening of 
telomeric chromosomal regions with increasing chronological age [14, 100-106]. 
Telomeres are short tandem repeat sequences located at the ends of chromosomes and 
range from 100 to 280 nucleotides. They function to maintain chromosomal end integrity 
and stability by preventing exonuclease DNA degradation as well as inappropriate 
chromosomal fusions and by protecting the ends of linear chromosomes from being 
recognized by the DNA repair machinery as damage. The telomere repeat core sequence 
in humans is TTAGGG and is present at the tips of chromosomes both as a block of 
contiguous perfect repeats and, more distally, as a block of imperfect tandem repeats. A 
subtelomeric region comprising additional sequences separates the telomere from the rest 
of the chromosome. Telomeres play an essential role in DNA replication in that after 
each cell division a number of tandem repeats are lost due to the inability of replicative 
DNA polymerases to synthesize DNA in the 5′ to 3′ direction (Figure 44) [103, 107]. 
This “end replication problem” results in a loss of ~50-200 bp of DNA and a progressive 
reduction in telomere length and generation of a G-rich 3′ overhang [103, 107, 108]. The 
current paradigm is that the structural integrity of the telomere is regularly monitored by 
the cellular machinery and a number of telomere-specific protein sensors (e.g. TRF1, 
TRF2, POT1, TIN1, TIN2) have been identified [109]. Although telomerase is an enzyme 
with reverse transcriptase activity that can reconstitute the lost repeats, its expression is 
normally restricted to germ and stem cells. Thus somatic cells exhibit a progressive 
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reduced telomere length as cells divide and eventually the protective effect of the 
telomere structure is overcome and genomic instability or reproductive senescence results 
[110]. Progressive reduction in telomere length in somatic tissues is thus correlated with 
the ‘biological age’ of the cell and its use as a predictor of organismal ‘chronological age’ 
has been suggested [102, 109, 111].  
Empirical observations in humans support the hypothesis that the average 
telomere length is inversely correlated with age [109]. Moreover reactive oxygen species 
(ROS) also cause telomere repeat loss and, since exposure to ROS is accumulative with 
age, telomere length might even be exacerbated in older individuals [112]. A number of 
other factors could potentially confound the use of telomere length. Nevertheless 
preliminary investigations by Ikeda and colleagues using bloodstains and teeth indicate 
that telomerase length estimation as an age indicator is possible with forensic specimens 
[14, 28].  
The generally accepted approach for telomere length determination involves 
terminal restriction fragment (TRF) analysis, in which DNA is enzymatically digested 
and segments detected using Southern hybridization to a probe containing the telomeric 
repeat. However, this method offers low resolution and suffers from a lack of sensitivity, 
requiring approximately 0.5 - 1 µg of human genomic DNA or more than 105 cells, (an 
almost unobtainable quantity from the common 50-µL bloodstain normally encountered 
in forensic situations), as well as the reduced ability to detect shorter telomeres [109, 
113]. In addition, TRF represents the mean telomere length of all chromosomes and 
includes the unknown length of the subtelomeric region, where the TRF value is 
dependent on the restriction site of the subtelomeric region by the restriction enzyme 
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[113]. Thus TRF does not provide information on actual telomere length. To overcome 
the downfalls of TRF analysis, two novel experimental approaches aimed at telomere 
length determination have been investigated. The first approach is based on real-time 
PCR amplification, and utilizes either the absolute quantification SYBR® Green I [56, 
114] or the relative quantification Taqman® platforms, while the second, a single 
telomere length analysis (STELA), uses a novel telomere-telorette ligation reaction [57]. 
Both technologies can determine whether accurate, high resolution ‘age of an individual’ 
estimates can be made from dried biological stains. 
Assessing Total Telomere Length by Delta Cycle Threshold Determination using 
Real-Time PCR and Telomere Specific Primers – SYBR Green I Assay 
In real-time absolute quantitative PCR, detection of product is monitored by 
measuring the increase in fluorescence caused by the binding of the SYBR Green dye to 
double-stranded DNA [115, 116]. Quantitative PCR determines, for each sample well, 
the Cycle threshold (Ct) value, i.e. the fractional cycle number at which the well’s 
accumulating fluorescence crosses a set threshold that is several standard deviations 
above baseline fluorescence [56, 117]. A recent paper by R. Cawthon measured the 
relative telomere length of an individual using a quantitative PCR approach [56]. This 
method of telomere length determination is based on measuring, for each DNA sample, 
the factor by which the “unknown” DNA sample differs from a reference DNA sample in 
its ratio of telomere repeat copy number (T), to a single copy gene number (S), thereby 
generating a final T/S ratio. The acidic ribosomal phosphoprotein PO gene, 36B4, was 
chosen as the single copy number gene due to its equal amplification in all DNA samples 
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tested [56, 118]. In theory, all samples should amplify the 36B4 single copy gene, at the 
same rate and hence, generate similar Ct values. In contrast, unknown DNA telomere 
lengths should vary between biological ages and therefore generate varying Ct values, 
corresponding to that specific samples telomere length (i.e. the younger the individual, 
longer the telomere, the lower the generated Ct value). The calculated difference in 
amplification rates between the telomere and single gene assays, the delta Ct (dCt = SCt – 
TCt), should reveal the quantity (length) of telomeres in relation to the single copy gene, 
assuming there is greater then one telomere present in each DNA sample. The calculated 
dCt values should then correlate with the biological age of the individual, whereby 
younger individuals generate larger dCt values, due to lower telomere Ct values; 
conversely, elderly individuals would generate smaller dCt values, because of increased 
telomere shortening. In our approach to relative telomere length determination, Ct values 
were generated according to the published primer and amplification specifications 
however; data interpretation consisted of calculating delta cycle threshold (dCt) values, 
instead of T/S ratios, for the standards and unknown DNA samples. 
Genomic DNA was extracted from individuals of various ages ranging from hour 
old neonates to a 91-year old elderly individual. Real-time PCR amplification was 
performed in duplicate, for both serially diluted DNA standards and the unknown 
samples of various biological ages. The average telomere length (T) and single copy gene 
number (S) values were calculated and an average delta Ct value was determined (Table 
22). Figure 45 illustrates the dCt values for each diluted standard (50 to 6.3ng) and all 
biological ages assayed (1-hour to 91-years).  
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The single copy gene, 36B4, was amplified in all samples as an internal reference 
for the delta Ct calculations. Table 22 illustrates that for the diluted DNA standards the 
36B4 and telomere Ct values increase, in correlation with decreased input DNA. Delta Ct 
analysis of the standards verify the correlation of 36B4 and telomere amplifications, 
independent of input DNA, the dCt values are relatively similar, ranging from 0.875 to 
1.620 (average 1.302 ± 0.2722). Analysis of the biologically aged blood samples revealed 
that the single gene amplification was consistent throughout, generating a range of Ct 
values from 26.580 to 32.240 (average 28.006 ± 1.4715), however, we did not detect any 
additional variation in the telomere amplification with Ct values ranging from 23.650 to 
29.395 (average 25.224 ± 1.4629). Figure 45 illustrates the calculated dCt values from 
the various biologically aged individuals and in contrast to our expectations of decreasing 
delta Ct values with increasing biological age, we actually find that the highest dCt value 
was generated by a 91-year old individual (dCt = 3.360), while a 45-year old generated 
the lowest dCt value of 2.050, while all other biological ages had dCt values in between 
the 45- and 91-year olds. 
Telomere Length Determination by Real-Time PCR Amplification using a Telomere 
Specific Probe – TaqMan Assay 
We developed a novel quantitative real-time PCR (qPCR) based assay for 
telomere length analysis of biologically aged individuals utilizing a TaqMan qPCR 
approach. This method utilizes a set of gene specific primers and a gene specific probe to 
determine the rate of amplification of a target gene sequence. Briefly, the fluorescently 
labeled oligonucleotide probe binds initially to the target DNA sequence due to its high 
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annealing temperature, followed by binding of the forward and reverse primers. As 
amplification occurs the probe is cleaved by the 5′ exonuclease activity of the polymerase 
enzyme, thereby releasing the fluorescent signal attached to the 5′ end of the probe, 
which is interpreted by the analysis software of the real-time PCR instrument. As 
amplification continues a Ct value (i.e. the fractional cycle number at which a samples 
accumulating fluorescence crosses a set threshold that is several standard deviations 
above baseline fluorescence) is generated [56, 117]. We designed two different 
primer/probe sets to specifically land-on and amplify the telomere repeats (Table 23). 
The first combination set of real-time primers and probe consisted of longer sequences 
(tel 1=37bp, tel2=39bp, tel3=31bp) and yielded a higher overall annealing temperature of 
68ºC, when compared to a second primer/probe set (tel 4=25bp, tel5=27bp, tel6=19bp), 
which was shorter in length and annealed at a lower temperature of 53ºC (Table 23). Our 
thought for developing this type of approach was that all biological ages have telomeres 
and all ages would amplify the telomeres, however if telomere length is correlated with 
age, then younger individuals would have longer telomeres, which would yield more 
fluorescent signal (due to more potential sites for primer and probe binding) and these 
samples would reach the predetermined threshold value at a lower fractional cycle 
number when compared to individuals of increasing biological age. 
Real-time PCR amplification of genomic DNA obtained from various biologically 
aged individuals yielded cycle threshold (Ct) values ranging from 8.438 to 11.243, primer 
set 1 and 5.261 to 6.911, primer set 2 (Table 23, Figure 46).  
The results in Table 23 and Figure 46, show that newborns and elderly 
individuals (1-hour, 89-years and 91-years) had the highest Ct values (mean = 9.75), 
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while all ages in between (4-, 14-, 47-, and 63-years) consistently generated lower Ct 
values (mean = 8.63). These results looked very promising, until we tested the 
primer/probe set with a non-template control (NTC) sample. It was shown that the NTC 
was able to generate a Ct value similar to the ones obtained with our DNA samples. It 
was determined that this amplification was due to primer and probe interactions, whereby 
the probe was binding to one of the primers and the TaqMan polymerase was cleaving 
the probe to release a fluorescent signal. Multiple reaction parameters were tested to try 
and overcome the NTC amplification, without success. 
Assessing the Length of Individual Telomeres using the STELA Telomere 
Amplification Reaction 
The single telomere length analysis (STELA) assay, has been developed for sizing 
the XpYp telomere, but has the potential of determining accurate telomere lengths for 
chromosomes 12q, 7q, 16q and 16p [57]. This method can successfully sizes telomeres, 
of all lengths, with as little as 250 pg template DNA. To describe the method briefly, six 
linker (‘telorettes’) comprising the seven bases with telomeric repeat homology 
(TTAGGG, TAGGGT, AGGGTT, GGGTTA, GGTTAG, and GTTAGG), followed by a 
20-basepair segment (TGCTCCGTGCATCTGGCATC) non-complementary to the 3′ 
overhang are annealed and ligated to all telomere ends. The downstream 20-basepair non-
complementary ‘telorette’ segment can then serve as a target for a PCR primer (‘teletail’). 
Chromosomal specificity is generated by using an upstream primer which is designed to 
bind in the subtelomeric region of the target chromosome. Post-amplified fragments are 
electrophoresed and visualized with nucleic acid staining on agarose gels.  
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To determine the length of the XpYp telomere in varying biological ages, we 
extracted DNA from sixteen different individuals aged 1-day (male), 1-day (female), 4-
months, 9-months, 15-months, 21-months, 8-years, 12-years, 17-years (male), 17-years 
(female), 29-years, 43-years, 56-years, 56-years, 91-years, and 92-years. We ligated each 
of the six linkers to the DNA samples and amplified each aliquot with the ‘teltail’ and 
XpYp chromosome specific primer.  
The results obtained from these experiments did not allow us to conclude that 
telomere length is correlated with biological age, based on the following results (Figure 
47). First, we found that there was inconsistent amplification of the samples between the 
linkers. For example, two of the linkers amplified fourteen of the sixteen samples 
(telorettes 1 and 6), one amplified twelve of the sixteen samples (telorette 3), while the 
three other linkers amplified only seven of the samples (telorettes 2, 4, 5). Second, the 
lengths of the amplified DNA samples did not correlate with the biological ages of the 
individuals. In linker two, a 4-month old individual had a longer telomere length then 
both of the 1-day old samples, and in linker three, the 91- and 92-year old individuals had 
longer telomeres then the 15- and 21-month old individuals. The only result that was 
semi-consistent with all of the six linkers was that, if multiple amplified products were 
produced during amplification (in a single DNA sample), their occurrence was restricted 
to the younger individuals. Overall both 1-day old, as well as the 4-month and 21-month 
old samples produced multiple amplimers, while other ages produced a single product. 
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CHAPTER FOUR: CONCLUSION 
We have identified seven biomarkers for human biological age determination. 
Through triplicate specificity studies, three of these candidate genes COL1A2, HBE1 and 
IGFBP3, were shown to be expressed at elevated levels in younger aged individuals, 
newborns, or post-pubertal individuals, respectively. Duplex real-time PCR 
amplifications were designed and developed for the individual age specific biomarkers 
with the incorporation of the ribosomal protein, S15 as an internal positive control (IPC) 
housekeeping gene. Biological age specificity results illustrated that these biomarkers are 
specific for their target age groups and further analysis will consist of complete Scientific 
Working Group on DNA Analysis Methods (SWGDAM) validation studies, including 
sensitivity, species specificity, body-fluid specificity, stability, and the ability of the 
biomarkers to determine biological age in body-fluid mixtures. 
It is estimated that up to 74% of all human genes produce more then one mRNA 
transcript [119] and given the amount of research that is conducted on the beta-
hemoglobin locus regarding the regulation and mechanism of hemoglobin gene switching 
and gene expression profiling analysis, it is not surprising that new hemoglobin genes are 
being discovered at an advanced rate. Recently, Goh and colleagues discovered a novel 
hemoglobin transcript, mu-globin, which aligned with the 3′ region of the pseudo-alpha2 
gene on chromosome 16p13.[120] Additionally, this group defined a new delta-globin 
mRNA (Alt-d), which is formed by an alternate upstream transcription initiation 
site.[121] This Alt-d transcript exhibited a restricted expression pattern being detected 
only in fetal liver, bone marrow and adult peripheral blood samples. 
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In addition to the three biomarkers listed above, we have also identified four 
novel gamma hemoglobin transcripts (HBG1n1, HBG1n2, HBG2n2 and HBG2n3) that 
exhibit restricted expression in the blood of (human) newborn children. Individual qRT-
PCR assays were developed to measure two of these transcripts in forensic specimens. 
Adjustment of the primer concentrations in the qRT-PCR reaction permitted the 
establishment of two temporally delimited assays, one of which was specific to blood 
from newborns 4-months or under (≤4 months) and the other to newborns who were 
hours old (<24 hours). Both assays may be useful in a variety of child kidnapping, assault 
and criminal abortion investigations with the latter (<24 hours) being of particular use for 
those cases involving hospital abductions.  
Validation studies on these qRT-PCR assays revealed that the HBG1n1 and 
HBG2n3 transcripts appear to be restricted to blood from newborns in the human (or at 
least, primate) lineage. The assays appear to be robust enough for forensic use, in that the 
newborn blood-specific transcripts are detectable at least up to 15 months in the dried 
state. Additionally, the sensitivity of the reactions are compatible with forensic 
applications, where only a few cell equivalents of total RNA are required (i.e. 50 pg) and 
>100ng of total RNA is recoverable from typical sized (50-ul) bloodstains [122]. The 
sensitivity of the assay is thus 50-500 cells assuming 0.1-1.0 pg total RNA per cell [123-
125]. 
Based on our results illustrating that these novel transcripts appear to be created 
by a rearrangement event occurring within exons two and three of the standard gamma 
mRNA transcripts (Figure 42), the remaining upstream and downstream gene structure 
would be preserved in all four new transcripts. These four isoforms would include ten of 
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the twelve nucleotides that form the upstream capping box, as well as the downstream 
3’hexanucleotide sequence (AATAAA) found in both gamma-hemoglobin genes and 
many eukaryotic mRNAs [126, 127]. At the present time the exact mechanism by which 
these isoforms are created is unknown, but due to the presence of four variable directly 
repeated sequences in these novel genes, a direct repeat mediated alternative splicing 
mechanism is theorized. Secondary structure analysis of the standard hemoglobin genes 
revealed the presence of a centralized multi-loop surrounded by branching stem loop 
structures. Additionally, determining if these highly regulated transcripts play a role in 
the functional development of an organism is yet to be determined. 
The location of the recombination events raised an additional question as to the 
ability of these newborn transcripts to encode proteins. Inputting the newly formed 
mRNA sequences into EditSeq translation software from DNAstar LaserGene, revealed 
that all four mRNAs contained an open reading frame (ORF), and hence contained the 
ability to encode a protein, even with partially deleted exons (Figure 43). It should be 
noted that the statistical probability of all four transcripts, each comprised of a specific 
and individual break-point sequence, forming an ORF is ~0.012 or (1/3)4. The conserved 
portions for mRNA translation and protein synthesis included an initiation start codon 
present in exon one, along with three new alternate stop codons formed by the HBG1n1, 
HBG1n2, and HBG2n3 sequences and one conserved stop codon, within the HBG2n2 
deleted sequence. Analysis of the alternate protein sequences in Figure 43 illustrated that 
the HBG1n1 and HBG1n2 sequences aligned with the standard HBG1 protein from AA1-
80 and AA1-75, respectively, and both had the entire C-terminal region of the HBG1 
protein deleted. The recombination region of the HBG1n2 transcript brings its reading 
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frame a single nucleotide in front of the termination codon of the HBG1 sequence and 
due to its alternate reading frame, the ORF continues into the 3’ UTR of the HBG1 
sequence. In the HBG1n1 isoform the downstream pentanucleotide recombining region 
occurs in the 3’ UTR of exon 3, and the encoded protein has a similar C-terminal 
sequence to the HBG1n2 isoform. Analysis of the G-gamma isoforms revealed that 
HBG2n2 aligns with the HBG2 sequence in the N-terminal region from amino acids 1-
86, and rejoins in the C-terminal region encoding the final six amino acids of the 
hemoglobin proteins. In contrast to the other isoforms, the HBG2n3 sequence creates a 
stop codon immediately after the recombination event, to generate a truncated protein of 
only 92 amino acids. At the present time, it is unknown whether proteins are actually 
being produced from these novel transcripts, however further analysis of these isoforms 
will consist of an immunoassay for the detection of the potentially encoded truncated 
proteins, in addition to transcript verification in newborn blood and select fetal tissues, by 
RNA specific northern blot examination.  
We have reported on the detection of seven mRNA transcripts whose expression 
levels are increased during specific developmental stages of the human lifecycle. 
Forensic real-time PCR assays have been designed, developed and optimized for facile 
sample analysis and biological age determination of newborns, younger aged individuals 
and post-pubertal populations. These assays therefore provide investigators additional 
probative information, in addition to the genetic profile of an individual, concerning the 
physical characteristic of biological age. 
 70
APPENDIX A: FIGURES 
 71
  
Figure 1: Two-Cycle cRNA Preparation Scheme for AFFYMETRIX GeneChip 
Hybridization. 
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  R = (PM - MM) / (PM + MM)    
               
               
  80 80 80 80 80 80 80 80 80 80    
 PM                        
 MM                        
  10 20 30 40 50 60 70 80 90 100    
Probe               
Pairs:  1 2 3 4 5 6 7 8 9 10    
               
               
 Probe Pairs PM score MM score R value   
 1 80 10 0.7778   
 2 80 20 0.6000   
 3 80 30 0.4545   
 4 80 40 0.3333   
 5 80 50 0.2308   
 6 80 60 0.1429   
 7 80 70 0.0667   
 8 80 80 0.0000   
 9 80 90 -0.0588   
 10 80 100 -0.1111   



















































































































































Figure 13: Amplification Results of the POLM Candidate Gene. 
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Figure 14: Real-Time PCR Candidate Gene Amplification Results. 
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Figure 16: Real-Time PCR Duplex Delta Ct Results. 
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Figure 18: COL1A2 Real-Time PCR Duplex Delta Ct Results. 
 111
 Average of all Samples per age group 
Average SD Average SD Average SD   Age Group 
(GOI) (GOI) (S15) (S15) (dCt) (dCt) n= 
Newborns & Infants 41.378 2.489 48.126 2.882 6.748 4.185 20 
Toddlers & Children 46.928 4.008 43.948 2.497 -2.980 5.020 31 
Juveniles, Adults,     
Middle-age & Elderly 48.751 2.491 43.921 2.052 -4.830 3.681 58 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
Figure 19: Newborn Candidate COL1A2 qPCR Duplex Biological Age Specificity. 
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Figure 21: HBE1 Real-Time PCR Duplex Delta Ct Results. 
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 Average of all Samples per age group 
Average SD Average SD Average SD   Age Group 
(GOI) (GOI) (S15) (S15) (dCt) (dCt) n= 
Newborns 30.750 2.270 33.838 1.531 3.088 2.523 17 
Infant, Toddlers, Children, Juveniles, 
Adults 36.189 0.338 33.210 0.275 -2.978 0.302 81 
Middle-age & Elderly 34.994 0.317 33.646 0.324 -1.348 0.330 41 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
Figure 22: Newborn Candidate HBE1 qPCR Duplex Biological Age Specificity. 
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Figure 23: IGFBP3 Real-Time PCR Singleplex Candidate Results. 
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Figure 24: IGFBP3 Real-Time PCR Duplex Delta Ct Results. 
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 Average of all Samples per age group 
Average SD Average SD Average SD   Age Group 
(GOI) (GOI) (S15) (S15) (dCt) (dCt) n= 
Newborns, Infants & Toddlers 45.298 5.576 35.384 1.131 -9.914 5.402 33 
Children & Juveniles 39.604 5.033 35.396 1.818 -4.208 4.260 23 
Adults, Mid-age & Elderly 36.914 3.143 36.189 1.331 -0.725 2.637 67 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 




Figure 26: Structure of the Human Beta-Hemoglobin Locus. 
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Figure 29: RT-PCR Amplification of Four Newborn-Specific Gene Transcripts. 
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Figure 30: RT-PCR Based Age Specificity of the HBG1n1 and HBG2n3 Transcripts. 
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Figure 33: Biological Age Specificity of the HBG1n1 and HBG2n3 qRT-PCR Assays. 
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Figure 35: Human Specificity for the qPCR Newborn Duplexes 
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Figure 39: Hemoglobin Expression Patterns in Fetal Tissues. 
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 Figure 40: Hemoglobin Expression Patterns in Adult Tissues. 
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Figure 41: Postulated Rearrangement Mechanisms for the Formation of the Novel 
Newborn Specific Gamma Hemoglobin Transcripts. 
 134





















Figure 47: STELA Telomere Amplification. 
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APPENDIX B: TABLES 
 141
 Table 1: Extracted RNA Samples for mRNA Profiling Analysis. 
 
Age Group Biological Age Total Samples          #                      % 
Newborns 1 hour - 3 months 18 12.24 
Infants 4 months - 9 months 13 8.84 
Toddlers 10 months - 3 years 12 8.16 
Children 4 years - 12 years 13 8.84 
Juveniles 13 years - 18 years 15 10.20 
Adults 19 years - 45 years 30 20.41 
Middle-age 46 years - 65 years 21 14.29 
Elderly 66 years - 102 years 25 17.01 










Accepted Candidates   
#                    % 
Rejected Candidates   
#                    % 
Newborns Affymetrix 20 2 10.00 18 90.00 
  Literature 16 7 43.75 9 56.25 
Juveniles Affymetrix 63 2 3.17 61 96.83 
  Literature 43 5 11.63 38 88.37 
Adults Affymetrix 0 0 0.00 0 0.00 
  Literature 6 0 0.00 6 100.00 
Elderly Affymetrix 28 2 7.14 26 92.86 
  Literature 143 8 5.59 135 94.41 
Totals   319 26 8.15 293 91.85 
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 Table 3: Summary and Explanation of Rejected Candidates from RT-PCR Analysis. 
 
A           
   Rejected Explaination 















mRNA Expressed    
in All Ages 
mRNA Expressed 
Sporadically 
      # % # % # % # % 
Newborns 20 18 1 5.6 11 61.1 6 33.3 0 0.0 
Juveniles 63 61 17 27.9 11 18.0 22 36.1 11 18.0 
Elderly 28 26 1 3.8 5 19.2 9 34.6 11 42.3 
Totals 111 105 19 6.0 27 8.5 37 11.6 22 6.9 
           
           
           
           
           
           
B           
   Rejected Explaination 












Same Size       
mRNA and 
DNA 
mRNA Expressed    
in All Ages 
mRNA Expressed 
Sporadically 
      # % # % # % # % 
Newborns 16 9 3 33.3 0 0.0 3 33.3 3 33.3 
Juveniles 43 38 19 50.0 3 7.9 3 7.9 13 34.2 
Adults 6 6 0 0.0 0 0.0 4 66.7 2 33.3 
Elderly 143 135 27 20.0 0 0.0 81 60.0 27 20.0 
Totals 208 188 49 15.4 3 0.9 91 28.5 45 14.1 
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 Table 4: Real-Time PCR Cycle Threshold Values for Candidate Gene Biological Age 
Testing. 
 
CDC2-Initial Amplification   CDC2-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 37.624 Child +RT M 9y 9.000 38.501 
Newborn -RT       Undet Child -RT       Undet 
Newborn +RT M 3m 0.250 36.091 Juvenile +RT M 15y 15.000 30.782 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT M 8m 0.667 35.623 Adult +RT F 31y 31.000 36.003 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 2y 2.000 36.085 Middle-Age +RT F 58y 58.000 38.134 
Toddler -RT       Undet Middle-Age -RT       Undet 
Child +RT M 4y 4.000 35.065 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT M 5y 5.000 34.271 NTC      Undet 
Child -RT       Undet NTC       Undet 
 
POLQ-Initial Amplification   POLQ-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 3m 0.250 35.634 Middle-Age +RT M 57y 57.000 36.809 
Newborn -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 2y 2.000 36.024 Elderly +RT F 66y 66.000 35.446 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT M 4y 4.000 34.012 Elderly +RT M 79y 79.000 35.209 
Child -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 13y 13.000 36.736 Elderly +RT F 89y 89.000 36.648 
Juvenile -RT       Undet Elderly -RT       Undet 
Adult +RT F 31y 31.000 35.004 DNA     Undet 
Adult -RT       Undet DNA       Undet 
Adult +RT F 40y 40.000 37.099 NTC     Undet 
Adult -RT       Undet NTC       Undet 
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 SRC-Initial Amplification    SRC-Initial Amplification    
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 38.635 Adult +RT F 40y 40.000 36.666 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT F 8d 0.022 34.962 Middle-Age +RT M 57y 57.000 36.769 
Newborn -RT       Undet Middle-Age -RT       Undet 
Newborn +RT M 3m 0.250 36.649 Elderly +RT F 66y 66.000 35.986 
Newborn -RT       Undet Elderly -RT       Undet 
Child +RT M 4y 4.000 35.684 Elderly +RT M 79y 79.000 37.333 
Child -RT       Undet Elderly -RT       Undet 
Juvenile +RT F 16y 16.000 36.712 DNA     Undet 
Juvenile -RT       3.000 DNA       Undet 
Adult +RT F 31y 31.000 37.135 NTC     Undet 
Adult -RT       Undet NTC       Undet 
 
LOH11CR2A-Initial Amplification  LOH11CR2A-Initial Amplification  
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 38.690 Adult +RT F 38y 38.000 38.227 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT M 2m 0.167 36.469 Middle-Age +RT F 53y 53.000 40.000 
Newborn -RT       Undet Middle-Age -RT       Undet 
Infant +RT M 8m 0.667 40.000 Middle-Age +RT F 63y 63.000 34.774 
Infant -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 18m 1.500 34.846 Elderly +RT F 71y 71.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT F 3y 3.000 34.157 Elderly +RT M 79y 79.000 34.505 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT M 5y 5.000 34.840 Elderly +RT M 89y 89.000 35.656 
Child -RT       Undet Elderly -RT       Undet 
Child +RT F 12y 12.000 36.659 DNA      Undet 
Child -RT       Undet DNA       Undet 
Juvenile +RT M 14y 14.000 36.144 NTC      Undet 
Juvenile -RT       Undet NTC       Undet 
Juvenile +RT F 16y 16.000 38.224      
Juvenile -RT       Undet      
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 ASL-Initial Amplification    ASL-Initial Amplification    
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.00274 36.386 Elderly +RT F 68y 68 40.244 
Newborn -RT       Undet Elderly -RT       Undet 
Newborn +RT F 17d 0.04658 34.818 Elderly +RT M 71y 71 37.519 
Newborn -RT       Undet Elderly -RT       Undet 
Infant +RT M 4m 0.33333 35.006 Elderly +RT M 74y 74 39.472 
Infant -RT       Undet Elderly -RT       Undet 
Toddler +RT M 10m 0.83333 33.996 Elderly +RT F 76y 76 38.187 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT F 3y 3 33.986 Elderly +RT F 81y 81 36.569 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT M 6y 6 34.661 Elderly +RT F 84y 84 34.954 
Child -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 14y 14 34.601 Elderly +RT M 89y 89 35.069 
Juvenile -RT       Undet Elderly -RT       Undet 
Juvenile +RT F 18y 18 35.188 Elderly +RT F 89y 89 36.139 
Juvenile -RT       Undet Elderly -RT       Undet 
Adult +RT M 29y 29 34.702 Elderly +RT F 91y 91 33.912 
Adult -RT       Undet Elderly -RT       Undet 
Adult +RT M 36y 36 36.078 Elderly +RT M 92y 92 35.481 
Adult -RT       Undet Elderly -RT       Undet 
Middle-Age +RT F 47y 47 36.137 Elderly +RT F 102y 102 32.619 
Middle-Age -RT       Undet Elderly -RT       Undet 
Middle-Age +RT M 59y 59 36.028 DNA      Undet 
Middle-Age -RT       Undet DNA       Undet 
Middle-Age +RT M 65y 65 38.008 NTC      Undet 
Middle-Age -RT       Undet NTC       Undet 
 
FLJ20344a-Initial Amplification   FLJ20344a-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 38.105 Adult +RT M 24y 24.000 40.000 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT F 1m 0.083 40.000 Adult +RT M 45y 45.000 38.559 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT M 2m 0.167 38.601 Middle-Age +RT F 60y 60.000 40.000 
Newborn -RT       Undet Middle-Age -RT       Undet 
Newborn +RT M 3m 0.250 39.272 Elderly +RT M 72y 72.000 40.000 
Newborn -RT       Undet Elderly -RT       Undet 
Infant +RT M 8m 0.667 40.000 Elderly +RT M 79y 79.000 40.000 
Infant -RT       Undet Elderly -RT       Undet 
Toddler +RT M 18m 1.500 38.428 Elderly +RT M 89y 89.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT F 3y 3.000 37.314 DNA     Undet 
Toddler -RT       Undet DNA       Undet 
Child +RT M 9y 9.000 40.000 NTC     Undet 
Child -RT       Undet NTC       Undet 
Juvenile +RT F 15y 15.000 40.000      
Juvenile -RT       Undet      
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 LOC151194-Initial Amplification  LOC151194-Initial Amplification  
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 35.389 Adult +RT M 24y 24.000 35.985 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT F 1m 0.083 33.941 Adult +RT M 45y 45.000 34.896 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT M 2m 0.167 36.287 Middle-Age +RT F 60y 60.000 34.940 
Newborn -RT       Undet Middle-Age -RT       Undet 
Newborn +RT M 3m 0.250 33.668 Elderly +RT M 72y 72.000 36.263 
Newborn -RT       Undet Elderly -RT       Undet 
Infant +RT M 8m 0.667 36.086 Elderly +RT M 79y 79.000 35.814 
Infant -RT       Undet Elderly -RT       Undet 
Toddler +RT M 18m 1.500 33.588 Elderly +RT M 89y 89.000 35.402 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT F 3y 3.000 32.604 DNA      Undet 
Toddler -RT       Undet DNA       Undet 
Child +RT M 9y 9.000 37.770 NTC      Undet 
Child -RT       Undet NTC       Undet 
Juvenile +RT F 15y 15.000 33.916      
Juvenile -RT       Undet      
 
SPTRX-1-Initial Amplification   SPTRX-1-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 40.000 Child +RT M 12y 12.000 37.864 
Newborn -RT       Undet Child -RT       Undet 
Newborn +RT F 1m 0.083 36.830 Juvenile +RT M 14y 14.000 40.000 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 3m 0.250 40.000 Juvenile +RT F 16y 16.000 40.000 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT F 5m 0.417 38.430 Juvenile +RT F 18y 18.000 36.509 
Infant -RT       Undet Juvenile -RT       Undet 
Infant +RT F 7m 0.583 40.000 Adult +RT F 31y 31.000 38.579 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 14m 1.167 40.000 Adult +RT F 40y 40.000 36.566 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 19m 1.583 40.000 Middle-Age +RT F 53y 53.000 40.000 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 2y 2.000 38.097 Elderly +RT M 66y 66.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 2.8y 2.800 39.197 Elderly +RT M 79y 79.000 37.852 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 3y 3.000 40.000 Elderly +RT M 89y 89.000 38.282 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT F 4y 4.000 40.000 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT F 6y 6.000 38.382 NTC      Undet 
Child -RT       Undet NTC       Undet 
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 SPTRX-2-Initial Amplification   SPTRX-2-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 40.000 Child +RT M 12y 12.000 35.984 
Newborn -RT       Undet Child -RT       Undet 
Newborn +RT F 1m 0.083 33.052 Juvenile +RT M 14y 14.000 37.840 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 3m 0.250 35.297 Juvenile +RT F 16y 16.000 37.005 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT F 5m 0.417 37.869 Juvenile +RT F 18y 18.000 36.661 
Infant -RT       Undet Juvenile -RT       Undet 
Infant +RT F 7m 0.583 36.700 Adult +RT F 31y 31.000 35.858 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 14m 1.167 38.775 Adult +RT F 40y 40.000 35.364 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 19m 1.583 35.808 Middle-Age +RT F 53y 53.000 40.000 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 2y 2.000 35.584 Elderly +RT M 66y 66.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 2.8y 2.800 36.214 Elderly +RT M 79y 79.000 35.581 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 3y 3.000 35.656 Elderly +RT M 89y 89.000 36.067 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT F 4y 4.000 40.000 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT F 6y 6.000 34.290 NTC      Undet 
Child -RT       Undet NTC       Undet 
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 POX-Initial Amplification    PPOX-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 35.933 Child +RT M 12y 12.000 38.058 
Newborn -RT       Undet Child -RT       Undet 
Newborn +RT F 1m 0.083 34.208 Juvenile +RT M 14y 14.000 39.812 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 3m 0.250 36.860 Juvenile +RT F 16y 16.000 40 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT F 5m 0.417 37.395 Juvenile +RT F 18y 18.000 37.258 
Infant -RT       Undet Juvenile -RT       Undet 
Infant +RT F 7m 0.583 36.486 Adult +RT F 31y 31.000 36.979 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 14m 1.167 39.953 Adult +RT F 40y 40.000 37.760 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 19m 1.583 37.035 Middle-Age +RT F 53y 53.000 40.000 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 2y 2.000 38.196 Elderly +RT M 66y 66.000 38.938 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 2.8y 2.800 36.802 Elderly +RT M 79y 79.000 37.102 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 3y 3.000 38.285 Elderly +RT M 89y 89.000 36.681 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT F 4y 4.000 40.000 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT F 6y 6.000 38.750 NTC      Undet 
Child -RT       Undet NTC       Undet 
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 TBC1-Initial Amplification    TBC1-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 40.000 Child +RT M 12y 12.000 39.450 
Newborn -RT       Undet Child -RT       Undet 
Newborn +RT F 1m 0.083 38.617 Juvenile +RT M 14y 14.000 40.000 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 3m 0.250 38.384 Juvenile +RT F 16y 16.000 40.000 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT F 5m 0.417 37.573 Juvenile +RT F 18y 18.000 36.475 
Infant -RT       Undet Juvenile -RT       Undet 
Infant +RT F 7m 0.583 35.573 Adult +RT F 31y 31.000 34.083 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 14m 1.167 39.714 Adult +RT F 40y 40.000 37.052 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 19m 1.583 38.165 Middle-Age +RT F 53y 53.000 40.000 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 2y 2.000 39.001 Elderly +RT M 66y 66.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 2.8y 2.800 39.849 Elderly +RT M 79y 79.000 38.653 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 3y 3.000 39.397 Elderly +RT M 89y 89.000 38.521 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT F 4y 4.000 36.400 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT F 6y 6.000 36.597 NTC      Undet 
Child -RT       Undet NTC       Undet 
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 TEKT2-Initial Amplification   TEKT2-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 40.000 Child +RT M 12y 12.000 40.000 
Newborn -RT       Undet Child -RT       Undet 
Newborn +RT F 1m 0.083 39.304 Juvenile +RT M 14y 14.000 39.077 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 3m 0.250 40.000 Juvenile +RT F 16y 16.000 40.000 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT F 5m 0.417 36.439 Juvenile +RT F 18y 18.000 40.000 
Infant -RT       Undet Juvenile -RT       Undet 
Infant +RT F 7m 0.583 40.000 Adult +RT F 31y 31.000 40.000 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 14m 1.167 40.000 Adult +RT F 40y 40.000 40.000 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 19m 1.583 39.248 Middle-Age +RT F 53y 53.000 40.000 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 2y 2.000 39.447 Elderly +RT M 66y 66.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 2.8y 2.800 38.297 Elderly +RT M 79y 79.000 39.257 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 3y 3.000 40.000 Elderly +RT M 89y 89.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT F 4y 4.000 40.000 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT F 6y 6.000 39.312 NTC      Undet 
Child -RT       Undet NTC       Undet 
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 PRL-Initial Amplification    PRL-Initial Amplification    
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 40.000 Child +RT M 12y 12.000 38.363 
Newborn -RT       Undet Child -RT       Undet 
Newborn +RT F 1m 0.083 35.424 Juvenile +RT M 14y 14.000 40.000 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 3m 0.250 40.000 Juvenile +RT F 16y 16.000 40.000 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT F 5m 0.417 38.798 Juvenile +RT F 18y 18.000 38.633 
Infant -RT       Undet Juvenile -RT       Undet 
Infant +RT F 7m 0.583 35.407 Adult +RT F 31y 31.000 40.000 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 14m 1.167 38.126 Adult +RT F 40y 40.000 40.000 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 19m 1.583 38.244 Middle-Age +RT F 53y 53.000 40.000 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 2y 2.000 37.261 Elderly +RT M 66y 66.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 2.8y 2.800 40.000 Elderly +RT M 79y 79.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 3y 3.000 40.000 Elderly +RT M 89y 89.000 40.000 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT F 4y 4.000 40.000 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT F 6y 6.000 38.700 NTC      Undet 
Child -RT       Undet NTC       Undet 
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 Table 5: Real-Time PCR First Round Candidate Results.  
 
AGGF1-Initial Amplification   AGGF1-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 37.910 Juvenile +RT M 17y 17.000 40.226 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT F 8d 0.022 34.738 Juvenile +RT M 18y 18.000 38.078 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT F 3m 0.250 35.838 Adult +RT M 23y 23.000 40.220 
Newborn -RT       Undet Adult -RT       Undet 
Infant +RT F 6m 0.500 36.086 Adult +RT F 31y 31.000 38.075 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 10m 0.833 37.095 Adult +RT F 38y 38.000 37.850 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 21m 1.750 35.942 Middle-Age +RT F 47y 47.000 36.699 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 3y 3.000 36.747 Middle-Age +RT F 56y 56.000 39.024 
Toddler -RT       Undet Middle-Age -RT       Undet 
Child +RT M 5y 5.000 35.635 Middle-Age +RT M 63y 63.000 40.325 
Child -RT       Undet Middle-Age -RT       Undet 
Child +RT F 9y 9.000 38.361 Elderly +RT F 69y 69.000 39.531 
Child -RT       Undet Elderly -RT       Undet 
Child +RT M 12y 12.000 37.210 Elderly +RT M 74y 74.000 38.497 
Child -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 13y 13.000 36.632 Elderly +RT M 83y 83.000 41.200 
Juvenile -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 13y 13.000 36.616 Elderly +RT F 89y 89.000 37.350 
Juvenile -RT       Undet Elderly -RT       Undet 
Juvenile +RT F 14y 14.000 35.855 Elderly +RT M 92y 92.000 38.659 
Juvenile -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 14y 14.000 37.084 DNA      Undet 
Juvenile -RT       Undet DNA       Undet 
Juvenile +RT F 15y 15.000 36.552 NTC      Undet 
Juvenile -RT       Undet NTC       Undet 
Juvenile +RT M 16y 16.000 36.262      
Juvenile -RT       Undet      
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 MAD1L1-Initial Amplification   MAD1L1-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 33.859 Juvenile +RT M 17y 17.000 38.530 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 1m 0.083 32.639 Adult +RT M 19y 19.000 32.931 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT M 2m 0.167 32.352 Adult +RT M 24y 24.000 32.286 
Newborn -RT       Undet Adult -RT       Undet 
Infant +RT M 5m 0.417 32.101 Adult +RT F 31y 31.000 32.262 
Infant -RT       Undet Adult -RT       Undet 
Infant +RT F 9m 0.750 31.655 Adult +RT M 38y 38.000 32.485 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 15m 1.250 32.464 Adult +RT M 45y 45.000 32.100 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 21m 1.750 31.636 Middle-Age +RT M 51y 51.000 32.777 
Toddler -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 3y 3.000 34.260 Middle-Age +RT F 58y 58.000 33.705 
Toddler -RT       Undet Middle-Age -RT       Undet 
Child +RT M 4y 4.000 31.075 Elderly +RT M 65y 65.000 33.602 
Child -RT       Undet Elderly -RT       Undet 
Child +RT F 4y 4.000 33.428 Elderly +RT F 71y 71.000 36.551 
Child -RT       Undet Elderly -RT       Undet 
Child +RT M 6y 6.000 32.105 Elderly +RT F 76y 76.000 33.497 
Child -RT       Undet Elderly -RT       Undet 
Child +RT F 9y 9.000 34.052 Elderly +RT M 83y 83.000 34.930 
Child -RT       Undet Elderly -RT       Undet 
Child +RT M 12y 12.000 32.586 Elderly +RT F 91y 91.000 33.187 
Child -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 13y 13.000 34.398 DNA      Undet 
Juvenile -RT       Undet DNA       Undet 
Juvenile +RT M 14y 14.000 32.349 NTC      Undet 
Juvenile -RT       Undet NTC       Undet 
Juvenile +RT M 15y 15.000 32.451      
Juvenile -RT       Undet      
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 PDCD6-Initial Amplification   PDCD6-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 32.705 Adult +RT F 35y 35.000 33.250 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT M 13d 0.036 32.089 Adult +RT M 38y 38.000 32.048 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT M 1m 0.083 29.960 Adult +RT F 43y 43.000 33.073 
Newborn -RT       Undet Adult -RT       Undet 
Newborn +RT M 2m 0.167 31.676 Middle-Age +RT M 47y 47.000 32.093 
Newborn -RT       Undet Middle-Age -RT       Undet 
Infant +RT M 5m 0.417 31.088 Middle-Age +RT F 53y 53.000 38.182 
Infant -RT       Undet Middle-Age -RT       Undet 
Infant +RT F 9m 0.750 30.036 Middle-Age +RT M 59y 59.000 33.505 
Infant -RT       Undet Middle-Age -RT       Undet 
Toddler +RT M 15m 1.250 32.980 Elderly +RT M 65y 65.000 32.479 
Toddler -RT       Undet Elderly -RT       Undet 
Toddler +RT M 2.8y 2.800 33.405 Elderly +RT F 68y 68.000 31.293 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT M 4y 4.000 29.344 Elderly +RT F 71y 71.000 31.672 
Child -RT       Undet Elderly -RT       Undet 
Child +RT M 8y 8.000 31.188 Elderly +RT F 76y 76.000 33.004 
Child -RT       Undet Elderly -RT       Undet 
Child +RT M 12y 12.000 32.183 Elderly +RT F 81y 81.000 33.258 
Child -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 15y 15.000 29.442 Elderly +RT M 86y 86.000 32.128 
Juvenile -RT       Undet Elderly -RT      Undet 
Adult +RT M 19y 19.000 30.664 Elderly +RT F 91y 91.000 29.600 
Adult -RT      Undet Elderly -RT       Undet 
Adult +RT M 24y 24.000 30.230 DNA       Undet 
Adult -RT       Undet DNA       Undet 
Adult +RT M 29y 29.000 30.743 NTC      Undet 
Adult -RT       Undet NTC       Undet 
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 PPARD-Initial Amplification   PPARD-Initial Amplification   
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 34.078 Juvenile +RT F 35y 35.000 34.372 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 1m 0.083 33.044 Juvenile +RT M 40y 40.000 33.203 
Newborn -RT       Undet Juvenile -RT       Undet 
Newborn +RT M 2m 0.167 32.827 Juvenile +RT M 45y 45.000 32.760 
Newborn -RT       Undet Juvenile -RT       Undet 
Infant +RT M 5m 0.417 31.710 Adult +RT M 51y 51.000 33.782 
Infant -RT       Undet Adult -RT       Undet 
Infant +RT F 9m 0.750 32.254 Adult +RT M 56y 56.000 34.921 
Infant -RT       Undet Adult -RT       Undet 
Toddler +RT M 15m 1.250 32.690 Adult +RT M 61y 61.000 33.688 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT F 21m 1.750 32.060 Adult +RT M 65y 65.000 33.723 
Toddler -RT       Undet Adult -RT       Undet 
Toddler +RT M 3y 3.000 34.412 Adult +RT F 71y 71.000 36.565 
Toddler -RT       Undet Adult -RT       Undet 
Child +RT M 5y 5.000 31.771 Middle-Age +RT F 76y 76.000 33.450 
Child -RT       Undet Middle-Age -RT       Undet 
Child +RT F 9y 9.000 34.561 Middle-Age +RT M 83y 83.000 37.131 
Child -RT       Undet Middle-Age -RT       Undet 
Child +RT M 14y 14.000 32.793 Elderly +RT F 91y 91.000 34.315 
Child -RT       Undet Elderly -RT       Undet 
Child +RT M 19y 19.000 33.232 DNA      Undet 
Child -RT       Undet DNA       Undet 
Child +RT M 24y 24.000 32.705 NTC      Undet 
Child -RT       Undet NTC       Undet 
Juvenile +RT F 31y 31.000 32.767      
Juvenile -RT       Undet      
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 Table 6: Real-Time PCR Duplex Delta Ct Results. 
 
AGGF1-S15 Titration    
Sample # Age Ct (GOI) Ct (S15) dCt Value 
Newborn +RT 1h 47.528 34.531 -12.997 
Newborn +RT 1m 42.358 32.725 -9.633 
Infant +RT 6m 42.544 33.715 -8.829 
Toddler +RT 14m 44.931 34.623 -10.308 
Child +RT 4y 45.015 36.543 -8.472 
Child +RT 12y 41.466 33.554 -7.912 
Juvenile +RT 17y 43.514 35.548 -7.966 
Adult +RT 21y 45.017 34.108 -10.909 
Adult +RT 25y 45.128 35.476 -9.652 
Adult +RT 31y 42.238 32.956 -9.282 
Adult +RT 36y 41.610 32.429 -9.181 
Adult +RT 40y 40.757 34.752 -6.005 
Adult +RT 45y 47.069 34.282 -12.787 
Middle-Age +RT 49y 50.000 37.761 -12.239 
Middle-Age +RT 53y 46.929 33.922 -13.007 
Middle-Age +RT 57y 44.332 32.686 -11.646 
Middle-Age +RT 60y 43.396 33.649 -9.747 
Middle-Age +RT 63y 48.022 33.334 -14.688 
Elderly +RT 66y 43.165 33.929 -9.236 
Elderly +RT 69y 44.958 35.218 -9.740 
Elderly +RT 72y 44.568 32.998 -11.570 
Elderly +RT 74y 47.145 35.558 -11.587 
Elderly +RT 76y 45.374 35.630 -9.744 
Elderly +RT 79y 48.204 21.633 -26.571 
Elderly +RT 81y 44.638 27.282 -17.356 
Elderly +RT 84y 40.969 34.405 -6.564 
Elderly +RT 86y 45.564 33.270 -12.294 
Elderly +RT 89y 44.987 33.242 -11.745 
Elderly +RT 91y 39.628 32.059 -7.569 
Elderly +RT 92y 44.128 34.138 -9.990 
Elderly +RT 102y 40.475 33.270 -7.205 
DNA   50.000 50.000 0.000 
NTC   50.000 50.000 0.000 
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 MAD1L1-S15 Titration    MAD1L1-S15 Titration    













Newborn +RT 1h 34.657 33.184 -1.473 Adult +RT 36y 33.486 33.820 0.334 
Newborn +RT 1h 33.066 32.755 -0.311 Adult +RT 36y 33.289 33.195 -0.094 
Newborn +RT 2d 36.374 34.912 -1.462 Adult +RT 38y 32.470 32.599 0.129 
Newborn +RT 8d 31.072 31.727 0.655 Adult +RT 40y 32.029 33.245 1.216 
Newborn +RT 17d 31.434 30.577 -0.857 Adult +RT 40y 32.114 33.744 1.630 
Newborn +RT 1m 32.413 33.488 1.075 Adult +RT 43y 34.106 34.803 0.697 
Newborn +RT 1m 30.697 31.740 1.043 Adult +RT 43y 33.830 34.155 0.325 
Newborn +RT 2m 33.176 33.156 -0.020 Adult +RT 45y 33.346 32.395 -0.951 
Newborn +RT 3m 32.052 33.406 1.354 Elderly +RT 46y 35.252 37.904 2.652 
Infant +RT 4m 33.452 33.402 -0.050 Elderly -RT 47y 35.807 36.876 1.069 
Infant +RT 5m 31.633 31.706 0.073 Middle-Age +RT 47y 33.711 34.854 1.143 
Infant +RT 7m 32.866 33.304 0.438 Middle-Age +RT 49y 37.889 40.000 2.111 
Infant +RT 9m 34.490 34.519 0.029 Middle-Age +RT 51y 35.641 39.000 3.359 
Toddler +RT 10m 31.316 33.520 2.204 Middle-Age +RT 53y 35.006 34.468 -0.538 
Toddler +RT 14m 33.411 34.015 0.604 Middle-Age +RT 53y 32.477 32.521 0.044 
Toddler +RT 18m 32.456 33.363 0.907 Middle-Age +RT 56y 34.712 35.610 0.898 
Toddler +RT 21m 32.736 33.922 1.186 Middle-Age +RT 56y 32.791 33.674 0.883 
Toddler +RT 2y 32.733 33.921 1.188 Middle-Age +RT 57y 33.684 34.341 0.657 
Toddler +RT 3y 32.592 32.248 -0.344 Middle-Age +RT 58y 33.345 33.724 0.379 
Child +RT 4y 31.477 32.272 0.795 Middle-Age +RT 60y 32.946 33.010 0.064 
Child +RT 4y 32.245 34.458 2.213 Middle-Age +RT 61y 32.485 33.306 0.821 
Child +RT 5y 31.107 31.242 0.135 Middle-Age +RT 63y 33.063 31.862 -1.201 
Child +RT 6y 34.500 34.311 -0.189 Middle-Age +RT 63y 32.158 31.917 -0.241 
Child +RT 8y 34.194 34.962 0.768 Elderly +RT 65y 33.872 33.400 -0.472 
Child +RT 9y 34.143 34.754 0.611 Elderly +RT 66y 32.819 33.518 0.699 
Child +RT 9y 33.163 34.156 0.993 Elderly +RT 68y 32.226 33.876 1.650 
Child +RT 12y 33.774 34.448 0.674 Elderly +RT 68y 33.649 34.080 0.431 
Child +RT 12y 32.587 33.080 0.493 Elderly +RT 69y 33.235 33.290 0.055 
Juvenile +RT 13y 33.190 31.698 -1.492 Elderly +RT 71y 33.436 32.865 -0.571 
Juvenile +RT 14y 33.060 32.323 -0.737 Elderly +RT 71y 34.692 33.247 -1.445 
Juvenile +RT 14y 32.396 32.899 0.503 Elderly +RT 72y 34.417 34.376 -0.041 
Juvenile +RT 15y 32.993 33.420 0.427 Elderly +RT 74y 33.026 33.457 0.431 
Juvenile +RT 15y 32.454 31.812 -0.642 Elderly +RT 76y 33.171 32.944 -0.227 
Juvenile +RT 16y 33.574 33.288 -0.286 Elderly +RT 76y 35.582 34.907 -0.675 
Juvenile +RT 16y 32.666 32.948 0.282 Elderly +RT 79y 34.132 34.388 0.256 
Juvenile +RT 17y 33.963 33.686 -0.277 Elderly +RT 80y 32.481 33.025 0.544 
Juvenile +RT 18y 33.975 34.138 0.163 Elderly +RT 81y 35.783 37.165 1.382 
Adult +RT 19y 33.151 33.562 0.411 Elderly +RT 83y 35.448 34.711 -0.737 
Adult +RT 21y 37.224 37.556 0.332 Elderly +RT 84y 31.489 32.333 0.844 
Adult +RT 23y 32.736 33.045 0.309 Elderly +RT 84y 34.094 33.945 -0.149 
Adult +RT 24y 31.290 32.101 0.811 Elderly +RT 86y 32.868 32.549 -0.319 
Adult +RT 25y 33.915 33.319 -0.596 Elderly +RT 89y 33.992 35.399 1.407 
Adult +RT 27y 33.964 34.138 0.174 Elderly +RT 89y 33.943 34.345 0.402 
Adult +RT 29y 33.441 32.180 -1.261 Elderly +RT 91y 32.281 32.060 -0.221 
Adult +RT 29y 32.816 33.583 0.767 Elderly +RT 92y 32.169 32.246 0.077 
Adult +RT 31y 32.110 32.224 0.114 Elderly +RT 102y 32.414 31.917 -0.497 
Adult +RT 35y 35.361 35.799 0.438 DNA   40.000 40.000 0.000 
Adult +RT 35y 33.675 34.706 1.031 NTC   40.000 40.000 0.000 
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 PDCD6-S15 Titration    PDCD6-S15 Titration    
Sample # Age Ct (GOI) Ct (S15) dCt Value Sample # Age Ct (GOI) Ct (S15) dCt Value 
Newborn +RT 1h 34.342 34.266 -0.076 Adult +RT 36y 35.388 34.184 -1.204 
Newborn +RT 1h 34.692 33.921 -0.771 Adult +RT 36y 35.932 35.482 -0.450 
Newborn +RT 2d 37.965 35.505 -2.460 Adult +RT 38y 33.189 32.762 -0.427 
Newborn +RT 8d 31.603 32.549 0.946 Adult +RT 40y 32.015 34.236 2.221 
Newborn +RT 17d 33.914 35.286 1.372 Adult +RT 40y 33.884 33.578 -0.306 
Newborn +RT 1m 32.438 34.809 2.371 Adult +RT 43y 34.821 34.720 -0.101 
Newborn +RT 1m 32.918 35.856 2.938 Adult +RT 43y 35.741 35.048 -0.693 
Newborn +RT 2m 33.641 33.266 -0.375 Adult +RT 45y 32.372 33.387 1.015 
Newborn +RT 3m 32.339 34.069 1.730 Elderly +RT 46y 34.858 34.562 -0.296 
Infant +RT 4m 34.348 34.272 -0.076 Elderly -RT 47y 34.272 35.563 1.291 
Infant +RT 5m 32.652 32.741 0.089 Middle-Age +RT 47y 35.365 33.391 -1.974 
Infant +RT 7m 32.871 34.650 1.779 Middle-Age +RT 49y 35.881 37.456 1.575 
Infant +RT 9m 35.446 35.856 0.410 Middle-Age +RT 51y 36.429 36.413 -0.016 
Toddler +RT 10m 31.657 34.360 2.703 Middle-Age +RT 53y 36.811 34.946 -1.865 
Toddler +RT 14m 35.100 34.404 -0.696 Middle-Age +RT 53y 33.509 34.125 0.616 
Toddler +RT 18m 32.384 33.219 0.835 Middle-Age +RT 56y 35.961 34.567 -1.394 
Toddler +RT 21m 32.843 34.050 1.207 Middle-Age +RT 56y 33.675 34.466 0.791 
Toddler +RT 2y 34.142 33.457 -0.685 Middle-Age +RT 57y 34.749 34.178 -0.571 
Toddler +RT 3y 32.026 33.264 1.238 Middle-Age +RT 58y 32.724 34.022 1.298 
Child +RT 4y 31.664 34.477 2.813 Middle-Age +RT 60y 33.282 33.259 -0.023 
Child +RT 4y 33.540 37.211 3.671 Middle-Age +RT 61y 32.480 33.699 1.219 
Child +RT 5y 31.020 32.129 1.109 Middle-Age +RT 63y 34.973 33.287 -1.686 
Child +RT 6y 33.472 35.373 1.901 Middle-Age +RT 63y 31.341 32.784 1.443 
Child +RT 8y 35.501 35.969 0.468 Elderly +RT 65y 35.832 34.261 -1.571 
Child +RT 9y 35.913 38.910 2.997 Elderly +RT 66y 33.469 34.411 0.942 
Child +RT 9y 33.854 36.516 2.662 Elderly +RT 68y 33.699 33.802 0.103 
Child +RT 12y 34.478 34.962 0.484 Elderly +RT 68y 33.303 35.199 1.896 
Child +RT 12y 33.784 33.559 -0.225 Elderly +RT 69y 33.738 33.833 0.095 
Juvenile +RT 13y 33.601 33.435 -0.166 Elderly +RT 71y 34.927 34.045 -0.882 
Juvenile +RT 14y 33.785 32.942 -0.843 Elderly +RT 71y 33.130 33.765 0.635 
Juvenile +RT 14y 32.669 30.514 -2.155 Elderly +RT 72y 34.257 33.965 -0.292 
Juvenile +RT 15y 32.462 33.528 1.066 Elderly +RT 74y 35.264 35.555 0.291 
Juvenile +RT 15y 31.584 32.249 0.665 Elderly +RT 76y 33.765 33.498 -0.267 
Juvenile +RT 16y 33.227 33.546 0.319 Elderly +RT 76y 35.292 34.823 -0.469 
Juvenile +RT 16y 32.204 33.615 1.411 Elderly +RT 79y 35.382 33.889 -1.493 
Juvenile +RT 17y 32.306 35.640 3.334 Elderly +RT 80y 34.087 33.718 -0.369 
Juvenile +RT 18y 34.445 34.859 0.414 Elderly +RT 81y 35.635 35.539 -0.096 
Adult +RT 19y 32.412 34.506 2.094 Elderly +RT 83y 36.555 35.441 -1.114 
Adult +RT 21y 37.960 35.500 -2.460 Elderly +RT 84y 33.128 33.305 0.177 
Adult +RT 23y 33.679 33.807 0.128 Elderly +RT 84y 33.061 33.669 0.608 
Adult +RT 24y 30.666 32.623 1.957 Elderly +RT 86y 34.494 33.554 -0.940 
Adult +RT 25y 34.548 33.863 -0.685 Elderly +RT 89y 34.224 33.479 -0.745 
Adult +RT 27y 34.569 34.606 0.037 Elderly +RT 89y 34.818 34.106 -0.712 
Adult +RT 29y 33.321 32.925 -0.396 Elderly +RT 91y 31.701 32.947 1.246 
Adult +RT 29y 34.837 34.101 -0.736 Elderly +RT 92y 34.167 32.953 -1.214 
Adult +RT 31y 31.355 32.654 1.299 Elderly +RT 102y 32.567 33.526 0.959 
Adult +RT 35y 35.770 34.575 -1.195 DNA   50.000 50.000 0.000 
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 Table 7: COL1A2 Real-Time PCR Singleplex Candidate Results. 
 
COL1A2-Initial Amplification   COL1A2-Initial Amplification  
Sample # Sex Age Ct value  Sample # Sex Age Ct value 
Newborn +RT M 1h 38.791  Child +RT F 6y 50.000 
Newborn -RT     Undet  Child -RT     Undet 
Newborn +RT F 17d 36.887  Child +RT F 12y 41.147 
Newborn -RT     Undet  Child -RT     Undet 
Newborn +RT F 1m 41.468  Juvenile +RT M 18y 50.000 
Newborn -RT     Undet  Juvenile -RT     Undet 
Newborn +RT F 3m 37.954  Adult +RT M 27y 50.000 
Newborn -RT     Undet  Adult -RT     Undet 
Infant +RT F 5m 50.000  Adult +RT M 40y 50.000 
Infant -RT     Undet  Adult -RT     Undet 
Infant +RT M 8m 45.571  Middle-Age +RT M 51y 50.000 
Infant -RT     Undet  Middle-Age -RT     Undet 
Toddler +RT F 14m 50.000  Middle-Age +RT M 61y 50.000 
Toddler -RT     Undet  Middle-Age -RT     Undet 
Toddler +RT F 19m 40.946  Elderly +RT M 76y 50.000 
Toddler -RT     Undet  Elderly -RT     Undet 
Toddler +RT M 2.8y 50.000  Elderly +RT M 86y 50.000 
Toddler -RT     Undet  Elderly -RT     Undet 
Child +RT M 4y 38.423  DNA     Undet 
Child -RT     Undet  DNA     Undet 
Child +RT F 4y 46.277  NTC     Undet 
Child -RT     Undet  NTC     Undet 
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Table 8: COL1A2 Real-Time PCR Duplex Delta Ct Results. 













Newborn +RT 1h 45.256 50.000 4.744 Adult +RT 36y 50.000 48.825 -1.175 
Newborn +RT 1h 40.197 50.000 9.803 Adult +RT 36y 50.000 43.970 -6.030 
Newborn +RT 2d 44.296 50.000 5.704 Adult +RT 38y 42.611 39.645 -2.966 
Newborn +RT 8d 36.656 50.000 13.344 Adult +RT 40y 50.000 41.516 -8.484 
Newborn +RT 17d 41.478 48.714 7.236 Adult +RT 40y 50.000 40.792 -9.208 
Newborn +RT 1m 39.251 47.951 8.700 Adult +RT 43y 50.000 41.325 -8.675 
Newborn +RT 1m 50.000 50.000 0.000 Adult +RT 43y 50.000 42.427 -7.573 
Newborn +RT 2m 40.341 46.056 5.715 Adult +RT 45y 50.000 38.497 -11.503 
Newborn +RT 3m 38.706 47.180 8.474 Elderly +RT 46y 50.000 40.595 -9.405 
Infant +RT 4m 43.222 43.090 -0.132 Elderly -RT 47y 41.897 43.741 1.844 
Infant +RT 5m 43.497 41.358 -2.139 Middle-Age +RT 47y 50.000 38.891 -11.109 
Infant +RT 7m 43.332 42.439 -0.893 Middle-Age +RT 49y 50.000 44.039 -5.961 
Infant +RT 9m 50.000 50.000 0.000 Middle-Age +RT 51y 50.000 41.160 -8.840 
Toddler +RT 10m 41.271 48.489 7.218 Middle-Age +RT 53y 50.000 40.988 -9.012 
Toddler +RT 14m 50.000 45.904 -4.096 Middle-Age +RT 53y 50.000 50.000 0.000 
Toddler +RT 18m 50.000 43.718 -6.282 Middle-Age +RT 56y 50.000 41.875 -8.125 
Toddler +RT 21m 50.000 43.215 -6.785 Middle-Age +RT 56y 50.000 40.611 -9.389 
Toddler +RT 2y 50.000 42.368 -7.632 Middle-Age +RT 57y 50.000 41.501 -8.499 
Toddler +RT 3y 50.000 41.687 -8.313 Middle-Age +RT 58y 50.000 40.335 -9.665 
Child +RT 4y 41.864 39.589 -2.275 Middle-Age +RT 60y 50.000 42.757 -7.243 
Child +RT 4y 40.689 42.658 1.969 Middle-Age +RT 61y 43.118 50.000 6.882 
Child +RT 5y 39.318 39.088 -0.230 Middle-Age +RT 63y 50.000 38.031 -11.969 
Child +RT 6y 50.000 40.970 -9.030 Middle-Age +RT 63y 42.383 36.639 -5.744 
Child +RT 8y 44.289 50.000 5.711 Elderly +RT 65y 50.000 42.035 -7.965 
Child +RT 9y 50.000 50.000 0.000 Elderly +RT 66y 50.000 47.742 -2.258 
Child +RT 9y 50.000 46.608 -3.392 Elderly +RT 68y 42.262 37.598 -4.664 
Child +RT 12y 50.000 46.480 -3.520 Elderly +RT 68y 50.000 44.386 -5.614 
Child +RT 12y 50.000 42.175 -7.825 Elderly +RT 69y 50.000 41.053 -8.947 
Juvenile +RT 13y 43.040 41.343 -1.697 Elderly +RT 71y 46.120 50.000 3.880 
Juvenile +RT 14y 50.000 35.288 -14.712 Elderly +RT 71y 50.000 41.181 -8.819 
Juvenile +RT 14y 45.600 40.692 -4.908 Elderly +RT 72y 50.000 50.000 0.000 
Juvenile +RT 15y 41.540 39.939 -1.601 Elderly +RT 74y 50.000 41.608 -8.392 
Juvenile +RT 15y 50.000 38.983 -11.017 Elderly +RT 76y 43.599 40.798 -2.801 
Juvenile +RT 16y 50.000 39.755 -10.245 Elderly +RT 76y 50.000 40.631 -9.369 
Juvenile +RT 16y 50.000 39.832 -10.168 Elderly +RT 79y 50.000 50.000 0.000 
Juvenile +RT 17y 50.000 40.995 -9.005 Elderly +RT 80y 50.000 38.305 -11.695 
Juvenile +RT 18y 42.170 46.590 4.420 Elderly +RT 81y 50.000 42.766 -7.234 
Adult +RT 19y 50.000 43.591 -6.409 Elderly +RT 83y 50.000 45.156 -4.844 
Adult +RT 21y 50.000 43.065 -6.935 Elderly +RT 84y 50.000 38.506 -11.494 
Adult +RT 23y 50.000 50.000 0.000 Elderly +RT 84y 50.000 50.000 0.000 
Adult +RT 24y 50.000 39.744 -10.256 Elderly +RT 86y 46.010 50.000 3.990 
Adult +RT 25y 50.000 40.392 -9.608 Elderly +RT 89y 50.000 43.349 -6.651 
Adult +RT 27y 43.390 42.501 -0.889 Elderly +RT 89y 50.000 42.636 -7.364 
Adult +RT 29y 50.000 38.550 -11.450 Elderly +RT 91y 50.000 39.317 -10.683 
Adult +RT 29y 50.000 40.104 -9.896 Elderly +RT 92y 50.000 40.486 -9.514 
Adult +RT 31y 50.000 39.025 -10.975 Elderly +RT 102y 50.000 50.000 0.000 
Adult +RT 35y 50.000 41.378 -8.622 DNA   50.000 50.000 0.000 
Adult +RT 35y 50.000 41.799 -8.201 NTC   50.000 50.000 0.000 
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 Table 9: COL1A2 Triplicate qPCR Results. 








dCt SD dCt 
Newborn +RT 1h 43.886 1.290 50.000 0.000 6.114 1.290 
Newborn +RT 1h 41.552 0.193 50.000 0.000 8.448 0.193 
Newborn +RT 1h 42.532 0.790 46.961 1.715 4.429 1.160 
Newborn +RT 1h 41.648 1.889 50.000 0.000 8.352 1.889 
Newborn +RT 1h 40.896 0.621 50.000 0.000 9.104 0.621 
Newborn +RT 1h 43.963 0.384 50.000 0.000 6.037 0.384 
Newborn +RT 1h 40.668 0.493 50.000 0.000 9.332 0.493 
Newborn +RT 1d 38.139 0.311 50.000 0.000 11.861 0.311 
Newborn +RT 2d 43.854 1.189 49.848 0.263 5.994 1.078 
Newborn +RT 8d 37.388 0.244 50.000 0.000 12.612 0.244 
Newborn +RT 13d 40.033 1.135 50.000 0.000 9.967 1.135 
Newborn +RT 17d 40.004 1.114 43.424 2.341 3.420 1.439 
Infant +RT 1m 40.222 0.630 50.000 0.000 9.778 0.630 
Infant +RT 1m 44.994 4.372 43.056 1.175 -1.938 3.385 
Infant +RT 2m 39.650 0.616 48.100 1.286 8.449 1.892 
Infant +RT 3m 38.037 0.280 41.981 0.694 3.945 0.431 
Infant +RT 3m 40.706 1.246 50.000 0.000 9.294 1.246 
Infant +RT 4m 47.282 4.708 44.045 1.226 -3.237 5.204 
Infant +RT 4m 39.991 1.852 50.000 0.000 10.009 1.852 
Infant +RT 5m 42.121 1.174 45.112 1.271 2.991 0.378 
Toddler +RT 6m 50.000 0.000 45.677 1.030 -4.323 1.030 
Toddler +RT 7m 50.000 0.000 41.693 1.283 -8.307 1.283 
Toddler +RT 7m 50.000 0.000 41.922 1.318 -8.078 1.318 
Toddler +RT 7m 42.385 0.670 50.000 0.000 7.615 0.670 
Toddler +RT 8m 44.901 4.426 46.547 2.214 1.646 2.356 
Toddler +RT 8m 50.000 0.000 47.171 0.518 -2.829 0.518 
Toddler +RT 8m 45.496 4.061 42.334 1.998 -3.162 3.044 
Toddler +RT 9m 40.543 1.171 48.134 1.807 7.592 2.970 
Toddler +RT 9m 50.000 0.000 43.834 0.681 -6.166 0.681 
Toddler +RT 10m 50.000 0.000 46.348 2.491 -3.652 2.491 
Toddler +RT 10m 39.394 0.536 44.314 0.992 4.920 0.459 
Toddler +RT 14m 50.000 0.000 43.159 0.617 -6.841 0.617 
Toddler +RT 15m 50.000 0.000 43.057 1.172 -6.943 1.172 
Toddler +RT 18m 50.000 0.000 43.093 2.356 -6.907 2.356 
Toddler +RT 19m 45.367 4.036 48.678 1.170 3.311 4.813 
Toddler +RT 21m 50.000 0.000 43.164 0.770 -6.836 0.770 
Toddler +RT 2y 50.000 0.000 42.657 0.418 -7.343 0.418 
Toddler +RT 2.8y 50.000 0.000 43.486 2.171 -6.514 2.171 
Toddler +RT 3y 41.396 0.547 41.065 0.583 -0.331 1.094 
Toddler +RT 3y 50.000 0.000 42.255 0.690 -7.745 0.690 
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dCt SD dCt 
Child +RT 4y 41.201 1.019 43.054 1.020 1.853 0.395 
Child +RT 4y 42.100 0.724 43.757 0.360 1.658 0.618 
Child +RT 4y 40.839 0.594 43.962 1.713 3.123 2.140 
Child +RT 5y 39.351 0.687 39.363 2.269 0.011 1.961 
Child +RT 6y 50.000 0.000 41.293 3.938 -8.707 3.938 
Child +RT 8y 44.933 4.405 47.211 2.459 2.278 6.719 
Child +RT 9y 50.000 0.000 43.840 0.935 -6.160 0.935 
Child +RT 12y 50.000 0.000 45.390 1.553 -4.610 1.553 
Child +RT 12y 50.000 0.000 40.897 1.515 -9.103 1.515 
Child +RT 12y 50.000 0.000 43.476 0.786 -6.524 0.786 
Child +RT 12y 46.861 5.437 41.560 2.573 -5.301 5.369 
Juvenile +RT 13y 50.000 0.000 41.881 2.569 -8.119 2.569 
Juvenile +RT 13y 50.000 0.000 42.489 0.726 -7.511 0.726 
Juvenile +RT 14y 50.000 0.000 42.667 4.225 -7.333 4.225 
Juvenile +RT 14y 50.000 0.000 38.952 2.576 -11.048 2.576 
Juvenile +RT 14y 50.000 0.000 43.646 1.057 -6.354 1.057 
Juvenile +RT 15y 50.000 0.000 42.970 2.163 -7.030 2.163 
Juvenile +RT 15y 41.335 1.673 44.333 1.620 2.998 3.282 
Juvenile +RT 15y 50.000 0.000 42.818 1.550 -7.182 1.550 
Juvenile +RT 16y 45.302 4.078 45.432 1.115 0.130 3.578 
Juvenile +RT 17y 50.000 0.000 44.379 2.201 -5.621 2.201 
Juvenile +RT 17y 50.000 0.000 44.544 2.009 -5.456 2.009 
Juvenile +RT 17y 50.000 0.000 45.018 1.796 -4.982 1.796 
Juvenile +RT 18y 50.000 0.000 43.583 1.020 -6.417 1.020 
Juvenile +RT 18y 45.147 4.248 43.758 2.022 -1.389 5.280 
Adult +RT 19y 48.024 3.423 47.186 2.761 -0.838 6.002 
Adult +RT 24y 50.000 0.000 45.658 1.423 -4.342 1.423 
Adult +RT 26y 50.000 0.000 44.300 1.074 -5.700 1.074 
Adult +RT 29y 50.000 0.000 43.917 2.233 -6.083 2.233 
Adult +RT 29y 50.000 0.000 45.175 0.642 -4.825 0.642 
Adult +RT 35y 50.000 0.000 44.768 0.613 -5.232 0.613 
Adult +RT 35y 50.000 0.000 46.108 1.467 -3.892 1.467 
Adult +RT 36y 50.000 0.000 44.930 1.783 -5.070 1.783 
Adult +RT 38y 50.000 0.000 41.480 0.415 -8.520 0.415 
Adult +RT 38y 50.000 0.000 42.031 1.055 -7.969 1.055 
Adult +RT 38y 47.561 4.224 45.297 4.075 -2.264 8.299 
Adult +RT 40y 48.983 1.761 37.840 3.453 -11.144 2.237 
Adult +RT 40y 50.000 0.000 42.796 0.507 -7.204 0.507 
Adult +RT 43y 50.000 0.000 44.101 0.756 -5.899 0.756 
Adult +RT 45y 44.696 4.642 42.578 1.399 -2.119 3.873 
Adult +RT 45y 50.000 0.000 42.193 0.528 -7.807 0.528 
Adult +RT 45y 41.079 0.315 43.518 1.719 2.438 2.023 
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dCt SD dCt 
Middle-Age +RT 47y 47.656 4.059 42.680 2.010 -4.976 5.906 
Middle-Age +RT 51y 50.000 0.000 43.148 1.283 -6.852 1.283 
Middle-Age +RT 53y 50.000 0.000 46.940 0.592 -3.060 0.592 
Middle-Age +RT 53y 50.000 0.000 43.976 1.983 -6.024 1.983 
Middle-Age +RT 56y 50.000 0.000 42.970 1.093 -7.030 1.093 
Middle-Age +RT 57y 50.000 0.000 46.294 1.531 -3.706 1.531 
Middle-Age +RT 58y 50.000 0.000 42.681 1.219 -7.319 1.219 
Middle-Age +RT 59y 50.000 0.000 42.914 0.527 -7.086 0.527 
Middle-Age +RT 60y 50.000 0.000 43.518 0.730 -6.482 0.730 
Middle-Age +RT 61y 48.101 3.289 46.222 0.627 -1.880 3.916 
Middle-Age +RT 61y 41.985 0.636 49.018 1.701 7.033 1.400 
Middle-Age +RT 63y 50.000 0.000 44.614 0.734 -5.386 0.734 
Middle-Age +RT 63y 42.738 1.602 42.804 0.414 0.066 1.225 
Elderly +RT 65y 50.000 0.000 44.799 4.573 -5.201 4.573 
Elderly +RT 68y 42.180 0.244 50.000 0.000 7.820 0.244 
Elderly +RT 71y 47.878 3.675 42.159 0.920 -5.719 4.532 
Elderly +RT 71y 50.000 0.000 44.437 2.132 -5.563 2.132 
Elderly +RT 76y 50.000 0.000 45.017 1.156 -4.983 1.156 
Elderly +RT 76y 50.000 0.000 46.260 1.787 -3.740 1.787 
Elderly +RT 80y 50.000 0.000 42.367 1.702 -7.633 1.702 
Elderly +RT 81y 50.000 0.000 42.744 1.182 -7.256 1.182 
Elderly +RT 84y 50.000 0.000 42.006 1.987 -7.994 1.987 
Elderly +RT 86y 47.308 4.663 44.190 0.133 -3.117 4.625 
Elderly +RT 89y 50.000 0.000 43.455 2.898 -6.545 2.898 
Elderly +RT 89y 47.564 4.219 47.109 3.505 -0.455 7.156 
Elderly +RT 92y 50.000 0.000 41.896 1.166 -8.104 1.166 
Elderly +RT 102y 50.000 0.000 42.832 1.240 -7.168 1.240 
 
 165
 Table 10: HBE1 Real-Time PCR Singleplex Candidate Results. 
 
HBE1-Initial Amplification    HBE1-Initial Amplification   









Newborn +RT F 1h 0.003 28.615  Juvenile +RT M 16y 16.000 34.536 
Newborn -RT       Undet  Juvenile -RT       Undet 
Newborn +RT M 1h 0.003 28.041  Adult +RT F 35y 35.000 38.329 
Newborn -RT       Undet  Adult -RT       Undet 
Newborn +RT F 17d 0.047 32.659  Middle-Age +RT M 56y 56.000 32.677 
Newborn -RT       Undet  Middle-Age -RT       Undet 
Newborn +RT M 2m 0.167 33.464  Elderly +RT F 69y 69.000 33.112 
Newborn -RT       Undet  Elderly -RT       Undet 
Toddler +RT M 10m 0.833 35.566  Elderly +RT M 80y 80.000 33.140 
Toddler -RT     Undet  Elderly -RT       Undet 
Toddler +RT F 3y 3.000 35.926  DNA       Undet 
Toddler -RT       Undet  DNA       Undet 
Child +RT M 8y 8.000 39.075  NTC       Undet 
Child -RT       Undet  NTC       Undet 
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Table 11: HBE1 Real-Time PCR Duplex Delta Ct Results. 













Newborn +RT 1h 30.334 35.600 5.266 Adult +RT 36y 33.663 34.571 0.908 
Newborn +RT 1h 29.454 36.348 6.894 Adult +RT 36y 34.011 36.938 2.927 
Newborn +RT 2d 31.497 36.344 4.847 Adult +RT 38y 33.939 33.635 -0.304 
Newborn +RT 8d 28.742 33.151 4.409 Adult +RT 40y 36.087 33.531 -2.556 
Newborn +RT 17d 36.419 34.528 -1.891 Adult +RT 40y 34.268 33.344 -0.924 
Newborn +RT 1m 31.793 34.283 2.490 Adult +RT 43y 35.758 34.431 -1.327 
Newborn +RT 1m 26.481 35.650 9.169 Adult +RT 43y 36.427 34.102 -2.325 
Newborn +RT 2m 34.816 34.115 -0.701 Adult +RT 45y 31.847 31.266 -0.581 
Newborn +RT 3m 31.477 36.650 5.173 Elderly +RT 46y 37.779 34.190 -3.589 
Infant +RT 4m 36.739 33.756 -2.983 Elderly -RT 47y 39.020 35.466 -3.554 
Infant +RT 5m 34.472 32.444 -2.028 Middle-Age +RT 47y 33.377 33.568 0.191 
Infant +RT 7m 37.068 33.692 -3.376 Middle-Age +RT 49y 32.288 41.326 9.038 
Infant +RT 9m 35.862 35.536 -0.326 Middle-Age +RT 51y 34.377 36.995 2.618 
Toddler +RT 10m 39.769 33.174 -6.595 Middle-Age +RT 53y 33.496 36.227 2.731 
Toddler +RT 14m 36.301 33.809 -2.492 Middle-Age +RT 53y 32.336 33.344 1.008 
Toddler +RT 18m 40.080 33.092 -6.988 Middle-Age +RT 56y 32.820 34.858 2.038 
Toddler +RT 21m 37.282 33.368 -3.914 Middle-Age +RT 56y 34.211 34.193 -0.018 
Toddler +RT 2y 33.388 33.307 -0.081 Middle-Age +RT 57y 36.067 33.589 -2.478 
Toddler +RT 3y 39.098 32.606 -6.492 Middle-Age +RT 58y 33.307 33.603 0.296 
Child +RT 4y 40.236 32.509 -7.727 Middle-Age +RT 60y 36.616 32.399 -4.217 
Child +RT 4y 32.761 30.136 -2.625 Middle-Age +RT 61y 33.694 33.490 -0.204 
Child +RT 5y 34.820 31.375 -3.445 Middle-Age +RT 63y 35.233 34.140 -1.093 
Child +RT 6y 38.535 34.825 -3.710 Middle-Age +RT 63y 32.970 33.969 0.999 
Child +RT 8y 39.831 35.021 -4.810 Elderly +RT 65y 33.069 34.779 1.710 
Child +RT 9y 38.202 34.347 -3.855 Elderly +RT 66y 34.380 33.692 -0.688 
Child +RT 9y 39.585 35.636 -3.949 Elderly +RT 68y 34.162 36.358 2.196 
Child +RT 12y 38.094 34.787 -3.307 Elderly +RT 68y 37.887 34.393 -3.494 
Child +RT 12y 34.692 33.182 -1.510 Elderly +RT 69y 35.421 33.888 -1.533 
Juvenile +RT 13y 33.955 33.331 -0.624 Elderly +RT 71y 34.532 33.328 -1.204 
Juvenile +RT 14y 38.146 32.170 -5.976 Elderly +RT 71y 34.341 34.017 -0.324 
Juvenile +RT 14y 38.379 32.333 -6.046 Elderly +RT 72y 36.528 34.682 -1.846 
Juvenile +RT 15y 36.141 32.941 -3.200 Elderly +RT 74y 32.297 34.526 2.229 
Juvenile +RT 15y 36.014 32.498 -3.516 Elderly +RT 76y 32.672 33.363 0.691 
Juvenile +RT 16y 34.429 33.673 -0.756 Elderly +RT 76y 33.382 34.562 1.180 
Juvenile +RT 16y 35.811 33.060 -2.751 Elderly +RT 79y 35.049 33.391 -1.658 
Juvenile +RT 17y 37.634 34.156 -3.478 Elderly +RT 80y 33.648 33.877 0.229 
Juvenile +RT 18y 36.059 34.722 -1.337 Elderly +RT 81y 34.027 35.334 1.307 
Adult +RT 19y 36.039 33.675 -2.364 Elderly +RT 83y 35.877 34.875 -1.002 
Adult +RT 21y 33.974 36.982 3.008 Elderly +RT 84y 38.792 33.043 -5.749 
Adult +RT 23y 36.217 33.207 -3.010 Elderly +RT 84y 36.862 33.858 -3.004 
Adult +RT 24y 35.201 32.410 -2.791 Elderly +RT 86y 35.139 33.535 -1.604 
Adult +RT 25y 34.418 33.117 -1.301 Elderly +RT 89y 36.299 32.876 -3.423 
Adult +RT 27y 32.107 33.770 1.663 Elderly +RT 89y 34.405 34.331 -0.074 
Adult +RT 29y 33.602 31.966 -1.636 Elderly +RT 91y 37.291 32.856 -4.435 
Adult +RT 29y 33.783 34.439 0.656 Elderly +RT 92y 31.672 33.053 1.381 
Adult +RT 31y 37.976 32.440 -5.536 Elderly +RT 102y 34.552 33.734 -0.818 
Adult +RT 35y 38.910 34.427 -4.483 DNA   50.000 50.000 0.000 
Adult +RT 35y 33.125 35.161 2.036 NTC   50.000 50.000 0.000 
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 Table 12: HBE1 Triplicate qPCR Results. 
 








dCt SD dCt 
Newborn +RT 1h 34.639 0.461 35.726 0.698 1.087 0.298 
Newborn +RT 1h 30.023 0.337 33.593 0.221 3.571 0.123 
Newborn +RT 1h 30.427 0.179 34.385 0.237 3.959 0.133 
Newborn +RT 1h 28.889 0.177 32.478 0.284 3.589 0.111 
Newborn +RT 1h 28.890 0.159 33.646 0.421 4.756 0.378 
Newborn +RT 1h 29.318 0.114 35.112 0.233 5.793 0.303 
Newborn +RT 1h 28.733 0.277 37.526 0.888 8.793 0.672 
Newborn +RT 1d 31.367 0.148 32.956 0.141 1.590 0.240 
Newborn +RT 2d 31.126 0.097 35.821 1.042 4.694 0.968 
Newborn +RT 8d 28.776 0.181 32.911 0.373 4.136 0.193 
Newborn +RT 13d 28.713 0.380 32.743 0.252 4.030 0.626 
Newborn +RT 17d 33.336 0.355 32.688 0.255 -0.647 0.116 
Newborn +RT 1m 32.845 0.363 33.944 0.574 1.099 0.264 
Newborn +RT 1m 27.493 0.112 32.049 0.028 4.556 0.084 
Newborn +RT 2m 33.575 0.145 32.343 0.118 -1.233 0.100 
Newborn +RT 3m 30.002 0.110 32.469 0.082 2.467 0.096 
Newborn +RT 3m 34.602 0.323 34.862 0.641 0.260 0.461 
Infant +RT 4m 36.031 0.307 32.667 0.116 -3.364 0.422 
Infant +RT 4m 34.593 0.456 31.943 0.084 -2.651 0.481 
Infant +RT 5m 36.198 1.215 32.806 0.325 -3.392 0.955 
Infant +RT 5m 37.554 0.949 33.829 0.774 -3.725 0.357 
Infant +RT 6m 35.244 0.459 32.742 0.283 -2.501 0.405 
Infant +RT 7m 36.819 0.745 31.405 0.246 -5.414 0.628 
Infant +RT 7m 33.533 0.733 32.645 0.520 -0.887 1.094 
Infant +RT 7m 34.485 0.080 33.470 0.128 -1.016 0.132 
Infant +RT 8m 36.568 1.072 32.066 0.334 -4.502 1.233 
Infant +RT 8m 34.552 0.487 35.270 0.248 0.718 0.378 
Infant +RT 8m 35.368 0.451 31.318 0.129 -4.050 0.353 
Infant +RT 9m 38.327 0.617 32.295 0.145 -6.031 0.593 
Infant +RT 9m 36.243 0.241 33.606 0.382 -2.637 0.596 
Toddler +RT 10m 37.774 0.376 32.868 0.453 -4.905 0.300 
Toddler +RT 10m 39.078 0.351 32.596 0.225 -6.482 0.573 
Toddler +RT 14m 36.184 0.330 33.664 0.329 -2.520 0.328 
Toddler +RT 14m 36.721 0.377 34.908 0.252 -1.814 0.324 
Toddler +RT 15m 35.537 0.540 33.814 0.521 -1.723 0.327 
Toddler +RT 18m 37.507 0.550 32.686 0.288 -4.820 0.600 
Toddler +RT 19m 35.122 0.347 32.914 0.349 -2.207 0.274 
Toddler +RT 21m 36.986 0.522 33.089 0.322 -3.897 0.537 
Toddler +RT 2y 35.672 0.668 33.690 0.460 -1.982 0.208 
Toddler +RT 2.8y 34.992 0.119 33.458 0.298 -1.534 0.324 
Toddler +RT 3y 40.691 0.881 32.838 0.170 -7.853 0.818 
Toddler +RT 3y 36.095 0.234 31.764 0.249 -4.330 0.251 
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dCt SD dCt 
Child +RT 4y 33.239 0.453 32.537 0.156 -0.702 0.317 
Child +RT 4y 39.946 0.764 31.998 0.508 -7.948 0.513 
Child +RT 4y 35.054 0.644 33.583 0.318 -1.471 0.357 
Child +RT 5y 35.224 0.115 30.800 0.286 -4.424 0.342 
Child +RT 6y 37.249 0.683 32.361 0.522 -4.888 0.279 
Child +RT 6y 38.796 0.880 33.669 0.237 -5.127 0.670 
Child +RT 8y 38.383 0.337 34.840 0.289 -3.544 0.614 
Child +RT 9y 37.478 0.683 33.591 0.362 -3.887 0.787 
Child +RT 9y 38.319 0.255 34.516 0.500 -3.803 0.704 
Child +RT 12y 38.077 1.369 33.992 0.358 -4.085 1.353 
Child +RT 12y 35.012 0.259 32.411 0.286 -2.601 0.230 
Child +RT 12y 35.721 0.126 32.905 0.307 -2.816 0.264 
Child +RT 12y 38.174 0.839 33.580 0.486 -4.594 0.353 
Juvenile +RT 13y 36.579 0.280 34.183 0.430 -2.396 0.513 
Juvenile +RT 13y 38.910 0.682 32.542 0.093 -6.368 0.670 
Juvenile +RT 14y 41.041 0.400 33.374 0.449 -7.667 0.848 
Juvenile +RT 14y 39.090 0.911 32.994 0.308 -6.096 0.926 
Juvenile +RT 14y 42.575 1.481 33.743 0.320 -8.832 1.362 
Juvenile +RT 15y 34.271 0.271 30.532 0.048 -3.739 0.283 
Juvenile +RT 15y 34.957 0.184 32.950 0.183 -2.007 0.151 
Juvenile +RT 15y 36.975 0.799 32.968 0.755 -4.007 0.964 
Juvenile +RT 16y 38.098 0.431 32.904 0.617 -5.194 0.416 
Juvenile +RT 16y 36.090 0.359 33.343 0.150 -2.747 0.337 
Juvenile +RT 17y 33.497 0.619 33.619 0.416 0.122 0.213 
Juvenile +RT 17y 32.082 0.586 35.314 0.521 3.232 0.135 
Juvenile +RT 17y 33.156 0.229 33.205 0.280 0.049 0.171 
Juvenile +RT 18y 33.952 0.236 31.615 0.384 -2.337 0.192 
Juvenile +RT 18y 34.323 0.476 32.079 0.796 -2.244 0.361 
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dCt SD dCt 
Adult +RT 19y 37.761 0.408 34.610 0.399 -3.151 0.268 
Adult +RT 19y 37.348 1.080 33.452 0.309 -3.896 0.947 
Adult +RT 21y 32.957 0.570 33.217 1.370 0.260 0.902 
Adult +RT 21y 33.743 0.286 32.924 0.639 -0.819 0.366 
Adult +RT 22y 36.813 0.377 34.482 0.247 -2.331 0.131 
Adult +RT 22y 36.532 0.144 33.301 0.093 -3.231 0.221 
Adult +RT 23y 37.093 0.734 32.734 0.288 -4.359 0.448 
Adult +RT 24y 36.691 0.341 32.084 0.226 -4.607 0.424 
Adult +RT 25y 37.374 0.951 36.054 1.148 -1.320 0.224 
Adult +RT 26y 34.100 0.356 32.009 0.288 -2.091 0.635 
Adult +RT 26y 40.495 1.415 33.920 0.273 -6.576 1.295 
Adult +RT 27y 32.948 0.193 33.828 0.326 0.881 0.145 
Adult +RT 29y 36.890 1.238 33.546 1.173 -3.344 0.430 
Adult +RT 29y 36.447 0.257 34.180 0.221 -2.267 0.140 
Adult +RT 35y 37.427 0.645 34.180 0.022 -3.248 0.659 
Adult +RT 35y 33.871 0.573 34.156 0.276 0.285 0.346 
Adult +RT 36y 37.773 0.636 33.359 0.547 -4.414 0.719 
Adult +RT 36y 32.424 0.315 33.371 0.285 0.947 0.097 
Adult +RT 38y 32.911 0.102 31.941 0.365 -0.970 0.293 
Adult +RT 38y 34.937 0.350 32.880 0.376 -2.057 0.207 
Adult +RT 38y 36.152 0.350 33.664 0.173 -2.487 0.182 
Adult +RT 40y 36.754 0.228 33.308 0.564 -3.446 0.372 
Adult +RT 40y 34.180 0.584 32.989 0.340 -1.191 0.287 
Adult +RT 43y 35.334 0.776 34.551 0.341 -0.783 0.444 
Adult +RT 43y 34.337 0.682 34.247 0.283 -0.091 0.645 
Adult +RT 45y 33.000 0.390 33.300 0.261 0.300 0.193 
Adult +RT 45y 33.019 0.377 32.757 0.389 -0.262 0.763 
Adult +RT 45y 37.822 1.606 34.479 1.697 -3.343 0.688 
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dCt SD dCt 
Middle-Age +RT 46y 36.400 0.623 33.405 0.202 -2.995 0.769 
Middle-Age +RT 47y 34.379 0.427 33.193 0.600 -1.186 0.354 
Middle-Age +RT 47y 39.753 0.844 34.446 1.049 -5.307 0.205 
Middle-Age +RT 51y 33.966 0.203 33.329 0.224 -0.638 0.124 
Middle-Age +RT 53y 34.616 0.868 33.152 0.608 -1.464 0.352 
Middle-Age +RT 53y 34.537 0.205 34.095 0.641 -0.442 0.762 
Middle-Age +RT 56y 33.200 0.737 34.682 0.846 1.483 0.879 
Middle-Age +RT 56y 34.232 0.523 33.719 0.679 -0.513 0.657 
Middle-Age +RT 57y 36.640 0.572 34.428 0.384 -2.212 0.224 
Middle-Age +RT 58y 35.420 0.533 35.219 0.943 -0.201 0.576 
Middle-Age +RT 59y 34.343 0.084 33.297 0.285 -1.046 0.201 
Middle-Age +RT 60y 36.811 0.356 32.951 1.291 -3.860 1.308 
Middle-Age +RT 61y 29.949 0.182 32.494 0.518 2.545 0.381 
Middle-Age +RT 61y 35.798 0.576 34.858 0.330 -0.940 0.621 
Middle-Age +RT 63y 31.241 0.173 31.172 0.306 -0.069 0.140 
Middle-Age +RT 63y 32.556 0.173 32.255 0.271 -0.301 0.165 
Middle-Age +RT 65y 31.965 0.177 33.168 0.131 1.202 0.060 
Elderly +RT 66y 37.121 0.312 35.042 0.140 -2.079 0.231 
Elderly +RT 66y 38.308 0.353 33.882 0.168 -4.425 0.468 
Elderly +RT 68y 36.408 0.562 34.371 0.391 -2.037 0.203 
Elderly +RT 68y 36.392 0.987 33.782 0.395 -2.610 1.261 
Elderly +RT 69y 35.221 0.280 33.547 0.473 -1.674 0.248 
Elderly +RT 71y 34.893 0.579 35.971 0.431 1.078 0.168 
Elderly +RT 71y 34.382 0.194 33.246 0.414 -1.136 0.249 
Elderly +RT 71y 35.324 0.213 33.338 0.286 -1.985 0.459 
Elderly +RT 72y 36.617 0.190 34.322 0.366 -2.295 0.177 
Elderly +RT 74y 32.468 0.160 33.839 0.424 1.371 0.539 
Elderly +RT 76y 34.318 0.397 33.890 0.431 -0.428 0.148 
Elderly +RT 76y 35.705 0.610 34.568 0.323 -1.137 0.357 
Elderly +RT 79y 34.739 0.143 34.091 1.088 -0.648 1.187 
Elderly +RT 80y 33.629 0.216 32.656 0.064 -0.974 0.258 
Elderly +RT 81y 31.964 0.189 32.923 0.216 0.959 0.220 
Elderly +RT 83y 34.704 0.540 33.695 0.020 -1.008 0.555 
Elderly +RT 84y 36.085 0.111 33.056 0.478 -3.029 0.368 
Elderly +RT 84y 37.379 0.600 33.194 0.307 -4.185 0.326 
Elderly +RT 86y 36.039 0.762 33.934 1.445 -2.105 0.689 
Elderly +RT 89y 35.420 1.554 32.444 0.807 -2.976 0.834 
Elderly +RT 89y 36.970 0.761 33.363 0.180 -3.607 0.648 
Elderly +RT 91y 37.940 0.380 35.794 0.614 -2.146 0.983 
Elderly +RT 92y 30.063 0.143 31.410 0.270 1.347 0.160 
Elderly +RT 102y 36.843 1.094 33.264 0.382 -3.579 0.823 
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 Table 13: IGFBP3 Real-Time PCR Singleplex Candidate Results. 
 
Sample # Sex Age Age (Yrs) Ct value Sample # Sex Age Age (Yrs) Ct value 
Newborn +RT M 1h 0.003 40.000 Middle-Aged +RT M 46y 46.000 36.918 
Newborn -RT       Undet Middle-Aged -RT       Undet 
Newborn +RT F 1m 0.083 40.000 Middle-Aged +RT M 51y 51.000 37.031 
Newborn -RT       Undet Middle-Aged -RT       Undet 
Infant +RT F 5m 0.417 40.000 Middle-Aged +RT F 56y 56.000 38.425 
Infant -RT       Undet Middle-Aged -RT       Undet 
Toddler +RT M 10m 0.833 40.000 Middle-Aged +RT M 61y 61.000 38.577 
Toddler -RT       Undet Middle-Aged -RT       Undet 
Toddler +RT F 19m 1.583 37.562 Elderly +RT M 66y 66.000 34.822 
Toddler -RT       Undet Elderly -RT       Undet 
Child +RT M 4y 4.000 40.000 Elderly +RT F 71y 71.000 37.476 
Child -RT       Undet Elderly -RT       Undet 
Child +RT F 12y 12.000 39.208 Elderly +RT M 76y 76.000 36.217 
Child -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 15y 15.000 35.557 Elderly +RT F 81y 81.000 34.500 
Juvenile -RT       Undet Elderly -RT       Undet 
Juvenile +RT M 18y 18.000 35.813 Elderly +RT F 84y 84.000 35.280 
Juvenile -RT       Undet Elderly -RT       Undet 
Adult +RT M 22y 22.000 37.572 Elderly +RT M 86y 86.000 36.229 
Adult -RT       28.176 Elderly -RT       Undet 
Adult +RT M 27y 27.000 39.987 Elderly +RT F 91y 91.000 36.459 
Adult -RT       Undet Elderly -RT       Undet 
Adult +RT M 35y 35.000 39.063 Elderly +RT M 92y 92.000 36.382 
Adult -RT       Undet Elderly -RT       Undet 
Adult +RT M 40y 40.000 35.493 DNA         
Adult -RT       Undet DNA         
Adult +RT M 43y 43.000 36.318 NTC         
Adult -RT       Undet NTC         
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Table 14: IGFBP3 Real-Time PCR Duplex Delta Ct Results. 













Newborn +RT 1h 40.000 35.618 -4.382 Adult +RT 36y 36.329 35.712 -0.617 
Newborn +RT 1h 40.000 40.000 0.000 Adult +RT 36y 36.693 36.955 0.262 
Newborn +RT 2d 40.000 37.407 -2.593 Adult +RT 38y 35.831 34.602 -1.229 
Newborn +RT 8d 36.605 34.137 -2.468 Adult +RT 40y 36.649 35.890 -0.759 
Newborn +RT 17d 40.000 35.880 -4.120 Adult +RT 40y 34.720 34.943 0.223 
Newborn +RT 1m 40.000 36.377 -3.623 Adult +RT 43y 37.365 35.865 -1.500 
Newborn +RT 1m 40.000 40.000 0.000 Adult +RT 43y 38.017 39.724 1.707 
Newborn +RT 2m 40.000 35.188 -4.812 Adult +RT 45y 35.068 34.117 -0.951 
Newborn +RT 3m 37.728 35.044 -2.684 Elderly +RT 46y 35.485 36.726 1.241 
Infant +RT 4m 38.677 34.410 -4.267 Elderly -RT 47y 39.947 40.000 0.053 
Infant +RT 5m 40.000 34.060 -5.940 Middle-Age +RT 47y 36.340 34.229 -2.111 
Infant +RT 7m 38.164 34.523 -3.641 Middle-Age +RT 49y 39.055 40.000 0.945 
Infant +RT 9m 40.000 37.713 -2.287 Middle-Age +RT 51y 36.384 36.170 -0.214 
Toddler +RT 10m 40.000 35.294 -4.706 Middle-Age +RT 53y 40.000 36.422 -3.578 
Toddler +RT 14m 40.000 35.862 -4.138 Middle-Age +RT 53y 34.370 36.711 2.341 
Toddler +RT 18m 40.000 35.584 -4.416 Middle-Age +RT 56y 36.037 37.489 1.452 
Toddler +RT 21m 40.000 35.930 -4.070 Middle-Age +RT 56y 36.392 39.560 3.168 
Toddler +RT 2y 40.000 35.701 -4.299 Middle-Age +RT 57y 35.489 36.810 1.321 
Toddler +RT 3y 38.164 35.136 -3.028 Middle-Age +RT 58y 38.215 35.917 -2.298 
Child +RT 4y 40.000 32.741 -7.259 Middle-Age +RT 60y 37.188 34.025 -3.163 
Child +RT 4y 40.000 36.483 -3.517 Middle-Age +RT 61y 37.657 39.238 1.581 
Child +RT 5y 38.097 33.272 -4.825 Middle-Age +RT 63y 37.585 39.318 1.733 
Child +RT 6y 40.000 36.590 -3.410 Middle-Age +RT 63y 39.234 33.748 -5.486 
Child +RT 8y 40.000 35.451 -4.549 Elderly +RT 65y 36.314 35.654 -0.660 
Child +RT 9y 40.000 36.488 -3.512 Elderly +RT 66y 35.238 39.637 4.399 
Child +RT 9y 38.375 36.635 -1.740 Elderly +RT 68y 34.411 37.674 3.263 
Child +RT 12y 40.000 36.751 -3.249 Elderly +RT 68y 35.321 32.247 -3.074 
Child +RT 12y 39.207 35.559 -3.648 Elderly +RT 69y 35.680 35.258 -0.422 
Juvenile +RT 13y 40.000 32.970 -7.030 Elderly +RT 71y 37.262 40.000 2.738 
Juvenile +RT 14y 36.370 34.298 -2.072 Elderly +RT 71y 36.505 35.812 -0.693 
Juvenile +RT 14y 34.154 36.280 2.126 Elderly +RT 72y 37.797 37.428 -0.369 
Juvenile +RT 15y 40.000 35.587 -4.413 Elderly +RT 74y 37.054 37.104 0.050 
Juvenile +RT 15y 36.442 33.560 -2.882 Elderly +RT 76y 34.124 35.432 1.308 
Juvenile +RT 16y 40.000 35.428 -4.572 Elderly +RT 76y 36.540 38.447 1.907 
Juvenile +RT 16y 37.381 34.729 -2.652 Elderly +RT 79y 37.995 40.000 2.005 
Juvenile +RT 17y 40.000 35.018 -4.982 Elderly +RT 80y 37.482 36.158 -1.324 
Juvenile +RT 18y 34.484 31.980 -2.504 Elderly +RT 81y 35.630 37.650 2.020 
Adult +RT 19y 35.387 34.980 -0.407 Elderly +RT 83y 40.000 35.812 -4.188 
Adult +RT 21y 40.000 38.267 -1.733 Elderly +RT 84y 34.619 34.887 0.268 
Adult +RT 23y 36.483 35.140 -1.343 Elderly +RT 84y 35.079 35.859 0.780 
Adult +RT 24y 35.216 37.270 2.054 Elderly +RT 86y 35.056 34.884 -0.172 
Adult +RT 25y 36.657 35.134 -1.523 Elderly +RT 89y 35.854 34.418 -1.436 
Adult +RT 27y 38.964 35.944 -3.020 Elderly +RT 89y 34.860 34.106 -0.754 
Adult +RT 29y 35.624 30.368 -5.256 Elderly +RT 91y 35.274 35.345 0.071 
Adult +RT 29y 37.118 35.717 -1.401 Elderly +RT 92y 36.073 34.559 -1.514 
Adult +RT 31y 35.212 34.600 -0.612 Elderly +RT 102y 31.403 22.654 -8.749 
Adult +RT 35y 39.757 36.147 -3.610 DNA   50.000 50.000 0.000 
Adult +RT 35y 36.306 36.550 0.244 NTC   50.000 50.000 0.000 
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 Table 15: IGFBP3 Triplicate qPCR Results. 








dCt SD dCt 
Newborn +RT 1h 50.000 0.000 38.570 0.522 -11.430 0.522 
Newborn +RT 1h 39.407 1.411 34.988 0.491 -4.419 1.871 
Newborn +RT 1h 50.000 0.000 33.631 0.202 -16.369 0.202 
Newborn +RT 1h 50.000 0.000 35.938 1.078 -14.062 1.078 
Newborn +RT 1d 38.087 0.862 34.066 0.395 -4.021 0.590 
Newborn +RT 2d 50.000 0.000 35.107 0.235 -14.893 0.235 
Newborn +RT 8d 39.029 0.176 35.840 0.235 -3.189 0.233 
Newborn +RT 17d 50.000 0.000 35.502 0.235 -14.498 0.235 
Newborn +RT 1m 42.714 1.414 35.418 0.436 -7.296 0.993 
Newborn +RT 1m 50.000 0.000 33.628 0.010 -16.372 0.010 
Newborn +RT 2m 50.000 0.000 34.336 0.547 -15.664 0.547 
Newborn +RT 3m 38.782 0.591 35.763 0.347 -3.018 0.284 
Newborn +RT 3m 50.000 0.000 36.902 0.810 -13.098 0.810 
Infant +RT 4m 38.146 0.690 35.441 0.444 -2.705 0.250 
Infant +RT 4m 38.012 2.273 34.384 1.587 -3.628 1.165 
Infant +RT 5m 50.000 0.000 34.733 0.256 -15.267 0.256 
Infant +RT 5m 50.000 0.000 35.547 0.848 -14.453 0.848 
Infant +RT 6m 50.000 0.000 35.691 0.396 -14.309 0.396 
Infant +RT 7m 39.634 0.560 34.934 0.589 -4.701 0.064 
Infant +RT 7m 38.247 0.439 35.108 0.201 -3.139 0.593 
Infant +RT 7m 49.245 1.307 35.536 0.104 -13.710 1.405 
Infant +RT 8m 50.000 0.000 34.021 0.317 -15.979 0.317 
Infant +RT 8m 50.000 0.000 37.711 0.589 -12.289 0.589 
Infant +RT 8m 37.256 0.360 33.955 0.295 -3.300 0.643 
Toddler +RT 10m 39.289 0.168 35.597 0.281 -3.692 0.113 
Toddler +RT 14m 50.000 0.000 36.456 1.170 -13.544 1.170 
Toddler +RT 14m 50.000 0.000 34.656 0.533 -15.344 0.533 
Toddler +RT 15m 50.000 0.000 37.107 0.709 -12.893 0.709 
Toddler +RT 18m 38.590 0.978 35.428 0.252 -3.161 1.011 
Toddler +RT 19m 39.169 0.508 34.943 0.505 -4.226 0.294 
Toddler +RT 2y 50.000 0.000 36.797 0.952 -13.203 0.952 
Toddler +RT 2.8y 50.000 0.000 34.670 0.920 -15.330 0.920 
Toddler +RT 3y 39.224 0.563 35.263 0.209 -3.961 0.443 
Child +RT 4y 38.398 0.431 35.682 0.764 -2.716 0.333 
Child +RT 4y 50.000 0.000 34.535 0.607 -15.465 0.607 
Child +RT 5y 36.425 0.346 32.738 0.333 -3.686 0.017 
Child +RT 6y 50.000 0.000 36.892 0.147 -13.108 0.147 
Child +RT 8y 36.771 0.984 35.901 0.392 -0.870 1.110 
Child +RT 9y 38.757 0.305 35.561 0.584 -3.195 0.471 
Child +RT 9y 38.836 0.541 38.401 0.628 -0.435 0.097 
Child +RT 12y 37.708 0.780 35.979 0.163 -1.729 0.937 
Child +RT 12y 38.628 0.655 36.171 0.175 -2.457 0.829 
Child +RT 12y 38.528 1.005 35.136 0.359 -3.393 0.947 
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dCt SD dCt 
Juvenile +RT 13y 38.718 0.405 35.536 0.215 -3.181 0.485 
Juvenile +RT 14y 37.083 0.963 34.896 0.280 -2.187 0.961 
Juvenile +RT 14y 34.963 0.298 34.661 0.608 -0.302 0.548 
Juvenile +RT 14y 36.474 0.214 35.355 0.547 -1.120 0.590 
Juvenile +RT 15y 37.191 1.536 32.871 0.527 -4.320 1.690 
Juvenile +RT 15y 35.983 0.621 33.838 1.148 -2.145 0.896 
Juvenile +RT 16y 36.094 0.127 32.933 0.249 -3.161 0.326 
Juvenile +RT 16y 37.115 0.249 35.348 0.344 -1.767 0.440 
Juvenile +RT 17y 50.000 0.000 36.925 0.374 -13.075 0.374 
Juvenile +RT 17y 50.000 0.000 40.366 0.583 -9.634 0.583 
Juvenile +RT 17y 39.957 1.932 36.517 0.362 -3.440 1.821 
Juvenile +RT 18y 35.116 0.113 32.522 0.357 -2.594 0.259 
Juvenile +RT 18y 38.153 2.200 35.351 0.869 -2.802 1.652 
Adult +RT 19y 37.441 0.137 37.079 0.181 -0.361 0.068 
Adult +RT 19y 36.567 0.697 35.985 0.287 -0.581 0.490 
Adult +RT 21y 50.000 0.000 37.798 0.671 -12.202 0.671 
Adult +RT 21y 38.887 1.142 35.585 1.127 -3.301 1.658 
Adult +RT 22y 35.130 0.685 37.705 1.089 2.576 1.566 
Adult +RT 22y 35.895 0.468 35.680 0.428 -0.215 0.825 
Adult +RT 23y 37.117 0.578 36.050 0.558 -1.067 0.303 
Adult +RT 24y 34.147 0.329 33.977 0.432 -0.171 0.220 
Adult +RT 25y 38.488 0.851 37.699 0.233 -0.789 1.014 
Adult +RT 26y 33.317 0.283 34.736 0.171 1.420 0.152 
Adult +RT 26y 38.590 0.824 37.115 0.292 -1.475 0.692 
Adult +RT 27y 37.427 0.733 35.920 0.285 -1.507 0.603 
Adult +RT 29y 35.950 0.550 35.067 0.675 -0.883 0.987 
Adult +RT 29y 35.837 0.469 35.680 0.049 -0.157 0.420 
Adult +RT 35y 37.977 0.651 36.385 0.898 -1.592 1.174 
Adult +RT 35y 35.787 0.223 36.768 1.040 0.981 1.050 
Adult +RT 36y 36.175 0.137 36.608 0.184 0.433 0.227 
Adult +RT 36y 36.768 0.607 35.465 0.234 -1.304 0.382 
Adult +RT 38y 35.467 0.546 33.341 0.268 -2.126 0.685 
Adult +RT 38y 36.300 0.164 36.247 0.139 -0.052 0.156 
Adult +RT 38y 34.283 0.648 35.318 0.265 1.035 0.457 
Adult +RT 40y 37.911 1.075 34.966 0.181 -2.945 1.086 
Adult +RT 40y 34.112 0.309 36.223 1.173 2.111 0.975 
Adult +RT 43y 36.559 0.610 36.939 0.728 0.380 0.588 
Adult +RT 45y 34.969 0.207 33.670 1.421 -1.298 1.401 
Adult +RT 45y 35.541 0.555 34.575 0.393 -0.966 0.905 
Adult +RT 45y 33.149 0.233 34.542 0.573 1.393 0.343 
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dCt SD dCt 
Middle-Age +RT 46y 36.191 0.863 36.864 0.672 0.673 1.176 
Middle-Age +RT 47y 35.795 0.384 36.751 1.103 0.956 0.770 
Middle-Age +RT 47y 37.376 0.893 36.643 0.439 -0.733 0.826 
Middle-Age +RT 51y 36.298 0.356 35.528 0.021 -0.770 0.347 
Middle-Age +RT 53y 50.000 0.000 41.367 0.611 -8.633 0.611 
Middle-Age +RT 53y 34.138 0.649 35.843 1.067 1.704 0.680 
Middle-Age +RT 56y 38.107 0.272 37.150 0.056 -0.957 0.292 
Middle-Age +RT 56y 36.877 0.481 35.947 0.167 -0.930 0.598 
Middle-Age +RT 57y 36.000 0.407 35.856 0.328 -0.143 0.265 
Middle-Age +RT 58y 37.855 0.910 36.846 0.201 -1.009 0.921 
Middle-Age +RT 59y 36.226 0.631 36.343 0.254 0.117 0.779 
Middle-Age +RT 60y 36.856 0.177 35.514 0.465 -1.342 0.336 
Middle-Age +RT 61y 36.764 0.713 36.297 1.603 -0.467 1.237 
Middle-Age +RT 61y 36.284 0.398 35.662 1.467 -0.622 1.096 
Middle-Age +RT 63y 38.499 0.686 37.161 0.210 -1.338 0.728 
Middle-Age +RT 63y 37.668 0.782 35.015 0.248 -2.653 0.740 
Elderly +RT 65y 38.641 0.486 37.875 0.419 -0.767 0.901 
Elderly +RT 66y 36.362 0.200 40.077 0.515 3.715 0.316 
Elderly +RT 66y 35.700 1.221 37.278 1.057 1.578 0.850 
Elderly +RT 68y 35.378 0.626 37.045 0.518 1.666 0.771 
Elderly +RT 68y 35.210 0.656 35.815 0.410 0.605 0.764 
Elderly +RT 69y 36.190 0.752 35.968 0.287 -0.222 0.502 
Elderly +RT 71y 50.000 0.000 37.466 0.842 -12.534 0.842 
Elderly +RT 71y 37.558 1.188 36.608 0.253 -0.950 1.342 
Elderly +RT 71y 37.155 1.963 35.963 0.688 -1.192 2.651 
Elderly +RT 72y 37.689 0.424 37.167 0.815 -0.522 1.162 
Elderly +RT 74y 36.982 1.253 38.339 0.679 1.357 1.009 
Elderly +RT 76y 34.893 0.582 36.091 1.359 1.198 1.179 
Elderly +RT 76y 36.849 1.373 36.681 0.287 -0.168 1.105 
Elderly +RT 79y 37.504 0.614 37.753 0.983 0.249 0.576 
Elderly +RT 80y 37.013 0.685 35.665 0.108 -1.347 0.579 
Elderly +RT 81y 33.966 0.211 35.334 0.309 1.368 0.217 
Elderly +RT 84y 35.291 0.272 35.880 0.269 0.588 0.480 
Elderly +RT 84y 33.947 0.427 34.742 0.910 0.796 1.288 
Elderly +RT 86y 35.380 0.293 34.175 0.319 -1.205 0.074 
Elderly +RT 89y 36.909 0.505 35.011 0.656 -1.897 0.486 
Elderly +RT 89y 35.134 0.375 35.417 1.039 0.282 1.388 
Elderly +RT 91y 36.501 0.523 36.352 0.582 -0.149 1.002 
Elderly +RT 92y 36.122 0.658 34.886 0.235 -1.236 0.824 
Elderly +RT 102y 36.158 0.876 35.149 0.573 -1.009 1.140 
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Assay Primer Sequences 5'→ 3' 
DNA 
(bp) RNA (bp) 
      
S15      
Forward 5’ TTC-CGC-AAG-TTC-ACC-TAC-C 3’ 361 361 
Reverse 5’ CGG-GCC-GGC-CAT-GCT-TTA-CG 3’      
GNAS      
Forward 5’ AAG-ATC-GAC-GTG-ATC-AAG-CA 3’ 855 371 
Reverse 5’ CCA-GCA-AGG-ACT-TTC-TCA-GC 3’      
HBG      
Forward 5’ GTG-GAT-CCT-GAG-AAC-TTC-AA 3’ 1040 154 
Reverse 5’ GAG-CTC-AGT-GGT-ATC-TGG-AG 3’      
HBG1     
Forward 5’ ACT-TCC-TTG-GGA-GAT-GCC-AC 3’ 1157 277 
Reverse 5’ AAA-GCC-TAT-CCT-TGA-AAG-CTC-TGA 3’      
HBG2     
Forward 5’ ACT-TCC-TTG-GGA-GAT-GCC-AT 3’ 1160 274 
Reverse 5’ GCC-TAT-CCT-TGA-AAG-CTC-TGC 3’      
HBG1n1      
Forward 5’ GAA-AGC-TCT-GAA-TCA-TCC-AGG-TG 3’ a 0 207 
Reverse 5’ GGG-CAA-GGT-GAA-TGT-GGA-AG 3’      
HBG1n2      
Forward 5’ AGT-GAG-CTC-AGT-GGC-ATC-TC 3' a 0 190 
Reverse 5’ GGG-CAA-GGT-GAA-TGT-GGA-AG 3’      
HBG2n2      
Forward 5’ CTG-GAG-GAC-AGG-GCA-AAG-G 3’ a 0 225 
Reverse 5’ GGG-CAA-GGT-GAA-TGT-GGA-AG 3’      
HBG2n3      
Forward 5’ GGC-AGT-GAG-CTC-AGT-GCA-GTT-C 3’ a 0 161 
Reverse 5’ CAG-CTT-TGG-CAA-CCT-GTC-CT 3’      
    








Assay  Primer & Probe Sequences 5'→ 3' 
      
S15      
Forward 5’ CCA-AAG-CGA-TCT-CTT-CTG-AGG-AT 3’  
Reverse 5' ACG-CCG-CGG-TAG-GTG-AA 3'  
Probe VIC CGG-CAA-GAT-GGC-AGA-AGT-AGA-GCA-GAA MGBNFQ b  
HBG1n1     
Forward 5' GAA-AGC-TCT-GAA-TCA-TCC-AGG-TG 3' a 
Reverse 5' AGT-CAA-GGC-ACA-TGG-CAA-GAA-G 3'  
Probe 6FAM TTT-GTG-GCA-TCT-CCC-AAG-GAA-GTC-AGC MGBNFQ b  
HBG2n3     
Forward 5' GCA-GTG-AGC-TCA-GTG-CAG-TTC 3' a 
Reverse 5' TTC-CTT-GGG-AGA-TGC-CAT-AAA 3'  
Probe 6FAM CAA-AGG-TGC-CCT-TGA-GAT-CAT-CCA-GG MGBNFQ b  
    
a Underlined sequence identifies the location of the newborn hemoglobin isoform 
breakpoints 
b MGBNFQ, minor groove binding non-fluorescent quencher 
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 Table 24: Affymetrix Comparisons. 
Age Group Newborn Juvenile    










P-Value Gene Symbol 
216317_x_at 1789.62 132.97 13.46 0.0426 RHCE 
224734_at 1204.95 93.34 9.41 0.0185 HMGB1 
219083_at 1866.19 205.48 9.08 0.0195 FLJ10539 
209066_x_at 981.98 85.46 7.67 0.0152 UQCRB 
239247_at 136.72 1037.14 7.59 0.0320   
212855_at 964.64 23.36 7.54 0.0124 KIAA0276 
227224_at 1001.40 134.83 7.43 0.0084 FLJ10244 
218515_at 942.25 119.00 7.36 0.0311 C21orf66 
222142_at 925.38 97.40 7.23 0.0203 CYLD 
202174_s_at 1084.95 151.12 7.18 0.0462 PCM1 
223391_at 916.99 35.87 7.16 0.0097 SGPP1 
225611_at 915.74 112.03 7.15 0.0039 KIAA0303 
242930_at 85.70 905.94 7.08 0.0138 OSGEP 
230448_at 123.38 901.11 7.04 0.0297 MGC15523 
216502_at 114.54 895.47 7.00 0.0410 FLJ12671 
218437_s_at 875.04 76.03 6.84 0.0495 LZTFL1 
201851_at 78.33 868.76 6.79 0.0041 SH3GL1 
217094_s_at 1404.47 212.11 6.62 0.0155 ITCH 
226561_at 849.01 129.13 6.57 0.0440 LOC285086 
204647_at 157.76 1021.12 6.47 0.0227 HOMER3 
215613_at 91.79 821.16 6.42 0.0084 ADAM12 
203202_at 801.70 71.74 6.26 0.0021 HRB2 
235196_at 799.74 62.44 6.25 0.0113 C1orf28 
223590_at 794.40 45.64 6.21 0.0438 DKFZp434I1610 
1562671_s_at 153.05 949.05 6.20 0.0066   
229285_at 787.24 20.48 6.15 0.0371 RNASEL 
236994_at 774.09 69.02 6.05 0.0022 na 
202209_at 771.57 126.59 6.03 0.0427 LSM3 
209798_at 1885.92 318.29 5.93 0.0196 NPAT 
225295_at 911.10 157.48 5.79 0.0426 KIAA1265 
227982_at 736.97 85.71 5.76 0.0428 SLA/LP 
204645_at 827.41 144.92 5.71 0.0258 CCNT2 
228366_at 806.95 142.11 5.68 0.0137 PPA2 
224728_at 874.62 163.82 5.34 0.0343 ATPAF1 
227548_at 874.07 164.00 5.33 0.0407 LOC51240 
1557706_at 136.94 728.38 5.32 0.0176   
1564257_at 157.50 825.01 5.24 0.0121 ACTA2 
1557873_at 269.76 1391.05 5.16 0.0449 LOC153218 
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 Age Group Newborn Juvenile    










P-Value Gene Symbol 
233987_at 55.32 658.47 5.14 0.0017 TFAP2BL1 
212938_at 117.35 658.04 5.14 0.0032 COL6A1 
228019_s_at 653.62 79.04 5.11 0.0177 MRPS18C 
1569566_at 41.97 642.02 5.02 0.0336 na 
239479_x_at 639.15 117.66 4.99 0.0127   
208520_at 155.17 769.23 4.96 0.0216 OR10H3 
210147_at 28.85 632.39 4.94 0.0491 ART3 
215226_at 131.10 642.86 4.90 0.0278   
235086_at 624.73 95.11 4.88 0.0122 THBS1 
201369_s_at 123.26 623.64 4.87 0.0319 ZFP36L2 
223328_at 622.08 111.87 4.86 0.0221 SVH 
230029_x_at 620.20 43.82 4.85 0.0114 KIAA2024 
206314_at 620.15 60.28 4.84 0.0102 ZFP 
242550_at 79.79 617.30 4.82 0.0488   
226807_at 610.45 59.68 4.77 0.0055 ZFP1 
207735_at 85.33 602.05 4.70 0.0208 RNF125 
201663_s_at 645.42 139.56 4.62 0.0056 SMC4L1 
212568_s_at 590.08 70.09 4.61 0.0145 DLAT 
219215_s_at 85.57 590.04 4.61 0.0222 SLC39A4 
218970_s_at 1047.18 227.84 4.60 0.0481 CGI-32 
235437_at 103.38 588.16 4.59 0.0099   
218599_at 85.33 586.81 4.58 0.0088 REC8 
207404_s_at 190.30 869.29 4.57 0.0492 HTR1E 
212243_at 958.18 211.50 4.53 0.0007 GRINL1A 
212567_s_at 90.46 578.66 4.52 0.0105 MAP4 
37201_at 40.26 577.24 4.51 0.0293 ITIH4 
229798_s_at 317.41 1420.69 4.48 0.0247 BRI3 
225455_at 1139.63 256.34 4.45 0.0379 STAF42 
212805_at 1513.82 341.03 4.44 0.0427 KIAA0367 
219354_at 77.36 567.91 4.44 0.0010 FLJ11078 
222559_s_at 563.43 59.38 4.40 0.0137 P15RS 
222204_s_at 562.44 95.30 4.39 0.0237 RRN3 
1554568_at 45.08 560.41 4.38 0.0370 DNCL2A 
1559654_s_at 202.69 874.37 4.31 0.0332   
243173_at 71.86 549.54 4.29 0.0482 MGC57793 
227934_at 2788.28 649.46 4.29 0.0213   
244076_at 103.96 549.35 4.29 0.0244 KIAA2022 
204955_at 45.54 549.19 4.29 0.0032 SRPX 
226438_at 1196.42 279.00 4.29 0.0097 SNTB1 
220992_s_at 548.68 26.10 4.29 0.0082 C1orf25 
233943_x_at 96.40 547.60 4.28 0.0238 FAPP2 
 187
 Age Group Newborn Juvenile    










P-Value Gene Symbol 
1561089_at 147.37 628.85 4.27 0.0149 na 
209512_at 544.11 58.44 4.25 0.0045 MGC10940 
236281_x_at 107.90 543.08 4.24 0.0293 HTR7 
231833_at 92.49 541.95 4.23 0.0072 MGC20460 
235738_at 107.09 538.81 4.21 0.0266   
227015_at 202.32 849.06 4.20 0.0298 LOC57168 
227836_at 535.18 124.80 4.18 0.0141 MGC14595 
1566001_at 335.48 1401.89 4.18 0.0337   
202260_s_at 123.58 520.58 4.07 0.0416 STXBP1 
201165_s_at 1571.61 386.86 4.06 0.0085 PUM1 
209919_x_at 218.18 880.48 4.04 0.0165 GGT1 
226437_at 91.68 515.16 4.02 0.0472 LOC90522 
232647_at 132.06 531.43 4.02 0.0181 MGC39650 
228381_at 2702.31 672.23 4.02 0.0115 ATF7IP2 
219009_at 115.95 513.11 4.01 0.0057 C14orf93 
222601_at 510.72 29.18 3.99 0.0002 FLJ10808 
218414_s_at 242.57 967.34 3.99 0.0236 NDE1 
219118_at 94.83 510.35 3.99 0.0036 FKBP11 
241342_at 595.22 149.73 3.98 0.0131 LOC157378 
231832_at 995.25 251.70 3.95 0.0383 TUWD12 
222156_x_at 1039.87 264.37 3.93 0.0472 CPR8 
230466_s_at 2484.72 631.85 3.93 0.0470   
230776_at 498.40 78.01 3.89 0.0119 KIAA1917 
1553523_at 147.88 573.01 3.87 0.0420 NALP14 
229335_at 128.33 496.30 3.87 0.0377 TSLL2 
231190_at 126.88 490.87 3.83 0.0402 na 
215135_at 294.12 1105.83 3.76 0.0042 DNPEP 
203341_at 480.27 40.37 3.75 0.0028 CBF2 
239532_at 198.87 742.54 3.73 0.0173 na 
216300_x_at 72.98 468.70 3.66 0.0283 RARA 
224827_at 468.52 77.36 3.66 0.0117 DC-UbP 
1557845_at 63.77 468.22 3.66 0.0227   
226687_at 1269.07 348.01 3.65 0.0294 FNBP3 
236712_at 90.67 460.73 3.60 0.0346   
213683_at 517.40 144.02 3.59 0.0216 FACL6 
1562137_at 111.12 459.36 3.59 0.0183   
225904_at 458.48 48.01 3.58 0.0022   
213256_at 1931.33 540.03 3.58 0.0338 MGC48332 
242003_at 164.38 585.70 3.56 0.0496   
219236_at 307.30 1084.54 3.53 0.0027 FLJ22672 
1557749_at 142.81 502.01 3.52 0.0180 DKFZp762C186 
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 Age Group Newborn Juvenile    










P-Value Gene Symbol 
227109_at 449.88 61.30 3.51 0.0087 CYP2R1 
242783_at 532.02 151.55 3.51 0.0380   
237112_at 449.03 79.36 3.51 0.0113   
230267_at 449.02 36.16 3.51 0.0005 na 
225254_at 219.30 768.23 3.50 0.0296 MGC20255 
231065_at 154.81 538.70 3.48 0.0455 PDE6D 
218045_x_at 73.58 442.50 3.46 0.0257 PTMS 
240069_at 119.30 442.05 3.45 0.0383   
232330_at 382.96 1320.92 3.45 0.0162 FLJ10803 
222350_at 99.73 437.33 3.42 0.0377   
209600_s_at 435.38 46.70 3.40 0.0211 ACOX1 
227193_at 632.74 186.36 3.40 0.0321   
229247_at 106.58 434.46 3.39 0.0281 FLJ37440 
238476_at 431.80 92.22 3.37 0.0477 LOC153222 
225711_at 930.97 276.12 3.37 0.0358 MGC33864 
226743_at 516.11 153.07 3.37 0.0433 FLJ34922 
1553905_at 97.31 428.48 3.35 0.0058 MGC34831 
202331_at 273.60 914.15 3.34 0.0078 BCKDHA 
238496_at 427.20 41.81 3.34 0.0088 WHSC1L1 
229812_at 426.80 58.08 3.33 0.0358 USP31 
221688_s_at 248.43 828.28 3.33 0.0405 C15orf12 
211856_x_at 173.07 575.94 3.33 0.0160 CD28 
219890_at 851.79 256.03 3.33 0.0374 CLECSF5 
205100_at 238.10 791.62 3.32 0.0198 GFPT2 
240971_x_at 61.11 423.34 3.31 0.0414   
204170_s_at 1063.48 322.49 3.30 0.0466 CKS2 
204608_at 242.66 789.67 3.25 0.0330 ASL 
227352_at 157.77 512.86 3.25 0.0200 FLJ35119 
1562098_at 243.91 791.45 3.24 0.0265   
226152_at 415.27 52.48 3.24 0.0187 TTC7L1 
230532_at 414.62 79.74 3.24 0.0236 MGC39350 
205803_s_at 141.13 454.80 3.22 0.0306 TRPC1 
1558147_a_at 437.79 1410.36 3.22 0.0100 na 
229414_at 654.70 203.98 3.21 0.0037 PITPNC1 
237309_at 171.98 550.63 3.20 0.0496   
1554544_a_at 407.62 74.16 3.18 0.0303 MBP 
205807_s_at 335.94 1067.13 3.18 0.0195 TUFT1 
213626_at 634.15 199.82 3.17 0.0402 FLJ14431 
221800_s_at 54.85 405.90 3.17 0.0307 FLJ22175 
1560250_s_at 154.05 488.22 3.17 0.0384 LOC284242 
239096_at 414.39 1307.99 3.16 0.0466   
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P-Value Gene Symbol 
31835_at 301.62 949.95 3.15 0.0218 HRG 
212373_at 780.45 248.02 3.15 0.0344 FEM1B 
214828_s_at 58.20 402.21 3.14 0.0159 dJ222E13.2 
219813_at 102.63 402.00 3.14 0.0172 LATS1 
237337_at 197.47 616.78 3.12 0.0166   
228604_at 585.15 187.50 3.12 0.0122 MGC34648 
203327_at 670.09 215.01 3.12 0.0060 IDE 
229016_s_at 178.56 551.92 3.09 0.0010 TReP-132 
207436_x_at 2064.25 6378.09 3.09 0.0457   
1556082_a_at 160.79 493.58 3.07 0.0179   
242294_at 57.28 391.98 3.06 0.0410   
1557193_at 243.13 737.28 3.03 0.0400   
221782_at 386.76 57.35 3.02 0.0357 ERdj5 
1563572_at 44.81 386.25 3.02 0.0301 LOC152274 
240326_at 2345.27 778.03 3.01 0.0357   
242914_at 258.41 778.23 3.01 0.0444 na 
244021_at 138.94 416.98 3.00 0.0405   
223128_at 217.90 652.90 3.00 0.0041 H17 
201382_at 110.78 383.17 2.99 0.0044 SIP 
209704_at 382.41 38.90 2.99 0.0075 M96 
202369_s_at 516.12 1540.60 2.98 0.0131 TRAM2 
219002_at 1086.70 365.53 2.97 0.0439 FLJ21901 
235759_at 690.70 233.22 2.96 0.0438 EFCBP1 
1558078_at 42.28 378.29 2.96 0.0406   
235430_at 98.80 377.82 2.95 0.0324 C14orf43 
1558612_a_at 176.14 518.91 2.95 0.0054 ATP1A4 
1562673_at 82.22 377.08 2.95 0.0390   
207098_s_at 374.69 57.65 2.93 0.0194 MFN1 
239370_at 64.58 373.76 2.92 0.0376   
244628_at 188.74 546.27 2.89 0.0119   
218394_at 173.73 501.29 2.89 0.0065 FLJ22386 
215331_at 131.55 379.55 2.89 0.0318 KIAA1000 
221771_s_at 368.96 57.70 2.88 0.0175 HSMPP8 
226478_at 367.58 77.76 2.87 0.0335 TM7SF3 
218799_at 43.32 366.43 2.86 0.0434 FLJ10349 
232293_at 414.51 145.57 2.85 0.0116 HCAP-G 
214867_at 420.79 1196.28 2.84 0.0246 NDST2 
1558996_at 2501.35 881.42 2.84 0.0163 FOXP1 
209088_s_at 482.78 1360.88 2.82 0.0120 UBN1 
221594_at 123.10 360.40 2.82 0.0405 DKFZP564O0523 
209840_s_at 2586.35 923.22 2.80 0.0366 LRRN3 
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226037_s_at 944.32 337.44 2.80 0.0473   
218692_at 222.64 622.12 2.79 0.0430 FLJ20366 
1556035_s_at 1712.24 612.95 2.79 0.0406 ZNF207 
1558969_a_at 332.38 923.98 2.78 0.0077 LOC132241 
242502_at 21.62 353.25 2.76 0.0171 KCNH5 
242407_at 342.47 944.18 2.76 0.0135   
1555522_s_at 1017.97 371.54 2.74 0.0101 CGI-27 
1552552_s_at 123.13 349.01 2.73 0.0389 CLECSF11 
230981_at 187.32 508.98 2.72 0.0133 CACRC 
1563080_at 19.04 346.55 2.71 0.0217   
232289_at 167.64 452.29 2.70 0.0463 FLJ14167 
214611_at 158.68 427.82 2.70 0.0371 GRIK1 
240128_at 356.65 961.20 2.70 0.0169   
202692_s_at 132.76 357.06 2.69 0.0371 UBTF 
213052_at 549.09 1476.63 2.69 0.0151 PRKAR2A 
242607_at 962.80 359.16 2.68 0.0179   
1568954_s_at 343.11 58.23 2.68 0.0100   
203857_s_at 326.61 875.31 2.68 0.0045 PDIR 
213370_s_at 510.70 1361.22 2.67 0.0364 SFMBT 
244433_at 419.19 1116.88 2.66 0.0254   
221522_at 989.20 371.34 2.66 0.0024 DKFZP434L0718 
1553132_a_at 338.53 33.62 2.64 0.0066 C14orf47 
211220_s_at 67.78 337.55 2.64 0.0199 HSF2 
205433_at 16.46 337.31 2.64 0.0401 BCHE 
226212_s_at 152.80 401.02 2.62 0.0196 INSR 
244147_at 59.09 335.55 2.62 0.0161   
223275_at 334.37 27.98 2.61 0.0218 PRMT6 
227682_at 334.21 42.08 2.61 0.0429   
236610_at 2410.15 928.79 2.59 0.0155   
241826_x_at 27.06 332.13 2.59 0.0242   
213952_s_at 257.09 664.88 2.59 0.0305 ALOX5 
243612_at 235.79 607.58 2.58 0.0082 NSD1 
230847_at 384.37 988.28 2.57 0.0036 WRNIP1 
209026_x_at 592.69 1515.31 2.56 0.0289 OK/SW-cl.56 
244705_at 78.33 327.09 2.56 0.0056   
1561179_s_at 483.52 1231.08 2.55 0.0499 KIAA1950 
203203_s_at 488.85 192.20 2.54 0.0069 HRB2 
244207_at 382.02 966.89 2.53 0.0117 HARS2 
213530_at 865.01 342.21 2.53 0.0374 RAB3GAP 
212204_at 1921.67 761.83 2.52 0.0237 DKFZP564G2022 
225882_at 77.08 322.82 2.52 0.0408 YEA 
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218659_at 743.98 1875.76 2.52 0.0027 KIAA1685 
225974_at 322.01 25.56 2.52 0.0434   
202892_at 1165.40 464.12 2.51 0.0105 CDC23 
1561038_at 46.99 321.03 2.51 0.0266 na 
236322_at 2751.33 1099.21 2.50 0.0091   
219194_at 326.78 813.47 2.49 0.0351 SEMA4G 
1557113_at 553.37 222.89 2.48 0.0426 LOC283588 
203652_at 438.98 1087.22 2.48 0.0023 MAP3K11 
1554599_x_at 314.13 769.95 2.45 0.0075   
242348_at 22.54 309.94 2.42 0.0135 FLJ25161 
203357_s_at 309.54 37.50 2.42 0.0443 CAPN7 
244328_x_at 6.56 307.87 2.41 0.0400 PAFAH1B1 
234807_x_at 1058.72 2545.55 2.40 0.0275   
226864_at 307.29 37.03 2.40 0.0246 PKIA 
1556339_a_at 345.63 829.52 2.40 0.0175   
201168_x_at 464.48 1114.34 2.40 0.0278 ARHGDIA 
213022_s_at 212.14 507.23 2.39 0.0157 UTRN 
231889_at 135.56 323.92 2.39 0.0155 RBAF600 
244182_at 372.77 888.72 2.38 0.0119 na 
205664_at 304.95 38.72 2.38 0.0231 KIN 
202051_s_at 2300.27 971.49 2.37 0.0059 ZNF262 
230346_x_at 408.25 966.63 2.37 0.0204   
204155_s_at 386.53 915.16 2.37 0.0273 KIAA0999 
212828_at 357.06 151.11 2.36 0.0271 SYNJ2 
1563796_s_at 234.24 547.37 2.34 0.0003 KIAA1970 
203900_at 195.94 457.24 2.33 0.0283 KIAA0467 
209556_at 228.14 531.95 2.33 0.0377 NCDN 
1558163_at 297.82 36.77 2.33 0.0172 PEX13 
229970_at 425.93 183.28 2.32 0.0026 DKFZP434E2318 
1565674_at 1011.58 435.58 2.32 0.0076 FCGR2A 
229488_at 316.29 734.48 2.32 0.0385 ZA20D1 
222955_s_at 985.03 426.98 2.31 0.0179 HT011 
226148_at 4796.79 2085.70 2.30 0.0223 HSPC063 
1552899_at 331.57 762.27 2.30 0.0183 MGC34034 
218998_at 1791.01 779.99 2.30 0.0275 FLJ20457 
220315_at 210.55 480.80 2.28 0.0480 C12orf6 
221238_at 123.74 291.65 2.28 0.0494 NSBP1 
238596_at 241.80 550.17 2.28 0.0355 C10orf4 
201748_s_at 273.10 621.31 2.28 0.0009 SAFB 
204276_at 267.07 606.20 2.27 0.0059 na 
204520_x_at 414.05 939.60 2.27 0.0484 BRD1 
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202471_s_at 399.72 906.63 2.27 0.0365 IDH3G 
236742_at 651.15 1476.70 2.27 0.0039   
218895_at 249.81 564.12 2.26 0.0412 FLJ12455 
221536_s_at 495.18 1117.35 2.26 0.0177 FLJ11301 
226628_at 648.09 287.95 2.25 0.0020 THOC2 
232096_x_at 578.95 1298.82 2.24 0.0466   
1554809_at 161.15 360.50 2.24 0.0128 na 
222713_s_at 207.07 461.83 2.23 0.0236 FANCF 
211977_at 362.46 808.29 2.23 0.0051 GPR107 
227042_at 156.20 346.91 2.22 0.0147 LOC150223 
230803_s_at 142.58 315.76 2.21 0.0411 DKFZP564B1162 
217551_at 184.20 407.18 2.21 0.0492 na 
214305_s_at 728.62 1604.89 2.20 0.0023 SF3B1 
1564688_a_at 45.71 281.22 2.20 0.0350 FLJ40346 
230120_s_at 145.58 319.37 2.19 0.0020   
217026_at 30.18 279.62 2.18 0.0030   
225708_at 256.92 557.44 2.17 0.0259 DKFZp434H247 
1565662_at 535.79 1161.43 2.17 0.0047 MUC6 
204020_at 2035.37 946.74 2.15 0.0105 PURA 
208447_s_at 285.43 610.62 2.14 0.0259 PRPS1 
225479_at 1456.69 682.26 2.14 0.0078 LOC116064 
229021_at 2745.11 1294.55 2.12 0.0223 FLJ11175 
1562792_at 395.78 835.82 2.11 0.0066   
240282_at 509.97 1075.97 2.11 0.0021 WDR1 
201957_at 488.12 1028.02 2.11 0.0127 PPP1R12B 
203572_s_at 386.77 814.37 2.11 0.0094 TAF6 
241799_x_at 766.40 1613.65 2.11 0.0256   
1553528_a_at 268.67 48.39 2.10 0.0264 TAF5 
236235_at 18.16 268.58 2.10 0.0037 ITCH 
216036_x_at 532.17 1110.81 2.09 0.0337 KIAA1037 
1555427_s_at 266.84 43.71 2.08 0.0409 NSAP1 
1558233_s_at 266.17 28.69 2.08 0.0127   
207627_s_at 265.98 98.99 2.08 0.0173 TFCP2 
201924_at 2646.48 1275.30 2.08 0.0088 MLLT2 
228930_at 478.70 992.51 2.07 0.0341 LOC123722 
212047_s_at 345.19 714.17 2.07 0.0021 DKFZP566H073 
212625_at 487.19 1006.83 2.07 0.0173 STX10 
231835_at 281.50 576.34 2.05 0.0106 MGC26818 
225335_at 380.02 776.95 2.04 0.0491   
218962_s_at 261.48 54.62 2.04 0.0302 FLJ13576 
230734_x_at 904.76 443.14 2.04 0.0163 STRN 
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229350_x_at 501.17 1020.59 2.04 0.0302 FLJ14464 
211004_s_at 349.54 710.04 2.03 0.0060 ALDH3B1 
235843_at 234.49 476.29 2.03 0.0481   
1558306_at 26.20 257.18 2.01 0.0367 na 
202738_s_at 1321.84 659.15 2.01 0.0394 PHKB 
240823_at 104.96 256.25 2.00 0.0161   
212427_at 364.35 182.56 2.00 0.0144 KIAA0368 
Age Group Newborn Elderly    










P-Value Gene Symbol 
1405_i_at 68.55 2855.50 22.31 0.0093 CCL5 
201108_s_at 85.26 1959.04 15.31 0.0478 THBS1 
229822_at 56.68 1833.31 14.32 0.0192 PARVG 
201904_s_at 342.61 4467.37 13.04 0.0480 C3orf8 
201125_s_at 109.05 1286.44 10.05 0.0362 ITGB5 
208791_at 77.40 1269.89 9.92 0.0211 CLU 
233898_s_at 1281.39 130.93 9.79 0.0375 DKFZP564O1863 
208159_x_at 252.93 2146.31 8.49 0.0046 DDX11 
226119_at 3083.18 384.97 8.01 0.0249 LOC115294 
212855_at 964.64 77.55 7.54 0.0320 KIAA0276 
222483_at 365.14 2708.43 7.42 0.0382 MGC4342 
212948_at 197.45 1327.42 6.72 0.0224 CAMTA2 
1569206_at 2346.46 353.75 6.63 0.0210 MGC40368 
203665_at 64.32 843.44 6.59 0.0161 HMOX1 
217778_at 104.43 827.98 6.47 0.0206 SLC39A1 
1555659_a_at 84.97 826.56 6.46 0.0452 TREML1 
200766_at 58.65 818.61 6.40 0.0247 CTSD 
213222_at 825.78 132.05 6.25 0.0349 PLCB1 
222553_x_at 912.68 154.68 5.90 0.0463 OXR1 
208581_x_at 58.25 754.92 5.90 0.0057 MT1X 
226099_at 1032.71 181.77 5.68 0.0383 ELL2 
209453_at 119.36 669.68 5.23 0.0302 SLC9A1 
225290_at 668.59 86.87 5.22 0.0400   
212567_s_at 90.46 660.55 5.16 0.0065 MAP4 
1554062_at 886.88 173.10 5.12 0.0370 XG 
227224_at 1001.40 196.05 5.11 0.0011 FLJ10244 
213262_at 759.19 149.30 5.08 0.0064 SACS 
238781_at 1128.74 223.91 5.04 0.0204 SFRS12 
202807_s_at 144.06 721.06 5.01 0.0285 TOM1 
228198_s_at 93.75 640.49 5.00 0.0030 LOC150763 
223243_s_at 775.99 155.46 4.99 0.0491 C1orf22 
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203227_s_at 65.25 632.98 4.95 0.0396 SAS 
230886_at 2163.80 447.38 4.84 0.0273   
213025_at 1310.94 271.71 4.82 0.0068 FLJ20274 
202262_x_at 128.30 608.18 4.74 0.0428 DDAH2 
244020_at 124.58 605.86 4.73 0.0280   
201613_s_at 78.39 602.19 4.70 0.0037 RUVBL1 
211968_s_at 599.03 105.70 4.68 0.0229 HSPCA 
225207_at 109.09 598.55 4.68 0.0033 PDK4 
228381_at 2702.31 578.39 4.67 0.0294 ATF7IP2 
205961_s_at 593.95 81.53 4.64 0.0341 PSIP2 
218747_s_at 56.72 587.79 4.59 0.0132 TAPBP-R 
224365_s_at 581.47 88.35 4.54 0.0309 TIGD7 
227146_at 680.92 152.12 4.48 0.0225 SOXN 
1558027_s_at 746.05 168.19 4.44 0.0295 PRKAB2 
229798_s_at 317.41 1382.71 4.36 0.0255 BRI3 
214626_s_at 139.22 605.26 4.35 0.0085 G2AN 
203328_x_at 231.53 1000.55 4.32 0.0366 IDE 
220507_s_at 54.07 548.44 4.28 0.0337 UPB1 
217264_s_at 732.79 171.21 4.28 0.0430   
227685_at 547.10 88.43 4.27 0.0153 TMF1 
1569573_at 541.90 44.03 4.23 0.0297   
212012_at 909.22 215.08 4.23 0.0117 D2S448 
208893_s_at 537.01 42.25 4.20 0.0319 DUSP6 
204655_at 676.60 2827.61 4.18 0.0427 CCL5 
204291_at 1177.85 284.00 4.15 0.0325 KIAA0335 
225295_at 911.10 224.43 4.06 0.0039 KIAA1265 
203517_at 691.07 173.48 3.98 0.0386 MTX2 
231426_at 508.82 111.44 3.98 0.0367   
227015_at 202.32 797.35 3.94 0.0270 LOC57168 
201745_at 1046.62 266.51 3.93 0.0046 PTK9 
219574_at 1215.54 312.52 3.89 0.0176 FLJ20668 
229879_at 321.54 1231.59 3.83 0.0008   
202557_at 488.32 74.65 3.82 0.0094 STCH 
222195_s_at 142.57 543.15 3.81 0.0488 NAP1 
204993_at 383.38 1437.38 3.75 0.0076 GNAZ 
229414_at 654.70 176.30 3.71 0.0119 PITPNC1 
242625_at 1708.31 464.54 3.68 0.0113 cig5 
241133_at 1007.29 3698.06 3.67 0.0480   
243286_at 1443.35 394.16 3.66 0.0449   
219009_at 115.95 467.14 3.65 0.0152 C14orf93 
207735_at 85.33 466.93 3.65 0.0463 RNF125 
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219396_s_at 176.88 629.03 3.56 0.0463 NEIL1 
218599_at 85.33 453.94 3.55 0.0333 REC8 
219399_at 448.25 24.21 3.50 0.0183 LIN7C 
220305_at 111.10 446.95 3.49 0.0057 MGC3260 
217854_s_at 310.76 1081.04 3.48 0.0029 POLR2E 
226366_at 655.40 189.53 3.46 0.0207 SHPRH 
201548_s_at 181.42 626.15 3.45 0.0300 PLU-1 
235331_x_at 440.37 91.98 3.44 0.0222 MGC16202 
228301_x_at 199.91 686.25 3.43 0.0403 NDUFB10 
219002_at 1086.70 318.52 3.41 0.0060 FLJ21901 
226780_s_at 105.34 436.33 3.41 0.0318 na 
222103_at 2099.59 617.65 3.40 0.0322 ATF1 
226437_at 91.68 430.55 3.36 0.0172 LOC90522 
204735_at 300.31 1003.77 3.34 0.0264 PDE4A 
226681_at 768.24 230.13 3.34 0.0302 UBE2H 
213507_s_at 3343.29 11159.29 3.34 0.0466 KPNB1 
238496_at 427.20 35.23 3.34 0.0039 WHSC1L1 
205434_s_at 637.33 2125.99 3.34 0.0370 AAK1 
215566_x_at 349.90 1166.91 3.33 0.0013 LYPLA2 
204645_at 827.41 251.48 3.29 0.0359 CCNT2 
232383_at 419.93 70.41 3.28 0.0097 TFEC 
228961_at 419.76 107.38 3.28 0.0191 FLJ35954 
204905_s_at 499.18 153.15 3.26 0.0410 TXNDC5 
235385_at 1960.62 603.83 3.25 0.0444 FLJ20668 
228087_at 584.24 180.64 3.23 0.0491 LOC90693 
213808_at 477.68 149.16 3.20 0.0282 na 
225144_at 999.83 312.73 3.20 0.0227 BMPR2 
228095_at 454.48 142.34 3.19 0.0182 PHF14 
206896_s_at 657.05 206.12 3.19 0.0411 FLJ00058 
206873_at 407.72 69.55 3.19 0.0228 CA6 
209434_s_at 406.97 81.65 3.18 0.0304 PPAT 
213320_at 698.74 221.97 3.15 0.0465 PRMT3 
222871_at 177.93 559.67 3.15 0.0185 FLJ10748 
219534_x_at 47.01 400.63 3.13 0.0471 CDKN1C 
240172_at 530.57 169.62 3.13 0.0324 LOC51290 
222197_s_at 616.55 198.40 3.11 0.0465   
206583_at 607.57 195.64 3.11 0.0072 FLJ20344 
204425_at 280.96 871.92 3.10 0.0388 ARHGAP4 
244803_at 313.25 967.06 3.09 0.0048   
1553743_at 469.85 152.35 3.08 0.0100 LOC151194 
226885_at 822.95 267.88 3.07 0.0113   
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206770_s_at 393.00 119.33 3.07 0.0170 SLC35A3 
229371_at 1349.11 439.95 3.07 0.0379   
215690_x_at 472.68 1447.77 3.06 0.0330 GPAA1 
228749_at 459.82 150.77 3.05 0.0493 KIAA1571 
202906_s_at 620.21 203.70 3.04 0.0267 NBS1 
213700_s_at 342.03 1040.11 3.04 0.0420 PKM2 
234050_at 1228.41 404.99 3.03 0.0468 TAGAP 
242136_x_at 1960.45 648.17 3.02 0.0151 ZRANB1 
224448_s_at 157.09 473.78 3.02 0.0077 MGC14833 
241027_at 384.18 72.50 3.00 0.0348 OPA1 
233833_at 221.00 661.54 2.99 0.0243   
209704_at 382.41 30.65 2.99 0.0002 M96 
203156_at 1584.66 531.63 2.98 0.0322 AKAP11 
212819_at 89.66 381.17 2.98 0.0441 ASB1 
226637_at 921.46 310.18 2.97 0.0123 UBE2H 
217518_at 754.93 254.65 2.96 0.0418 FER1L3 
236994_at 774.09 261.84 2.96 0.0304 na 
224060_s_at 588.36 199.65 2.95 0.0028 CGI-30 
222425_s_at 198.64 584.88 2.94 0.0366 PDIP38 
203710_at 792.63 269.87 2.94 0.0282 ITPR1 
218394_at 173.73 510.15 2.94 0.0329 FLJ22386 
204038_s_at 169.48 495.04 2.92 0.0246 EDG2 
213021_at 156.94 456.53 2.91 0.0280 GOSR1 
229618_at 500.60 172.20 2.91 0.0217 SNX16 
235630_at 178.47 518.03 2.90 0.0361   
225755_at 451.15 1308.29 2.90 0.0026 MGC35097 
239647_at 93.00 370.97 2.90 0.0269 CHST13 
230740_at 505.01 1453.61 2.88 0.0300 EHD3 
202438_x_at 368.20 82.70 2.88 0.0438 na 
228258_at 185.41 532.36 2.87 0.0350   
203290_at 109.26 366.78 2.87 0.0069 HLA-DQA1 
229449_at 281.38 804.84 2.86 0.0381   
221957_at 650.20 1842.55 2.83 0.0417 PDK3 
206958_s_at 1943.51 687.53 2.83 0.0231 UPF3A 
202830_s_at 177.61 502.07 2.83 0.0480 G6PT1 
218236_s_at 612.20 216.59 2.83 0.0096 PRKCN 
213930_at 861.00 304.63 2.83 0.0218 na 
226646_at 446.38 1251.54 2.80 0.0274 KLF2 
203611_at 612.11 1713.93 2.80 0.0348 TERF2 
210527_x_at 731.48 2047.72 2.80 0.0018 TUBA2 
242294_at 57.28 358.24 2.80 0.0166   
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203035_s_at 208.81 582.79 2.79 0.0295 PIAS3 
225775_at 255.98 714.39 2.79 0.0326 MGC50844 
213372_at 507.85 182.00 2.79 0.0332 LOC152559 
37796_at 283.65 791.44 2.79 0.0426 LRRN4 
211460_at 429.50 154.61 2.78 0.0390 TTTY9 
219736_at 354.78 98.85 2.77 0.0272 TRIM36 
244778_x_at 583.79 1616.46 2.77 0.0485   
204140_at 236.72 652.52 2.76 0.0106 TPST1 
226897_s_at 352.15 110.98 2.75 0.0330 HSPC055 
231035_s_at 1139.11 414.46 2.75 0.0086 LOC220213 
243213_at 1006.61 366.36 2.75 0.0213 STAT3 
225239_at 542.73 1488.74 2.74 0.0030   
1552375_at 169.25 462.70 2.73 0.0042 ZNF333 
223506_at 501.32 184.44 2.72 0.0359 LOC84524 
1557430_at 345.38 66.50 2.70 0.0070 LOC147670 
208896_at 825.24 306.45 2.69 0.0129 DDX18 
201404_x_at 1353.81 505.33 2.68 0.0147 PSMB2 
229891_x_at 522.24 195.02 2.68 0.0131   
235061_at 570.15 213.00 2.68 0.0477 DKFZp761G058 
203655_at 161.15 431.12 2.68 0.0374 XRCC1 
218951_s_at 419.05 1120.52 2.67 0.0053 FLJ11323 
201139_s_at 712.60 266.93 2.67 0.0434 SSB 
233480_at 368.39 979.69 2.66 0.0134 MGC3222 
209175_at 806.01 303.23 2.66 0.0180 SEC23IP 
225005_at 471.50 1252.93 2.66 0.0323 PHF13 
204156_at 339.98 75.92 2.66 0.0025 KIAA0999 
209891_at 22.61 339.47 2.65 0.0042 AD024 
235607_at 401.69 151.76 2.65 0.0161 HNRPD 
1553132_a_at 338.53 115.25 2.64 0.0410 C14orf47 
222868_s_at 391.91 1035.98 2.64 0.0000 IL18BP 
225455_at 1139.63 436.65 2.61 0.0178 STAF42 
213269_at 448.11 172.11 2.60 0.0416 LOC57209 
203459_s_at 564.10 1462.34 2.59 0.0447 VPS16 
202169_s_at 1464.33 565.84 2.59 0.0037 AASDHPPT 
215268_at 34.44 329.40 2.57 0.0165 KIAA0754 
221664_s_at 464.89 1194.68 2.57 0.0018 F11R 
202950_at 630.32 245.67 2.57 0.0364 CRYZ 
202770_s_at 924.31 361.95 2.55 0.0456 CCNG2 
1555274_a_at 544.29 213.29 2.55 0.0465 KIAA1724 
1552927_at 435.33 171.73 2.53 0.0075 MGC45404 
226852_at 429.81 169.60 2.53 0.0200 MTA3 
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223207_x_at 304.80 770.09 2.53 0.0486 PHP14 
212599_at 2968.74 1176.33 2.52 0.0075 AUTS2 
235843_at 234.49 590.39 2.52 0.0357   
221536_s_at 495.18 1241.67 2.51 0.0077 FLJ11301 
225134_at 292.63 733.22 2.51 0.0086 FLJ14800 
227060_at 266.79 668.29 2.50 0.0260 TNFRSF19L 
226943_at 54.39 319.59 2.50 0.0276   
225882_at 77.08 318.60 2.49 0.0361 YEA 
226285_at 858.87 345.30 2.49 0.0015 M11S1 
218929_at 442.45 178.05 2.49 0.0175 CARF 
220140_s_at 694.63 1720.98 2.48 0.0209 SNX11 
201416_at 1694.52 684.31 2.48 0.0206 SOX4 
244512_at 30.76 316.54 2.47 0.0158   
235844_at 316.47 66.87 2.47 0.0353 PHTF1 
222839_s_at 735.45 297.52 2.47 0.0466 PAPOLG 
213737_x_at 4581.77 1865.67 2.46 0.0137   
238273_at 197.99 486.01 2.45 0.0486   
211930_at 827.28 337.16 2.45 0.0304 na 
225350_s_at 2067.35 5071.32 2.45 0.0426 FLJ13456 
220768_s_at 774.71 319.09 2.43 0.0115 CSNK1G3 
222448_s_at 1433.75 593.36 2.42 0.0104 UMP-CMPK 
201913_s_at 534.65 1285.41 2.40 0.0256 NBP 
232486_at 811.99 1949.50 2.40 0.0478 KIAA1484 
226864_at 307.29 31.68 2.40 0.0148 PKIA 
225731_at 966.55 402.70 2.40 0.0330 KIAA1223 
202654_x_at 801.38 334.23 2.40 0.0216 AXOT 
226855_at 202.39 484.14 2.39 0.0218   
220239_at 277.27 654.09 2.36 0.0347 SBBI26 
217456_x_at 3242.94 7648.60 2.36 0.0345 HLA-E 
1569629_x_at 40.32 301.32 2.35 0.0497 na 
238299_at 583.34 1365.29 2.34 0.0165   
200957_s_at 544.80 1273.61 2.34 0.0047 SSRP1 
227375_at 335.03 143.45 2.34 0.0448 DKFZP566D1346 
218331_s_at 733.90 314.34 2.33 0.0431 FLJ20360 
206005_s_at 298.76 30.33 2.33 0.0004 C6orf84 
217436_x_at 987.93 2285.28 2.31 0.0199   
1555978_s_at 737.13 319.09 2.31 0.0373 MRCL3 
43544_at 297.32 686.55 2.31 0.0356 TRAP95 
219276_x_at 494.36 214.27 2.31 0.0465 FLJ13657 
208993_s_at 294.44 114.65 2.30 0.0133   
209284_s_at 1057.34 461.51 2.29 0.0277 RAP140 
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205407_at 293.13 18.40 2.29 0.0046 RECK 
228106_at 306.50 700.89 2.29 0.0007 FLJ20280 
205986_at 736.02 1678.00 2.28 0.0252 AATK 
213022_s_at 212.14 483.27 2.28 0.0053 UTRN 
201165_s_at 1571.61 694.04 2.26 0.0470 PUM1 
233946_at 346.74 783.46 2.26 0.0082 na 
219118_at 94.83 288.85 2.26 0.0371 FKBP11 
222731_at 2041.36 906.48 2.25 0.0290 ZDHHC2 
214867_at 420.79 940.56 2.24 0.0119 NDST2 
1558448_a_at 18.16 285.80 2.23 0.0077   
241438_at 285.68 82.32 2.23 0.0375   
1561144_at 108.34 285.55 2.23 0.0364   
209667_at 40.47 285.01 2.23 0.0250 CES2 
242121_at 716.90 1594.55 2.22 0.0181   
201382_at 110.78 284.37 2.22 0.0029 SIP 
214730_s_at 680.25 1510.71 2.22 0.0359 GLG1 
241823_at 730.26 329.29 2.22 0.0277   
203607_at 190.59 422.00 2.21 0.0037 INPP5F 
222756_s_at 372.18 822.51 2.21 0.0466 ARRB1 
227042_at 156.20 345.07 2.21 0.0113 LOC150223 
200035_at 448.67 990.81 2.21 0.0090 DULLARD 
215764_x_at 560.19 1226.93 2.19 0.0334 AP2A2 
200827_at 421.64 923.10 2.19 0.0150 PLOD 
219630_at 381.08 833.12 2.19 0.0054 MAP17 
238057_at 279.20 29.54 2.18 0.0462   
227962_at 544.22 1184.28 2.18 0.0261 ACOX1 
200846_s_at 45.48 278.45 2.18 0.0466 PPP1CA 
200621_at 586.74 1273.95 2.17 0.0415 CSRP1 
1557966_x_at 968.73 446.48 2.17 0.0172 MGC61716 
225431_x_at 1645.32 758.46 2.17 0.0262 ACY1L2 
1553677_a_at 372.80 806.61 2.16 0.0383 MGC3794 
227352_at 157.77 339.62 2.15 0.0354 FLJ35119 
242073_at 635.89 297.38 2.14 0.0038   
231578_at 273.04 34.43 2.13 0.0098 GBP1 
216233_at 156.65 334.09 2.13 0.0459 CD163 
229129_at 768.33 360.65 2.13 0.0496 HNRPD 
206555_s_at 967.62 457.42 2.12 0.0260 FLJ20274 
219012_s_at 21.17 270.56 2.11 0.0010 C11ORF30 
221575_at 328.15 692.76 2.11 0.0234 SCLY 
228239_at 636.19 301.40 2.11 0.0303 C21orf51 
239329_at 982.11 468.16 2.10 0.0061 RAB21 
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204521_at 611.45 292.05 2.09 0.0126 HSU79274 
203572_s_at 386.77 807.47 2.09 0.0285 TAF6 
217844_at 1146.23 2384.11 2.08 0.0159 NLIIF 
1558233_s_at 266.17 40.71 2.08 0.0485   
242772_x_at 443.19 913.62 2.06 0.0015   
202330_s_at 524.85 1078.82 2.06 0.0418 UNG 
204798_at 778.34 379.26 2.05 0.0050 MYB 
219648_at 502.95 245.64 2.05 0.0284 FLJ10116 
239603_x_at 1027.26 502.09 2.05 0.0063   
204069_at 355.56 726.82 2.04 0.0099 MEIS1 
202874_s_at 1101.37 540.98 2.04 0.0206 ATP6V1C1 
202795_x_at 855.42 1739.34 2.03 0.0264 HRIHFB2122 
1559490_at 652.54 1326.62 2.03 0.0114 MGC4126 
202531_at 967.08 1965.05 2.03 0.0259 IRF1 
212306_at 824.02 405.92 2.03 0.0396 CLASP2 
236922_at 470.19 232.22 2.02 0.0413   
213387_at 1257.39 624.39 2.01 0.0410 KIAA1240 
226895_at 554.31 1112.65 2.01 0.0195 NFIC 
204164_at 287.44 576.69 2.01 0.0298 SIPA1 
206715_at 962.14 480.53 2.00 0.0401 TFEC 
213052_at 549.09 1098.90 2.00 0.0372 PRKAR2A 
Age Group Juvenile Elderly    










P-Value Gene Symbol 
219607_s_at 146.29 3796.82 25.95 0.0424 MS4A4A 
207072_at 242.43 5654.21 23.32 0.0492 IL18RAP 
206390_x_at 749.72 16650.55 22.21 0.0446 PF4 
205033_s_at 1351.98 29923.18 22.13 0.0162 DEFA1 
202446_s_at 518.56 10132.74 19.54 0.0495 PLSCR1 
225447_at 135.32 2604.11 19.24 0.0332 GPD2 
235568_at 2452.87 40793.35 16.63 0.0478 LOC199675 
205863_at 2180.02 35998.71 16.51 0.0353 S100A12 
200934_at 115.50 2098.95 16.40 0.0478 DEK 
229285_at 20.48 1985.36 15.51 0.0045 RNASEL 
226277_at 128.89 1929.12 14.97 0.0465 COL4A3BP 
238439_at 188.21 2632.62 13.99 0.0247 MGC22805 
201694_s_at 801.86 10970.27 13.68 0.0432 EGR1 
220496_at 454.82 5359.07 11.78 0.0383 CLEC2 
224587_at 60.97 1461.32 11.42 0.0478 PC4 
227038_at 129.40 1433.68 11.08 0.0252 MGC26963 
201061_s_at 1145.01 12341.17 10.78 0.0439 STOM 
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227438_at 68.56 1366.58 10.68 0.0325 LAK 
221505_at 60.89 1338.11 10.45 0.0425 ANP32E 
225633_at 417.51 4363.10 10.45 0.0455 LOC147991 
208708_x_at 149.53 1511.50 10.11 0.0447 EIF5 
209301_at 232.90 2272.33 9.76 0.0314 CA2 
202441_at 233.09 2153.67 9.24 0.0341 KEO4 
203310_at 100.39 1141.73 8.92 0.0481 STXBP3 
222692_s_at 102.88 1137.16 8.88 0.0354 FAD104 
217986_s_at 89.84 1107.97 8.66 0.0336 BAZ1A 
226280_at 132.41 1123.65 8.49 0.0050 BNIP2 
218865_at 326.84 2741.00 8.39 0.0029 FLJ22390 
206698_at 340.78 2786.41 8.18 0.0385 XK 
209063_x_at 130.32 1053.65 8.09 0.0242 PAIP1 
212688_at 455.84 3597.44 7.89 0.0472 PIK3CB 
219035_s_at 283.34 2173.06 7.67 0.0458 RNF34 
212157_at 1204.88 159.44 7.56 0.0368 SDC2 
201111_at 176.51 1331.95 7.55 0.0339 CSE1L 
1562597_at 925.40 115.08 7.23 0.0087   
229615_at 112.31 923.26 7.21 0.0174   
219697_at 1202.76 172.88 6.96 0.0268 HS3ST2 
240131_at 122.85 879.33 6.87 0.0246   
202078_at 179.04 1217.50 6.80 0.0314 COPS3 
209513_s_at 158.45 1073.73 6.78 0.0424 MGC10940 
235973_at 857.88 120.33 6.70 0.0168 TRIP11 
220034_at 148.72 991.14 6.66 0.0158 IRAK3 
212631_at 279.73 1863.42 6.66 0.0437 na 
210156_s_at 215.99 1435.51 6.65 0.0257 PCMT1 
208933_s_at 286.45 1871.37 6.53 0.0324 FLJ10359 
226910_at 137.77 891.68 6.47 0.0277 LOC51122 
226105_at 137.63 889.55 6.46 0.0126 na 
236081_at 43.33 817.14 6.38 0.0214   
1569401_at 150.31 953.96 6.35 0.0198 CLL-1 
226338_at 96.24 797.75 6.23 0.0389 DKFZp762O076 
201407_s_at 333.93 2075.36 6.21 0.0309 PPP1CB 
221260_s_at 79.88 787.86 6.16 0.0369 C12orf22 
202055_at 159.78 980.59 6.14 0.0447 KPNA1 
213119_at 369.64 2260.16 6.11 0.0453 SLC36A1 
203196_at 132.12 806.36 6.10 0.0375 ABCC4 
203996_s_at 865.56 142.56 6.07 0.0156 C21orf2 
231996_at 768.21 98.80 6.00 0.0045 N4BP2 
208775_at 478.88 2859.05 5.97 0.0400 XPO1 
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237097_at 755.40 105.65 5.90 0.0308 SPTBN5 
244185_at 1156.89 197.55 5.86 0.0137 METAP2 
227368_at 125.71 746.57 5.83 0.0300 C6orf166 
217167_x_at 74.76 738.02 5.77 0.0206   
225519_at 178.98 1024.27 5.72 0.0387 PPP4R2 
202776_at 175.83 993.07 5.65 0.0179 HSU15552 
215987_at 721.91 84.14 5.64 0.0335 PDZGEF1 
238738_at 704.34 49.28 5.50 0.0261 PSMD7 
202745_at 106.79 702.29 5.49 0.0026 USP8 
229642_at 1271.04 232.16 5.47 0.0044 ARHGEF7 
205368_at 695.61 55.93 5.43 0.0104 KIAA0773 
234219_at 850.88 157.55 5.40 0.0343   
212250_at 295.32 1583.97 5.36 0.0209 LYRIC 
227215_at 683.92 69.24 5.34 0.0073   
220180_at 681.91 103.59 5.33 0.0083 SE57-1 
205689_at 717.63 134.94 5.32 0.0049 FLJ11383 
225678_at 903.37 172.10 5.25 0.0301 RPC8 
205098_at 1495.32 7835.56 5.24 0.0467 CCR1 
208716_s_at 111.84 670.19 5.24 0.0023 LOC54499 
203333_at 51.11 668.42 5.22 0.0010 KIFAP3 
200749_at 82.51 665.92 5.20 0.0177 RAN 
242338_at 1238.93 241.30 5.13 0.0355   
228791_at 705.36 137.41 5.13 0.0075 MGC61550 
226152_at 52.48 654.51 5.11 0.0152 TTC7L1 
242280_x_at 648.43 92.97 5.07 0.0020 CPEB4 
217094_s_at 212.11 1071.96 5.05 0.0073 ITCH 
224734_at 93.34 646.75 5.05 0.0027 HMGB1 
204125_at 401.20 2020.36 5.04 0.0360 CIA30 
224832_at 100.77 643.92 5.03 0.0045 DUSP16 
205505_at 126.70 642.09 5.02 0.0110 GCNT1 
242738_s_at 639.09 104.87 4.99 0.0260 ATBF1 
210147_at 632.39 52.42 4.94 0.0133 ART3 
1559950_at 630.73 51.41 4.93 0.0169   
1557540_at 629.17 109.14 4.92 0.0410 na 
204212_at 652.90 134.95 4.84 0.0127 PTE1 
207034_s_at 615.77 111.74 4.81 0.0392 GLI2 
230261_at 157.79 756.36 4.79 0.0446 SIAT8D 
226221_at 84.01 605.77 4.73 0.0206 KIAA1432 
1567107_s_at 151.77 717.66 4.73 0.0285 TPM4 
212779_at 142.10 665.55 4.68 0.0189 KIAA1109 
219531_at 110.90 599.50 4.68 0.0453 FLJ10565 
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209666_s_at 212.00 986.93 4.66 0.0259 CHUK 
233433_at 840.94 183.70 4.58 0.0183   
205839_s_at 585.95 127.89 4.58 0.0148 BZRAP1 
242003_at 585.70 61.33 4.58 0.0274   
208975_s_at 130.57 593.62 4.55 0.0402 KPNB1 
206197_at 602.12 133.13 4.52 0.0090 NME5 
212536_at 692.08 3129.66 4.52 0.0424 ATP11B 
212500_at 127.11 572.73 4.47 0.0186 FLJ14547 
227987_at 85.47 572.52 4.47 0.0115 CHAC 
203398_s_at 604.71 135.38 4.47 0.0029 GALNT3 
216942_s_at 103.64 570.49 4.46 0.0176 CD58 
1569947_at 568.87 115.74 4.44 0.0110   
209066_x_at 85.46 568.46 4.44 0.0172 UQCRB 
243579_at 196.93 870.37 4.42 0.0319 MSI2 
206007_at 563.81 43.80 4.40 0.0164 PRG4 
208782_at 164.84 725.64 4.40 0.0188 FSTL1 
242778_at 843.27 191.95 4.39 0.0471 LPXN 
212007_at 203.75 891.79 4.38 0.0378 UBXD2 
219620_x_at 203.71 887.05 4.35 0.0111 SLC34A3 
204905_s_at 666.40 153.15 4.35 0.0138 TXNDC5 
201614_s_at 83.09 555.51 4.34 0.0391 RUVBL1 
1559654_s_at 874.37 201.65 4.34 0.0128   
204615_x_at 479.36 2071.68 4.32 0.0415 IDI1 
229800_at 621.74 143.92 4.32 0.0369   
202545_at 71.83 550.83 4.30 0.0339 PRKCD 
222572_at 80.03 549.60 4.29 0.0237   
202538_s_at 150.13 643.60 4.29 0.0270 DKFZP564O123 
233943_x_at 547.60 115.57 4.28 0.0481 FAPP2 
217851_s_at 88.83 545.47 4.26 0.0424 C20orf45 
201821_s_at 86.30 544.29 4.25 0.0328 TIMM17A 
244321_at 541.91 43.06 4.23 0.0260 FLJ12377 
201513_at 111.20 536.86 4.19 0.0285 TSN 
225611_at 112.03 534.31 4.17 0.0048 KIAA0303 
217512_at 583.36 139.97 4.17 0.0452 KNG 
204898_at 529.69 114.46 4.14 0.0072 SAP30 
232647_at 531.43 128.59 4.13 0.0031 MGC39650 
217264_s_at 706.97 171.21 4.13 0.0209   
219210_s_at 227.70 939.70 4.13 0.0332 LOC51762 
1561089_at 628.85 152.54 4.12 0.0144 na 
201298_s_at 1314.32 5403.27 4.11 0.0437 C2orf6 
215613_at 821.16 200.59 4.09 0.0091 ADAM12 
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203725_at 466.35 1907.13 4.09 0.0301 GADD45A 
204955_at 549.19 134.52 4.08 0.0473 SRPX 
239544_at 1192.90 292.94 4.07 0.0168 SETBP1 
240106_at 607.80 149.43 4.07 0.0174 MGC4170 
229467_at 520.11 65.49 4.06 0.0452 PCBP2 
226743_at 153.07 619.47 4.05 0.0055 FLJ34922 
219496_at 515.64 58.68 4.03 0.0383 FLJ21870 
230123_at 758.78 189.04 4.01 0.0183 FLJ10420 
218904_s_at 223.61 894.70 4.00 0.0314 FLJ10110 
240290_at 948.69 237.20 4.00 0.0448   
227721_at 985.16 247.59 3.98 0.0153 VIP 
208849_at 508.66 92.33 3.97 0.0349   
203477_at 507.34 86.74 3.96 0.0418 COL15A1 
244535_at 801.40 203.01 3.95 0.0084   
1570315_at 1054.81 269.50 3.91 0.0273 na 
239247_at 1037.14 265.01 3.91 0.0158   
201001_s_at 374.97 1467.20 3.91 0.0125 UBE2V1 
243676_at 1376.98 351.93 3.91 0.0454 C20orf59 
1565863_at 500.29 55.11 3.91 0.0313   
222051_s_at 499.68 113.76 3.90 0.0437 E2F5 
226161_at 41.47 497.69 3.89 0.0052 SLC30A6 
228090_at 140.76 547.22 3.89 0.0046 NMNAT3 
211367_s_at 52.39 496.64 3.88 0.0008 CASP1 
219153_s_at 550.67 141.99 3.88 0.0270 FLJ13710 
201234_at 371.18 1434.37 3.86 0.0196 ILK 
220881_at 494.46 100.03 3.86 0.0243 LMO2 
237337_at 616.78 159.77 3.86 0.0092   
230267_at 36.16 493.77 3.86 0.0016 na 
219160_s_at 491.63 118.95 3.84 0.0006 PAPOLG 
1566646_at 490.94 119.05 3.84 0.0391 LOC149086 
212076_at 923.51 241.75 3.82 0.0120 MLL 
224994_at 487.87 74.17 3.81 0.0406 CAMK2D 
220178_at 834.44 219.10 3.81 0.0121 FZR1 
205049_s_at 486.59 107.68 3.80 0.0036 CD79A 
205260_s_at 107.38 486.49 3.80 0.0404 ACYP1 
238614_x_at 531.62 139.94 3.80 0.0257 ZNF430 
218979_at 88.66 485.65 3.79 0.0126 FLJ12888 
1557480_a_at 909.02 239.83 3.79 0.0021 LOC284121 
235215_at 485.07 95.52 3.79 0.0392 na 
1562671_s_at 949.05 251.00 3.78 0.0010   
232386_at 482.78 29.23 3.77 0.0102 KIAA1421 
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243742_at 479.53 68.08 3.75 0.0114   
243855_at 477.12 70.83 3.73 0.0422   
210406_s_at 1263.85 4709.25 3.73 0.0382 RAB6A 
242431_at 660.31 177.25 3.73 0.0288   
52741_at 923.71 248.58 3.72 0.0315 FLJ40452 
1566001_at 1401.89 377.46 3.71 0.0122   
210858_x_at 917.83 248.28 3.70 0.0303 ATM 
242177_at 713.88 193.40 3.69 0.0188   
240282_at 1075.97 292.02 3.68 0.0028 WDR1 
209967_s_at 33.26 471.52 3.68 0.0072 CREM 
244700_at 653.79 177.72 3.68 0.0487 SEC61B 
203693_s_at 548.00 2009.03 3.67 0.0177 E2F3 
211744_s_at 301.76 1105.06 3.66 0.0085 CD58 
200688_at 950.58 259.90 3.66 0.0382 SF3B3 
237461_at 465.43 116.13 3.64 0.0324 PYPAF3 
211863_x_at 965.18 265.60 3.63 0.0245 HFE 
240400_at 464.24 95.97 3.63 0.0377   
230860_at 106.94 463.50 3.62 0.0155   
242059_at 462.85 82.37 3.62 0.0281   
244627_at 813.49 225.31 3.61 0.0271 DKFZP586B1621 
217534_at 1017.92 282.48 3.60 0.0192 PAK2 
235662_at 780.55 216.76 3.60 0.0301 MGC15407 
242407_at 944.18 262.71 3.59 0.0107   
242550_at 617.30 172.31 3.58 0.0237   
224341_x_at 526.92 1883.06 3.57 0.0452 TLR4 
204332_s_at 525.19 1867.64 3.56 0.0157 AGA 
200813_s_at 81.29 454.80 3.55 0.0218 PAFAH1B1 
209512_at 58.44 453.63 3.54 0.0017 MGC10940 
208943_s_at 412.77 1462.06 3.54 0.0385 TLOC1 
218297_at 138.90 491.68 3.54 0.0242 FLJ13397 
209137_s_at 414.37 1460.34 3.52 0.0134 USP10 
233083_at 451.10 57.19 3.52 0.0467 FLJ13105 
1562364_at 451.08 19.53 3.52 0.0188 na 
216444_at 450.29 34.99 3.52 0.0198   
227949_at 448.46 105.29 3.50 0.0294 H17739 
203321_s_at 1243.16 355.16 3.50 0.0141 KIAA0863 
212610_at 584.02 2042.00 3.50 0.0270 PTPN11 
233902_at 657.60 188.91 3.48 0.0312 GUCA1C 
207262_at 444.25 44.24 3.47 0.0454 APOF 
235619_at 443.00 115.34 3.46 0.0304 ASB4 
224480_s_at 503.02 1739.24 3.46 0.0216 MGC11324 
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P-Value Gene Symbol 
1569906_s_at 524.61 151.87 3.45 0.0420 C20orf104 
201798_s_at 383.44 1322.62 3.45 0.0171 FER1L3 
214668_at 1030.78 300.05 3.44 0.0217 C13orf1 
1569573_at 436.66 44.03 3.41 0.0379   
235338_s_at 57.18 436.55 3.41 0.0162 SETDB2 
217518_at 867.78 254.65 3.41 0.0347 FER1L3 
1553693_s_at 613.13 180.33 3.40 0.0244 FLJ14431 
221522_at 371.34 1261.38 3.40 0.0073 DKFZP434L0718 
242011_at 1033.64 304.72 3.39 0.0230 na 
1553561_at 506.16 149.30 3.39 0.0340 TAS2R50 
205038_at 386.39 1305.21 3.38 0.0487 ZNFN1A1 
1565661_x_at 605.20 179.56 3.37 0.0174 FUT6 
218739_at 713.68 2404.69 3.37 0.0288 ABHD5 
239371_at 444.56 132.12 3.36 0.0419   
224295_at 430.39 43.02 3.36 0.0281   
229086_at 747.24 223.57 3.34 0.0143 LOC148898 
39835_at 427.56 45.06 3.34 0.0122 SBF1 
225068_at 599.73 2002.76 3.34 0.0369 C3IP1 
235086_at 95.11 427.12 3.34 0.0381 THBS1 
202918_s_at 50.31 426.73 3.33 0.0312 PREI3 
1562716_at 508.08 152.47 3.33 0.0417 LOC284632 
231244_at 426.50 55.51 3.33 0.0350 CAS1 
220509_at 425.02 24.34 3.32 0.0044 C13orf10 
237719_x_at 424.81 17.11 3.32 0.0212   
210116_at 65.53 424.10 3.31 0.0078 SH2D1A 
217315_s_at 643.09 194.15 3.31 0.0190 KLK13 
237006_at 1416.74 4692.28 3.31 0.0404   
212365_at 969.61 292.81 3.31 0.0452 MYO1B 
224679_at 111.49 423.19 3.31 0.0412 MESDC2 
209460_at 443.42 1460.22 3.29 0.0231 NPD009 
236621_at 742.88 226.09 3.29 0.0261   
218578_at 78.23 419.46 3.28 0.0472 C1orf28 
235800_at 662.60 202.28 3.28 0.0253   
212036_s_at 73.65 419.05 3.27 0.0312 PNN 
1555145_at 591.75 180.82 3.27 0.0414 LOC126731 
238999_at 501.36 153.29 3.27 0.0454   
1559582_at 1917.36 586.85 3.27 0.0203   
1557778_at 467.30 143.21 3.26 0.0167 na 
239306_at 416.01 116.95 3.25 0.0325 C14orf93 
232293_at 145.57 470.78 3.23 0.0201 HCAP-G 
236692_at 175.90 567.55 3.23 0.0349 na 
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207847_s_at 563.94 175.63 3.21 0.0453 MUC1 
217627_at 1027.12 319.94 3.21 0.0447 FLJ30921 
210102_at 214.27 685.70 3.20 0.0056 LOH11CR2A 
211464_x_at 1213.01 379.55 3.20 0.0434 CASP6 
215957_at 408.36 65.74 3.19 0.0494 UBE2D1 
230466_s_at 631.85 2012.42 3.18 0.0184   
225411_at 55.76 406.68 3.18 0.0168 FLJ14681 
221390_s_at 405.98 39.62 3.17 0.0261 MTMR8 
233467_s_at 660.79 208.60 3.17 0.0324 PHEMX 
228661_s_at 252.19 798.84 3.17 0.0216   
201416_at 2163.97 684.31 3.16 0.0269 SOX4 
1562546_at 403.85 95.51 3.16 0.0128   
222564_at 403.10 65.44 3.15 0.0344 POGK 
234362_s_at 621.78 197.48 3.15 0.0338 CTLA4 
230852_at 464.84 147.68 3.15 0.0258 MGC2793 
1557810_at 402.55 28.36 3.14 0.0448   
243134_at 401.78 62.28 3.14 0.0300   
1553536_at 1041.13 331.91 3.14 0.0252 MBNL2 
1561749_at 1191.80 380.48 3.13 0.0152   
218970_s_at 227.84 712.31 3.13 0.0228 CGI-32 
1555814_a_at 147.90 462.36 3.13 0.0190 ARHA 
223087_at 219.41 685.45 3.12 0.0448 LOC55862 
202394_s_at 610.90 196.08 3.12 0.0028 ABCF3 
212997_s_at 302.44 941.95 3.11 0.0101 TLK2 
1559093_at 858.83 276.94 3.10 0.0379 na 
232432_s_at 127.01 396.56 3.10 0.0490 SLC30A5 
233968_at 396.37 37.00 3.10 0.0250 CST11 
212888_at 403.03 1241.88 3.08 0.0359 DICER1 
239603_x_at 1547.04 502.09 3.08 0.0129   
212037_at 511.23 1565.31 3.06 0.0409 PNN 
236167_at 391.30 57.11 3.06 0.0224   
224743_at 735.57 2244.13 3.05 0.0169 FLJ20421 
221773_at 323.91 987.06 3.05 0.0025 ELK3 
234757_at 771.47 253.26 3.05 0.0420 FLJ22624 
207501_s_at 389.87 54.96 3.05 0.0106 FGF12 
243511_at 703.22 231.02 3.04 0.0039   
1561311_at 389.51 35.13 3.04 0.0194   
228186_s_at 592.78 194.89 3.04 0.0402 THSD2 
201595_s_at 355.80 1077.84 3.03 0.0486 LEREPO4 
224514_x_at 615.47 203.30 3.03 0.0280 IL17RC 
1561210_at 387.37 59.34 3.03 0.0424   
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214023_x_at 386.68 77.52 3.02 0.0076 TUBB 
210607_at 386.65 52.84 3.02 0.0139 FLT3LG 
209471_s_at 148.31 447.97 3.02 0.0470 FNTA 
1561187_at 633.17 209.70 3.02 0.0224   
204216_s_at 128.35 385.60 3.00 0.0361 FLJ11806 
1559976_at 641.02 213.43 3.00 0.0212   
214377_s_at 481.74 160.40 3.00 0.0312 JAK1 
223646_s_at 567.94 189.25 3.00 0.0498 CYorf15B 
235935_at 424.26 141.53 3.00 0.0148 na 
223894_s_at 271.84 813.79 2.99 0.0313 FTS 
213986_s_at 663.67 222.01 2.99 0.0074 C19orf6 
219194_at 813.47 272.54 2.98 0.0317 SEMA4G 
216232_s_at 543.99 182.37 2.98 0.0217 GCN1L1 
1570153_at 381.60 41.79 2.98 0.0079 FLJ20449 
215245_x_at 298.37 886.83 2.97 0.0267 FMR1 
213227_at 70.18 379.97 2.97 0.0088 PGRMC2 
1564209_at 379.88 43.09 2.97 0.0354 LOC282980 
236146_at 379.58 110.59 2.97 0.0462 NSAP1 
229126_at 555.13 187.26 2.96 0.0476 FLJ10936 
201098_at 590.80 1748.57 2.96 0.0378 COPB2 
228204_at 33.49 378.78 2.96 0.0124 PSMB4 
1552520_at 786.48 266.43 2.95 0.0222 FLJ30668 
238718_at 377.55 30.35 2.95 0.0236 HRASLS3 
239759_at 377.23 49.62 2.95 0.0197   
232574_at 377.12 91.70 2.95 0.0076 XYLT1 
241499_at 376.56 88.52 2.94 0.0206   
236624_at 759.61 258.55 2.94 0.0109   
229172_at 716.62 243.95 2.94 0.0463 HSPA12B 
229629_at 128.48 377.31 2.94 0.0312   
206127_at 798.25 271.83 2.94 0.0491 ELK3 
230395_at 211.01 617.33 2.93 0.0488   
212783_at 873.82 298.92 2.92 0.0280 RBBP6 
203327_at 215.01 625.82 2.91 0.0172 IDE 
202611_s_at 207.08 602.06 2.91 0.0187 CRSP2 
1553024_at 371.87 63.17 2.91 0.0172 G30 
208741_at 131.73 382.08 2.90 0.0444 SAP18 
242249_at 370.89 105.45 2.90 0.0303   
1555711_x_at 370.80 64.23 2.90 0.0330   
1561905_at 1304.25 450.50 2.90 0.0140   
1552649_a_at 370.53 55.92 2.89 0.0226 LOC117584 
1558356_at 370.46 54.99 2.89 0.0400 UACA 
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206460_at 369.87 38.41 2.89 0.0218 SHREW1 
208546_x_at 91.41 369.42 2.89 0.0076 HIST1H4G 
225658_at 333.06 960.08 2.88 0.0279 LOC339745 
209337_at 302.49 871.35 2.88 0.0167 PSIP2 
225477_s_at 516.41 1485.53 2.88 0.0421 NR2C2 
231806_s_at 603.27 209.73 2.88 0.0199 STK36 
207367_at 762.39 265.07 2.88 0.0178 ATP12A 
212351_at 494.73 172.05 2.88 0.0343 EIF2B5 
210039_s_at 416.23 1194.02 2.87 0.0187 PRKCQ 
213480_at 857.64 2460.23 2.87 0.0442 VAMP4 
241857_at 555.98 194.77 2.85 0.0245 RAET1E 
203989_x_at 365.07 110.64 2.85 0.0413 F2R 
238145_at 987.12 348.32 2.83 0.0299   
206904_at 815.49 288.35 2.83 0.0394 MATN1 
1560550_at 621.87 219.98 2.83 0.0442 na 
216294_s_at 1026.90 363.35 2.83 0.0190 KIAA1109 
218554_s_at 637.82 225.71 2.83 0.0128 ASH1L 
240307_at 724.48 256.97 2.82 0.0146   
224271_x_at 360.78 76.46 2.82 0.0008 FKSG44 
1569374_at 721.13 256.10 2.82 0.0487   
239021_at 360.02 63.82 2.81 0.0124   
218414_s_at 967.34 343.99 2.81 0.0125 NDE1 
214363_s_at 2099.37 5885.19 2.80 0.0064 MATR3 
204340_at 156.60 438.71 2.80 0.0417 CXorf12 
233023_at 358.23 31.74 2.80 0.0075   
201663_s_at 139.56 390.29 2.80 0.0143 SMC4L1 
244752_at 484.38 173.24 2.80 0.0487 LOC220929 
203202_at 71.74 357.06 2.79 0.0002 HRB2 
214163_at 409.49 146.84 2.79 0.0483 LOC51668 
206415_at 356.46 21.40 2.78 0.0492 TLL1 
224856_at 738.98 2057.00 2.78 0.0295 FKBP5 
204495_s_at 1298.32 466.50 2.78 0.0068 DKFZP434H132 
208523_x_at 489.27 176.15 2.78 0.0469 HIST1H2BI 
217594_at 355.28 35.61 2.78 0.0191 KIAA0191 
224216_at 354.86 38.10 2.77 0.0068   
58916_at 354.85 93.02 2.77 0.0014 MGC2376 
220452_x_at 1539.85 555.73 2.77 0.0198   
209546_s_at 218.09 604.23 2.77 0.0130 APOL1 
226829_at 416.22 150.78 2.76 0.0161 FLJ14564 
201618_x_at 519.36 188.79 2.75 0.0479 GPAA1 
230936_at 987.97 359.37 2.75 0.0325 TSARG3 
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238476_at 92.22 351.49 2.75 0.0462 LOC153222 
213140_s_at 84.74 350.62 2.74 0.0117 SS18L1 
226438_at 279.00 763.72 2.74 0.0066 SNTB1 
243741_at 714.44 261.12 2.74 0.0425   
219905_at 655.77 1787.21 2.73 0.0320 ERMAP 
202247_s_at 474.17 174.16 2.72 0.0438 MTA1 
234463_at 348.16 100.33 2.72 0.0120   
239165_at 752.82 276.95 2.72 0.0314   
227273_at 347.91 124.96 2.72 0.0175   
228104_at 742.86 273.44 2.72 0.0347 PLXNA4 
226851_at 327.03 888.36 2.72 0.0376 LYPLAL1 
1563080_at 346.55 11.40 2.71 0.0057   
237174_at 438.76 162.43 2.70 0.0314   
231602_at 1374.92 509.69 2.70 0.0061   
218698_at 190.08 512.28 2.70 0.0301 MMRP19 
208188_at 884.12 328.21 2.69 0.0314 KRT9 
213374_x_at 442.86 1192.33 2.69 0.0267 HIBCH 
1560851_at 344.48 44.92 2.69 0.0264   
240149_at 344.37 41.12 2.69 0.0157 FLJ22087 
218041_x_at 594.94 1597.24 2.68 0.0299 SLC38A2 
215136_s_at 280.15 750.19 2.68 0.0474 OIP2 
205005_s_at 402.08 150.53 2.67 0.0312 NMT2 
208315_x_at 842.44 315.54 2.67 0.0257 TRAF3 
204831_at 173.06 461.12 2.66 0.0109 CDK8 
203403_s_at 345.02 918.71 2.66 0.0174 RNF6 
1556153_s_at 611.44 229.71 2.66 0.0315 MAIL 
202301_s_at 793.22 298.68 2.66 0.0064 FLJ11021 
216697_at 339.68 34.22 2.65 0.0187 TRIO 
209412_at 46.67 339.23 2.65 0.0410 TMEM1 
238164_at 355.43 937.88 2.64 0.0267 RNTRE 
204650_s_at 886.19 335.99 2.64 0.0108 APBB3 
233673_at 978.25 371.06 2.64 0.0158 LOC339524 
208882_s_at 434.22 1138.81 2.62 0.0121 DD5 
244828_x_at 467.10 178.65 2.61 0.0145 LOC92345 
222627_at 541.41 1413.91 2.61 0.0392 HCC8 
229247_at 434.46 166.45 2.61 0.0218 FLJ37440 
230091_at 162.98 424.83 2.61 0.0091 SRPK2 
214028_x_at 333.22 58.53 2.60 0.0357 TDRD3 
207323_s_at 933.99 358.77 2.60 0.0343 MBP 
231103_at 852.23 327.48 2.60 0.0301   
202892_at 464.12 1207.79 2.60 0.0084 CDC23 
 211
 Age Group Juvenile Elderly    










P-Value Gene Symbol 
1564287_at 633.44 244.05 2.60 0.0334 LOC144776 
218826_at 997.55 385.10 2.59 0.0191 HSNOV1 
235902_at 721.43 278.59 2.59 0.0095 na 
1556339_a_at 829.52 320.67 2.59 0.0068   
242967_at 329.62 88.25 2.58 0.0196   
234752_x_at 329.36 16.06 2.57 0.0051 DMD 
239452_at 1675.60 651.57 2.57 0.0461 CCBP2 
213018_at 171.98 441.19 2.57 0.0052 ODAG 
225318_at 362.88 930.42 2.56 0.0469 KIAA0725 
235331_x_at 327.89 91.98 2.56 0.0220 MGC16202 
203746_s_at 379.73 970.79 2.56 0.0187 HCCS 
225207_at 234.16 598.55 2.56 0.0271 PDK4 
1562408_at 1086.38 425.11 2.56 0.0001 na 
244705_at 327.09 33.14 2.56 0.0295   
203250_at 1164.35 2974.87 2.55 0.0375 RBM16 
206706_at 782.12 306.51 2.55 0.0355 NTF3 
230241_at 46.49 325.11 2.54 0.0145   
214657_s_at 451.11 1145.17 2.54 0.0127 TncRNA 
230098_at 332.83 842.63 2.53 0.0294 FLJ21615 
203618_at 771.00 304.77 2.53 0.0257 FAIM2 
225958_at 966.89 382.59 2.53 0.0145 M6PR 
233560_x_at 701.15 278.46 2.52 0.0256 MCM8 
223707_at 455.70 181.12 2.52 0.0472 ST5 
208868_s_at 142.17 357.20 2.51 0.0143 GABARAPL1 
1562468_at 798.11 2002.53 2.51 0.0210   
231224_x_at 954.42 382.15 2.50 0.0179   
204181_s_at 873.60 350.34 2.49 0.0466 ZNF297B 
238823_at 1216.07 488.97 2.49 0.0271 WBP3 
219747_at 478.02 192.25 2.49 0.0475 FLJ23191 
225088_at 482.29 194.06 2.49 0.0113 FLJ31153 
236882_at 317.81 25.72 2.48 0.0073   
207627_s_at 98.99 317.34 2.48 0.0144 TFCP2 
244784_at 316.19 16.14 2.47 0.0093 DHX57 
205471_s_at 70.98 316.05 2.47 0.0076 DACH 
223189_x_at 1034.60 419.68 2.47 0.0104 MLL5 
223958_s_at 315.02 74.89 2.46 0.0427 MGC12435 
230624_at 314.99 126.06 2.46 0.0136 UCP4 
222792_s_at 1234.42 501.97 2.46 0.0250 HSPC128 
225853_at 1128.12 460.11 2.45 0.0492 GNPNAT1 
1554537_at 1013.13 413.24 2.45 0.0216 HT007 
226452_at 620.03 1518.55 2.45 0.0045 PDK1 
 212
 Age Group Juvenile Elderly    










P-Value Gene Symbol 
1566037_at 682.12 279.59 2.44 0.0322 DGCR7 
1568954_s_at 58.23 312.24 2.44 0.0048   
241342_at 149.73 364.83 2.44 0.0083 LOC157378 
219236_at 1084.54 445.34 2.44 0.0014 FLJ22672 
226628_at 287.95 700.51 2.43 0.0049 THOC2 
222815_at 77.18 310.84 2.43 0.0401   
233161_at 1389.32 572.27 2.43 0.0123   
233132_at 616.95 255.44 2.42 0.0183 LOC96610 
225086_at 34.94 308.00 2.41 0.0024 FLJ38426 
230029_x_at 43.82 307.85 2.41 0.0063 KIAA2024 
244628_at 546.27 227.15 2.40 0.0263   
231255_at 1456.24 606.01 2.40 0.0177 RHOIP3 
216961_s_at 307.22 105.98 2.40 0.0006   
214305_s_at 1604.89 669.24 2.40 0.0143 SF3B1 
205481_at 594.96 248.76 2.39 0.0326 ADORA1 
223479_s_at 383.16 160.70 2.38 0.0482 C2orf9 
238768_at 523.10 219.72 2.38 0.0456   
1558822_at 945.33 397.60 2.38 0.0393   
226917_s_at 389.20 921.55 2.37 0.0412 ANAPC4 
219676_at 328.15 775.98 2.36 0.0181 ZNF435 
224450_s_at 77.76 302.21 2.36 0.0292 RIOK1 
1556555_at 727.82 308.64 2.36 0.0396 LOC285778 
219991_at 1477.24 626.67 2.36 0.0257 SLC2A9 
229891_x_at 459.40 195.02 2.36 0.0448   
211685_s_at 683.16 290.10 2.35 0.0409 NCALD 
1556053_at 2165.74 920.13 2.35 0.0460 DNAJC7 
202684_s_at 300.93 112.89 2.35 0.0304 RNMT 
212238_at 1260.71 537.44 2.35 0.0231 ASXL1 
204371_s_at 619.60 264.30 2.34 0.0132 KHSRP 
1562698_x_at 2204.85 942.47 2.34 0.0290 LOC339988 
223217_s_at 1346.18 576.22 2.34 0.0396 MAIL 
229506_at 99.95 298.97 2.34 0.0258   
224712_x_at 837.84 358.79 2.34 0.0377   
227540_at 966.68 414.42 2.33 0.0237 SELB 
226736_at 598.71 1395.31 2.33 0.0301 C14orf52 
211095_at 403.76 173.94 2.32 0.0150 NF1 
1552632_a_at 349.53 150.75 2.32 0.0354 KIAA1001 
201518_at 640.81 1482.84 2.31 0.0396 CBX1 
234347_s_at 599.03 259.25 2.31 0.0469 DENR 
220742_s_at 1052.84 2424.92 2.30 0.0489 NGLY1 
200764_s_at 317.57 731.23 2.30 0.0402 CTNNA1 
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211113_s_at 989.62 430.20 2.30 0.0391 ABCG1 
224286_at 992.16 431.99 2.30 0.0373 C1QTNF5 
204781_s_at 563.24 1292.49 2.29 0.0248 TNFRSF6 
202166_s_at 564.74 1295.19 2.29 0.0137 PPP1R2 
206229_x_at 583.92 254.99 2.29 0.0333 PAX2 
232008_s_at 852.01 372.48 2.29 0.0250 BBX 
228822_s_at 289.89 660.69 2.28 0.0348 USP16 
219983_at 143.15 326.24 2.28 0.0419 HRASLS 
240773_at 290.09 90.28 2.27 0.0279   
216573_at 290.08 39.96 2.27 0.0114   
209600_s_at 46.70 289.00 2.26 0.0199 ACOX1 
202331_at 914.15 404.93 2.26 0.0043 BCKDHA 
204983_s_at 67.19 288.16 2.25 0.0393 GPC4 
211702_s_at 626.68 1405.60 2.24 0.0207 USP32 
244182_at 888.72 397.48 2.24 0.0419 na 
222989_s_at 476.01 1063.07 2.23 0.0030 UBQLN1 
1555437_at 662.25 296.74 2.23 0.0394 KIAA1970 
229697_at 637.39 285.75 2.23 0.0080 HIRIP3 
206267_s_at 407.20 182.64 2.23 0.0377 MATK 
201687_s_at 327.14 729.34 2.23 0.0279 API5 
227236_at 589.67 1312.73 2.23 0.0450 TSPAN-2 
224303_x_at 331.12 736.61 2.22 0.0064 NIN 
232253_at 905.29 406.97 2.22 0.0158   
219700_at 607.38 273.08 2.22 0.0491 TEM7 
1557319_at 1603.55 722.03 2.22 0.0199   
1555306_a_at 1103.77 497.36 2.22 0.0138 ECE2 
208914_at 1547.21 697.51 2.22 0.0365 GGA2 
207821_s_at 597.10 269.53 2.22 0.0016 PTK2 
201627_s_at 108.93 281.61 2.20 0.0367 INSIG1 
232786_at 281.55 72.06 2.20 0.0060 COG6 
209357_at 39.09 281.44 2.20 0.0431 CITED2 
219917_at 548.37 249.48 2.20 0.0443 ZCCHC4 
213168_at 39.77 281.20 2.20 0.0063 SP3 
47773_at 1336.71 608.59 2.20 0.0477 KIAA1332 
221588_x_at 1253.69 571.00 2.20 0.0211 ALDH6A1 
230888_at 931.88 425.41 2.19 0.0247 na 
220050_at 913.84 417.65 2.19 0.0173 C9orf9 
204481_at 606.24 277.77 2.18 0.0044 BRPF1 
206414_s_at 399.64 872.03 2.18 0.0357 DDEF2 
227179_at 325.24 707.58 2.18 0.0310 STAU2 
59644_at 428.44 930.94 2.17 0.0105 BMP2K 
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204304_s_at 381.49 175.62 2.17 0.0442 PROM1 
64438_at 923.40 425.58 2.17 0.0456 FLJ22222 
235798_at 48.15 277.46 2.17 0.0371  
209585_s_at 69.70 276.69 2.16 0.0270 MINPP1 
202637_s_at 1332.96 618.55 2.15 0.0036 ICAM1 
37004_at 403.36 187.39 2.15 0.0391 SFTPB 
217266_at 1344.38 625.68 2.15 0.0006  
233750_s_at 58.20 274.18 2.14 0.0446 C1orf25 
219734_at 1276.13 596.31 2.14 0.0174 FLJ20174 
210313_at 1214.58 568.19 2.14 0.0102 LIR9 
241795_at 822.06 384.70 2.14 0.0119  
1563321_s_at 273.50 96.19 2.14 0.0245 MLL 
202778_s_at 635.73 1357.86 2.14 0.0238 ZNF198 
225269_s_at 1069.68 2284.25 2.14 0.0122 HCC-4 
229773_at 737.57 1571.41 2.13 0.0012 SNAP23 
222480_at 94.56 272.27 2.13 0.0385 UBE2Q 
217207_s_at 1519.99 716.25 2.12 0.0093 BTNL3 
1555464_at 557.33 262.77 2.12 0.0158 MDA5 
216979_at 893.19 421.78 2.12 0.0296 NR4A3 
218878_s_at 323.06 683.34 2.12 0.0126 SIRT1 
241799_x_at 1613.65 763.39 2.11 0.0096  
224200_s_at 288.47 136.59 2.11 0.0390 RAD18 
227775_at 677.44 321.16 2.11 0.0369 BRUNOL6 
223213_s_at 333.94 704.07 2.11 0.0391 ZHX1 
1555380_at 918.25 436.30 2.10 0.0388 ADAMTS4 
223177_at 961.77 2022.77 2.10 0.0238 NT5C2L1 
236961_at 989.46 471.27 2.10 0.0080  
209430_at 501.93 1050.66 2.09 0.0325 BTAF1 
212450_at 437.38 914.80 2.09 0.0489 KIAA0256 
1557768_at 925.80 442.84 2.09 0.0343  
244704_at 267.57 81.67 2.09 0.0190 NFYB 
214283_at 1051.96 503.37 2.09 0.0115 LOC90410 
201626_at 616.40 1284.39 2.08 0.0260 INSIG1 
229362_at 266.41 53.73 2.08 0.0325 FLJ32312 
1556464_a_at 1326.16 638.93 2.08 0.0176  
212427_at 182.56 377.45 2.07 0.0106 KIAA0368 
235872_at 1399.47 677.18 2.07 0.0190 TERF2 
219429_at 490.44 237.42 2.07 0.0373 FAXDC1 
212568_s_at 70.09 264.24 2.06 0.0390 DLAT 
1559094_at 231.05 476.04 2.06 0.0176 FBXO9 
212301_at 412.14 846.55 2.05 0.0011 KIAA0252 
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P-Value Gene Symbol 
227394_at 1257.53 612.84 2.05 0.0164 na 
206186_at 1302.84 635.35 2.05 0.0406 MPP3 
218808_at 777.49 379.41 2.05 0.0227 FLJ10496 
217945_at 523.02 1071.11 2.05 0.0435 BTBD1 
236994_at 69.02 261.84 2.05 0.0090 na 
1553523_at 573.01 280.12 2.05 0.0077 NALP14 
31835_at 949.95 464.66 2.04 0.0130 HRG 
225243_s_at 348.35 711.02 2.04 0.0430 SLMAP 
242361_at 1041.43 510.93 2.04 0.0303 IMMT 
218799_at 366.43 180.13 2.03 0.0433 FLJ10349 
214241_at 1029.84 506.37 2.03 0.0125 NDUFB8 
215786_at 861.00 425.07 2.03 0.0484   
211693_at 1106.80 547.12 2.02 0.0228 MGC27165 
242604_at 258.40 32.85 2.02 0.0493   
1555522_s_at 371.54 749.58 2.02 0.0170 CGI-27 
210070_s_at 803.59 399.88 2.01 0.0071 CPT1B 
243852_at 446.79 222.36 2.01 0.0465 LUC7L2 
209082_s_at 772.05 385.18 2.00 0.0456 COL18A1 
202630_at 355.18 711.22 2.00 0.0232 APPBP2 
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 Table 25: Candidate Gene Database. 
Candidate 





Accession      
ID Number 
ABL1 Elderly NM_007313 
      
  
Homo sapiens v-abl Abelson murine 
leukemia viral oncogene homolog 1, 
transcript variant b 
Oncogene 
    
ACD Elderly NM_022914 
      
  
Homo sapiens adrenocortical dysplasia 
homolog (mouse), transcript variant 2 Disease 
    
ACTA2 Juvenile AK093340 
      
  
Homo sapiens cDNA FLJ36021 fis, 
clone TESTI2016568 Affymetrix 
    
ACTN3 Elderly NM_001104 
      
  
Homo sapiens actinin, alpha 3 
Transcription 
& Gene 
Regulation     
ADAM12 Juvenile AU145357 
      
  
AU145357 HEMBA1 Homo sapiens 
cDNA clone HEMBA1004611 3- Affymetrix 
    
ADAM12a Juvenile AU145357 
      
  
AU145357 HEMBA1 Homo sapiens 
cDNA clone HEMBA1004611 3- Affymetrix 
    
AFP Newborn NM_001134 
      
  
Homo sapiens alpha-fetoprotein Fetal Protein 
    
AGGF1 Elderly NM_018046 
      
  
Homo sapiens angiogenic factor with 
G patch and FHA domains 1 Affymetrix 
    
AIF1 Elderly NM_001623 
      
  
Homo sapiens allograft inflammatory 
factor 1, transcript variant 3 
Immunology 
& Interferons 
    
AKT1 Elderly NM_005163 
      
  
Homo sapiens v-akt murine thymoma 
viral oncogene homolog 1, transcript 
variant 1 
Oncogene 
    
AMID Elderly NM_032797 
      
  
Homo sapiens apoptosis-inducing 
factor, mitochondrion-associated, 2 
(AIFM2) 
Mitochondria 
    
ANKH Elderly NM_054027 
      
  
Homo sapiens ankylosis, progressive 
homolog (mouse) Bone 
    
APEX1 Elderly NM_001641 
      
  
Homo sapiens APEX nuclease 
(multifunctional DNA repair enzyme) 




Arrest     
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 Candidate 





Accession      
ID Number 
APOE (1) Newborn M12529 
      
  
Human apolipoprotein E mRNA, 
complete cds Fetal Protein 
    
APOE (2) Newborn NM_000041 
      
  
Homo sapiens apolipoprotein E  Fetal Protein 
    
ARMC7 Elderly NM_024585 
      
  
Homo sapiens armadillo repeat 
containing 7  Affymetrix 
    
Art3a Juvenile U47054 
      
  
Human putative mono-ADP-
ribosyltransferase (htMART) Affymetrix 
    
Art3b Juvenile U47054 
      
  
Human putative mono-ADP-
ribosyltransferase (htMART) Affymetrix 
    
ASL Juvenile NM_000048 
      
  
Homo sapiens argininosuccinate 
lyase, transcript variant 2 Affymetrix 
    
ATF7IP2 Newborn AV7169647 
      
  
DCB Homo sapiens cDNA clone 
DCBBOG12 5' Affymetrix 
    
ATPAF2 Elderly NM_145691 
      
      
  
Homo sapiens ATP synthase 
mitochondrial F1 complex assembly 
factor 2, nuclear gene encoding 
mitochondrial protein 
Affymetrix 
    
AUF1 Newborn NM_001003810 
hnRNPD     
p37     
  
Homo sapiens heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 




    
AUF1 Adult NM_031370 
hnRNPD     
p45     
  
Homo sapiens heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 




    
BAX-(all) Elderly NM_138764 
      
  
Homo sapiens BCL2-associated X 
protein, transcript variant epsilon Apoptosis 
    
BAX-a/d Elderly NM_138761 
      
  
Homo sapiens BCL2-associated X 
protein, transcript variant alpha Apoptosis 









Accession      
ID Number 
BAX-all(e) Elderly NM_138764 
      
  
Homo sapiens BCL2-associated X 
protein, transcript variant epsilon Apoptosis 
    
BAX-b Elderly NM_004324 
      
  
Homo sapiens BCL2-associated X 
protein, transcript variant beta Apoptosis 
    
BAX-d Elderly NM_138763 
      
  
Homo sapiens BCL2-associated X 
protein, transcript variant delta Apoptosis 
    
BAX-e Elderly NM_138764 
      
  
Homo sapiens BCL2-associated X 
protein, transcript variant epsilon Apoptosis 
    
BAX-s Elderly NM_138765 
      
  
Homo sapiens BCL2-associated X 
protein, transcript variant sigma Apoptosis 
    
BCKDHA Juvenile NM_000709 
      
  
Homo sapiens branched chain keto 
acid dehydrogenase E1, alpha 
polypeptide 
Affymetrix 
    
BCL2A1 Elderly NM_004049 
      
  
Homo sapiens BCL2-related protein 
A1 Apoptosis 
    
BGLAP Elderly NM_199173 
      
  
Homo sapiens bone gamma-
carboxyglutamate (gla) protein 
(osteocalcin) 
Bone 
    
BIRC5 Elderly NM_001012271 
      
  
Homo sapiens baculoviral IAP repeat-
containing 5 (survivin), transcript 
variant 3 
Apoptosis 
    
c5229134 Juvenile BC037976 
      
  
Homo sapiens, clone 
IMAGE:5229134 Affymetrix 
    
c5286506 Juvenile BC043160 
      
  
Homo sapiens cDNA clone 
IMAGE:5286506 Affymetrix 
    
CABP7 Juvenile NM_182527 
      
  
Homo sapiens calcium binding protein 
7 Affymetrix 
    
CABYR Juvenile NM_012189 
      
  
Homo sapiens calcium binding 
tyrosine-(Y)-phosphorylation 
regulated (fibrousheathin 2), transcript 
variant 1 
Hormone 









Accession      
ID Number 
CAMK2D Elderly NM_172127 
      
  
Homo sapiens calcium/calmodulin-
dependent protein kinase (CaM 
kinase) II delta, transcript variant 1 
Growth 
Factor 
    
CASP2 Elderly NM_032982 
      
      
  
Homo sapiens caspase 2, apoptosis-
related cysteine peptidase (neural 
precursor cell expressed, 
developmentally down-regulated 2), 
transcript variant 1 
Apoptosis 
    
CBL Elderly NM_005188 
      
  
Homo sapiens Cas-Br-M (murine) 
ecotropic retroviral transforming 
sequence  
Oncogene 
    
CCL5 Elderly NM_002985 
      
  
Homo sapiens chemokine (C-C motif) 
ligand 5 Affymetrix 
    
CCM2 Elderly NM_001029835 
      
  
Homo sapiens cerebral cavernous 
malformation 2, transcript variant 1 Disease 
    
CCND1 Elderly NM_053056 
      
  
Homo sapiens cyclin D1 Cyclin 
    
CD200 Juvenile NM_001004196 
      
  
Homo sapiens CD200 molecule, 
transcript variant 2 
Immunology 
& 
Interferons     
CD28 Juvenile NM_006139 
      
  
Homo sapiens CD28 molecule Affymetrix 
    
CD28 Elderly NM_006139 
      
  
Homo sapiens CD28 molecule 
Immunology 
& 
Interferons     
CD86 Elderly NM_175862 
      
  
Homo sapiens CD86 molecule, 
transcript variant 1 
Immunology 
& 
Interferons     
CDC2 Elderly NM_001786 
      
  
Homo sapiens cell division cycle 2, 
G1 to S and G2 to M, transcript 
variant 1 
Cyclin 
    
CDC25C Elderly NM_022809 
      
  
Homo sapiens cell division cycle 25 
homolog C (S. pombe), transcript 
variant 2 
Cyclin 
    
CDKN1A Elderly NM_078467 
      
  
Homo sapiens cyclin-dependent 
kinase inhibitor 1A (p21, Cip1), 
transcript variant 2 
Cyclin 









Accession      
ID Number 
CDKN1B Elderly NM_004064 
      
  
Homo sapiens cyclin-dependent kinase 
inhibitor 1B (p27, Kip1)  Cyclin 
    
CDKN2C Elderly NM_001262 
      
  
Homo sapiens cyclin-dependent kinase 
inhibitor 2C (p18, inhibits CDK4), 
transcript variant 1  
Cyclin 
    
CFIX Juvenile NM_000133 
      
  
Homo sapiens coagulation factor IX 
(plasma thromboplastic component, 
Christmas disease, hemophilia B) (F9) 
Growth 
Factor 
    
CGI-96 Juvenile AL157851 
      
  
Novel human gene mapping to 
chomosome 22 Affymetrix 
    
CHR1orf28 Newborn AA447464 
      




sapiens cDNA clone IMAGE:784177 
5- similar to contains Alu repetitive 
element. 
Affymetrix 
    
CIITA Elderly NM_000246 
      
  





Regulation     
CLEC2 Elderly NM_016509 
      
  
Homo sapiens C-type lectin domain 
family 1, member B (CLEC1B) Affymetrix 
    
CLEC2a Elderly NM_016509 
      
  
Homo sapiens C-type lectin domain 
family 1, member B (CLEC1B) Affymetrix 
    
CLEC2b Elderly NM_016509 
      
  
Homo sapiens C-type lectin domain 
family 1, member B (CLEC1B) Affymetrix 
    
COL1A1 Elderly NM_000088 
CTx     
  
Homo sapiens collagen, type I, alpha 1 Bone 
    
COL1A2 Newborn NM_000089 
      
  
Homo sapiens collagen, type I, alpha 2 Bone 
    
COL6A1a Juvenile M20776 
      
  
Homo sapiens, alpha-1 (VI) Affymetrix 
    
COL6A1b Juvenile M20776 
      
  
Homo sapiens, alpha-1 (VI) Affymetrix 









Accession      
ID Number 
CTBP1 Elderly NM_001012614 
      
  
Homo sapiens C-terminal binding 
protein 1, transcript variant 2 
Transcription 
& Gene 
Regulation     
CTSB Elderly NM_147780 
      
  
Homo sapiens cathepsin B, transcript 
variant 2 Bone 
    
CTSK Elderly NM_000396 
      
  
Homo sapiens cathepsin K 
(pycnodysostosis) Bone 
    
CTSL Elderly NM_001912 
      
  
Homo sapiens cathepsin L1 (CTSL1), 
transcript variant 1 Bone 
    
CXorf22 Juvenile NM_152632 
      
  
Homo sapiens chromosome X open 
reading frame 22 (CXorf22) Affymetrix 
    
CYP17A1 Juvenile NM_000102 
      
  
Homo sapiens cytochrome P450, 
family 17, subfamily A, polypeptide 1 Hormone 
    
CYP1B1 Juvenile NM_000104 
      
  
Homo sapiens cytochrome P450, 
family 1, subfamily B, polypeptide 1 Hormone 
    
CYP7B1 Juvenile NM_004820 
      
  
Homo sapiens cytochrome P450, 
family 7, subfamily B, polypeptide 1 
(CYP7B1), 
Hormone 
    
CYTBC2 Elderly D49737 
      
  
Homo sapiens mRNA for cytochrome 
b large subunit of complex II, 
complete cds 
Affymetrix 
    
DDB2 Elderly NM_000107 
      
  
Homo sapiens damage-specific DNA 




Arrest     
DHEA Juvenile NM_003167 
      
  
Homo sapiens sulfotransferase 
family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA)-
preferring, member 1 (SULT2A1) 
Hormone 
    
DNCL2A-1 Juvenile NM_014183 
      
  
Homo sapiens dynein, light chain, 
roadblock-type 1 (DYNLRB1), 
transcript variant 1 
Affymetrix 
    
DNCL2A-2 Juvenile NM_177953 
      
  
Homo sapiens dynein, cytoplasmic, 
light polypeptide 2A, transcript 
variant 2 
Affymetrix 









Accession      
ID Number 
DNCL2A-3 Juvenile NM_177954 
      
  
Homo sapiens dynein, cytoplasmic, 
light polypeptide 2A, transcript variant 
3 
Affymetrix 
    
DNPEP Juvenile NM_012100 
      
  
Homo sapiens aspartyl aminopeptidase Affymetrix 
    
DUSP6 Newborn BC005047 
      
  
Homo sapiens dual specificity 




    
DYRK2 Elderly NM_006482 
      
  
Homo sapiens dual-specificity 
tyrosine-(Y)-phosphorylation regulated 
kinase 2, transcript variant 2 
Growth 
Factor 
    
E2F1 Elderly NM_005225 
      
  




Regulation     
E2IG2 Juvenile NM_016565 
      
  
Homo sapiens coiled-coil-helix-coiled-
coil-helix domain containing 8 Hormone 
    
ECGF1 Elderly NM_001953 
      
  
Homo sapiens endothelial cell growth 
factor 1 (platelet-derived) 
Growth 
Factor 
    
ELAVL1  Elderly NM_001419 
HuR     
  
Homo sapiens ELAV (embryonic 
lethal, abnormal vision, Drosophila)-
like 1 (Hu antigen R) 
Transcription 
& Gene 
Regulation     
EMD Elderly NM_000117 
      
  
Homo sapiens emerin (Emery-Dreifuss 
muscular dystrophy) Disease 
    
ERBP Juvenile NM_014597 




interacting protein 2 (DNTTIP2) 
Hormone 
    
EREG Elderly NM_001432 
      
  
Homo sapiens epiregulin Growth Factor 
    
ERF Elderly NM_006494 
      
  
Homo sapiens Ets2 repressor factor 
Tumor 
Suppressor 
Genes     
ESR1 Juvenile NM_000125 
      
  
Homo sapiens estrogen receptor 1 Hormone 









Accession      
ID Number 
ESR2 Juvenile NM_001437 
      
  
Homo sapiens estrogen receptor 2 (ER 
beta), transcript variant a Hormone 
    
FACL6 Newborn AV727634 
      
  
AV727634 HTC Homo sapiens cDNA 
clone HTCAYH08 5- Affymetrix 
    
FKBP11 Juvenile NM_016594 
      
  
Homo sapiens FK506 binding protein 
11, 19 kDa Affymetrix 
    
FKLF Newborn AF272830 
      
  
Homo sapiens kruppel-like fetal and 
embryonic globin gene activator, 
complete cds 
Fetal Protein 
    
FLJ11078 Juvenile NM_018316 
      
  
Homo sapiens kelch-like 26 
(Drosophila) (KLHL26) Affymetrix 
    
FLJ20245 Elderly NM_017723 
      
  
Homo sapiens chromosome 9 open 
reading frame 167 (C9orf167) Affymetrix 
    
FLJ20344a Newborn NM_017776 
      
  
Homo sapiens zinc finger protein 673 
(ZNF673) Affymetrix 
    
FLJ20344b Newborn NM_017776 
      
  
Homo sapiens zinc finger protein 673 
(ZNF673) Affymetrix 
    
FLJ20421 Elderly BF674724 
      
  
602136866F1 NIH_MGC_83 Homo 
sapiens cDNA clone IMAGE:4273120 
5- 
Affymetrix 
    
FLJ21901 Newborn NM_024622 
      
  
Homo sapiens FAST kinase domains 1 
(FASTKD1) Affymetrix 
    
FLJ22175 Juvenile NM_025161 
      
  
Homo sapiens chromosome 17 open 
reading frame 70 (C17orf70) Affymetrix 
    
FLJ22672 Juvenile NM_024897 
PAQR6     
  
Homo sapiens progestin and adipoQ 
receptor family member VI, transcript 
variant 1 
Affymetrix 
    
FLJ30658 Newborn AW770868 
      
  
hn54d06.x1 NCI_CGAP_Co17 Homo 
sapiens cDNA clone IMAGE:3027467 
3- 
Affymetrix 










Accession      
ID Number 
FLJ35119 Juvenile NM_175871 
      
  
Homo sapiens chromosome 19 open 
reading frame 39 (C19orf39) Affymetrix 
    
FLJ35954 Newborn R66534 
      
  
yi35b09.s1 Soares placenta Nb2HP 
Homo sapiens cDNA clone 
IMAGE:141209 3- 
Affymetrix 
    
FLJ35982 Juvenile AK093301 
      
  
Homo sapiens cDNA FLJ35982 fis, 
clone TESTI2013604 Affymetrix 
    
FLJ35982a Juvenile AK093301 
      
  
Homo sapiens cDNA FLJ35982 fis, 
clone TESTI2013604 Affymetrix 
    
FLJ35984 Elderly AK093303 
      
  
Homo sapiens cDNA FLJ35984 fis, 
clone TESTI2014097, highly similar to 
V_segment translation product 
Affymetrix 
    
FLJ37440 Juvenile NM_153214 
      
  
Homo sapiens hypothetical protein 
FLJ37440 Affymetrix 
    
FLJ38628 Elderly NM_152267 
      
  
Homo sapiens ring finger protein 185 
(RNF185) Affymetrix 
    
FLJ38745 Juvenile AK096064 
      
  
Homo sapiens cDNA FLJ38745 fis, 
clone KIDNE2012291 Affymetrix 
    
FLJ43159 Juvenile AI972146 
      
  
wr63b05.x1 NCI_CGAP_Ut1 Homo 
sapiens cDNA clone IMAGE:2492337 
3- 
Affymetrix 
    
GADD45A Elderly NM_001924 
      
  
Homo sapiens growth arrest and DNA-





Arrest     
GADD45B Elderly NM_015675 
      
  
Homo sapiens growth arrest and DNA-





Arrest     
GAL Juvenile NM_015973 
      
  
Homo sapiens galanin Hormone 
    
GFPT2 Juvenile NM_005110 
      
  
Homo sapiens glutamine-fructose-6-
phosphate transaminase 2 Affymetrix 









Accession      
ID Number 
GGT1 Juvenile NM_005265 
      
  
Homo sapiens gamma-
glutamyltransferase 1, transcript variant 
1 
Affymetrix 
    
GHRH Juvenile NM_021081 
      
  
Homo sapiens growth hormone 
releasing hormone Hormone 
    
GLO1 Juvenile NM_006708 
      
  
Homo sapiens glyoxalase I Immunology & Interferons 
    
GNAS HSK NM_016592 
      
  
Homo sapiens GNAS complex locus, 
transcript variant 4 
Housekeeping 
Gene 
    
GNAS2 HSK NM_016592 
      
  
Homo sapiens GNAS complex locus, 
transcript variant 4 
Housekeeping 
Gene 
    
GNRH1 Juvenile NM_000825 
      
  
Homo sapiens gonadotropin-releasing 
hormone 1 (luteinizing-releasing 
hormone), transcript variant 1 
Hormone 
    
GNRH2 Juvenile NM_001501 
      
  
Homo sapiens gonadotropin-releasing 
hormone 2, transcript variant 1 Hormone 
    
GNRHR Juvenile NM_000406 
      
  
Homo sapiens gonadotropin-releasing 
hormone receptor, transcript variant 1 Hormone 
    
GPR54 Juvenile NM_032551 
      
  
Homo sapiens KISS1 receptor 
(KISS1R) Hormone 
    
GRIN1 Juvenile NM_000832 
NR1-1     
  
Homo sapiens glutamate receptor, 
ionotropic, N-methyl D-aspartate 1, 
transcript variant NR1-1 
Hormone 
    
GRIN1 Juvenile NM_021569 
NR1-2     
  
Homo sapiens glutamate receptor, 
ionotropic, N-methyl D-aspartate 1, 
transcript variant NR1-2 
Hormone 
    
GRIN1 Juvenile NM_007327 
NR1-3     
  
Homo sapiens glutamate receptor, 
ionotropic, N-methyl D-aspartate 1, 
transcript variant NR1-3 
Hormone 
    
GRIN2A Juvenile NM_000833 
      
  
Homo sapiens glutamate receptor, 
ionotropic, N-methyl D-aspartate 2A Hormone 










Accession      
ID Number 
GRIN2B Juvenile NM_000834 
      
  
Homo sapiens glutamate receptor, 
ionotropic, N-methyl D-aspartate 2B Hormone 
    
GSTP1 Elderly NM_000852 
      
  
Homo sapiens glutathione S-transferase 
pi Affymetrix 
    
H17 Juvenile NM_017547 
      
  
Homo sapiens FAD-dependent 
oxidoreductase domain containing 1 
(FOXRED1) 
Affymetrix 
    
HBA1 Adult NM_000558 
      
  
Homo sapiens hemoglobin, alpha 1 Hemoglobin 
    
HBA2 Adult NM_000517 
      
  
Homo sapiens hemoglobin, alpha 2 Hemoglobin 
    
HBB Adult NM_000518 
      
  
Homo sapiens hemoglobin, beta Hemoglobin 
    
HBD Adult NM_000519 
      
  
Homo sapiens hemoglobin, delta Hemoglobin 
    
HBE1 Newborn NM_005330 
      
  
Homo sapiens hemoglobin, epsilon 1 Hemoglobin 
    
HBG1 Newborn NM_000559 
      
  
Homo sapiens hemoglobin, gamma A Hemoglobin 
    
HBG1n1 Newborn   
      
  
Novel transcript isoform of 
hemoglobin, gamma A Hemoglobin 
    
HBG1n2 Newborn   
      
  
Novel transcript isoform of 
hemoglobin, gamma A Hemoglobin 
    
HBG2 Newborn NM_000184 
      
  
Homo sapiens hemoglobin, gamma G Hemoglobin 
    
HBG2n2 Newborn   
      
  
Novel transcript isoform of 
hemoglobin, gamma G Hemoglobin 
    
HBG2n3 Newborn   
      
  
Novel transcript isoform of 
hemoglobin, gamma G Hemoglobin 
    
 228
 Candidate 





Accession      
ID Number 
HBZ Newborn NM_005332 
      
  
Homo sapiens hemoglobin, zeta Hemoglobin 
    
HBQ Adult NM_005331 
      
  
Homo sapiens hemoglobin, theta 1 Hemoglobin 
    
HIC2 Elderly NM_015094 
      
  
Homo sapiens hypermethylated in 
cancer 2 Affymetrix 
    
HIF1A Elderly NM_001530 
      
  
Homo sapiens hypoxia-inducible factor 
1, alpha subunit (basic helix-loop-helix 




Regulation     
HOMER3 Juvenile NM_004838 
      
  
Homo sapiens homer homolog 3 
(Drosophila) Affymetrix 
    
HPCAL4 Elderly NM_016257 
      
  
Homo sapiens hippocalcin like 4 Affymetrix 
    
HRAS Elderly NM_176795 
      
  
Homo sapiens v-Ha-ras Harvey rat 
sarcoma viral oncogene homolog, 
transcript variant 2 
Oncogene 
    
HRG Juvenile NM_000412 
      
  
Homo sapiens histidine-rich 
glycoprotein Affymetrix 
    
HTATIP Elderly NM_182710 
      
  
Homo sapiens HIV-1 Tat interacting 




Arrest     
HTR1E Juvenile NM_000865 
      
  
Homo sapiens 5-hydroxytryptamine 
(serotonin) receptor 1E Affymetrix 
    
HTR7 Juvenile NM_000872 
      
  
Homo sapiens 5-hydroxytryptamine 
(serotonin) receptor 7 (adenylate 
cyclase-coupled), transcript variant a 
Affymetrix 
    
IFNG Elderly NM_000619 
      
  
Homo sapiens interferon, gamma 
Immunology 
& 
Interferons     
IGF1 Elderly NM_000618 
      
  
Homo sapiens insulin-like growth 
factor 1 (somatomedin C) 
Growth 
Factor 









Accession      
ID Number 
IGF2 Elderly NM_000612 
      
  
Homo sapiens insulin-like growth 




    
IGFBP3 Elderly NM_001013398 
      
  
Homo sapiens insulin-like growth 




    
IGFBP5 Elderly NM_000599 
      
  
Homo sapiens insulin-like growth 
factor binding protein 5 
Growth 
Factor 
    
IL1A Elderly NM_000575 
      
  
Homo sapiens interleukin 1, alpha 
Immunology 
& 
Interferons     
INHA Juvenile NM_002191 
      
  
Homo sapiens inhibin, alpha Bone 
    
IRF1 Elderly NM_002198 
      
  




Interferons     
ITIH4 Juvenile NM_002218 
      
  
Homo sapiens inter-alpha (globulin) 
inhibitor H4 (plasma Kallikrein-
sensitive glycoprotein) 
Affymetrix 
    
ITSN2 Newborn NM_006277 
      
  
Homo sapiens intersectin 2, 
transcript variant 1 Affymetrix 
    
KIAA0276 Newborn D87466 
      
  
Homo sapiens mRNA for KIAA0276 
gene, partial cds Affymetrix 
    
KIAA0894 Juvenile NM_014896 
      
  
Homo sapiens KIAA0894 protein Affymetrix 
    
KIAA1265 Newborn AB033091 
      
  
Homo sapiens mRNA for KIAA1265 
protein, partial cds Affymetrix 
    
KIAA2022 Juvenile AB095942 
      
  
Homo sapiens mRNA for KIAA2022 
protein Affymetrix 
    
KISS-1 Juvenile NM_002256 
      
  
Homo sapiens KiSS-1 metastasis-
suppressor Hormone 










Accession      
ID Number 
KITLG Newborn NM_000899 
      
  
Homo sapiens KIT ligand, transcript 
variant b Fetal Protein 
    
KL Elderly NM_153683 
      
  
Homo sapiens klotho, transcript variant 
2 Bone 
    
KLF13 Elderly NM_015995 
      
  
Homo sapiens Kruppel-like factor 13 
Transcription 
& Gene 
Regulation     
LASS5 Elderly NM_147190 
      
  
Homo sapiens LAG1 homolog, 
ceramide synthase 5 (S. cerevisiae) Affymetrix 
    
LATS1 Juvenile NM_004690 
      
  
Homo sapiens LATS, large tumor 
suppressor, homolog 1 (Drosophila) Affymetrix 
    
LEP Juvenile NM_000230 
      
  
Homo sapiens leptin (obesity homolog, 
mouse) Hormone 
    
LHB Juvenile NM_000894 
      
  
Homo sapiens luteinizing hormone beta 
polypeptide Hormone 
    
LHCGR Juvenile NM_000233 
      
  
Homo sapiens luteinizing 
hormone/choriogonadotropin receptor Hormone 
    
LMNA 
(norm) Elderly NM_170707 
      
  





    
LMNA 
(RT) Elderly NM_170707 
      
  





    
LMNA 
(spec) Elderly NM_170707 
      
  





    
LOC151194 Newborn NM_145280 
      
  
Homo sapiens family with sequence 
similarity 119, member A (FAM119A) Affymetrix 
    
LOC152274 Juvenile AK056398 
      
  
Homo sapiens cDNA FLJ31836 fis, 
clone NT2RP7000041 Affymetrix 









Accession      
ID Number 
LOC284242 Juvenile BC035844 
      
  
Homo sapiens, clone 
IMAGE:5745916 Affymetrix 
    
LOH11CR2A Elderly BC001234 
      
      
  
Homo sapiens loss of heterozygosity, 
11, chromosomal region 2, gene A, 
mRNA (cDNA clone MGC:4904 
IMAGE:3461486), complete cds 
Affymetrix 
    
LZTFL1 Newborn NM_020347 
      
  
Homo sapiens leucine zipper 
transcription factor-like 1 Affymetrix 
    
MAD1L1 Elderly NM_003550 
      
  
Homo sapiens MAD1 mitotic arrest 
deficient-like 1 (yeast), transcript 
variant 1 
Cyclin 
    
MCPH1 Elderly NM_024596 
      
  
Homo sapiens microcephaly, primary 
autosomal recessive 1 
Tumor 
Suppressor 
Genes     
MDM2 Elderly NM_002392 
      
  
Homo sapiens Mdm2, transformed 
3T3 cell double minute 2, p53 binding 




Genes     
MEPE Elderly NM_020203 
      
  
Homo sapiens matrix, extracellular 
phosphoglycoprotein with ASARM 
motif (bone) 
Bone 
    
MET Elderly NM_000245 
      
  
Homo sapiens met proto-oncogene 
(hepatocyte growth factor receptor) Oncogene 
    
MGC14288 Elderly NM_032901 
      
  
Homo sapiens chromosome 12 open 
reading frame 62 (C12orf62) Affymetrix 
    
MGC20460 Juvenile NM_053043 
      
  
Homo sapiens proline rich 8 (PRR8) Affymetrix 
    
MGC39650 Juvenile AL137531 
      
  
Homo sapiens mRNA; cDNA 
DKFZp434F0919 (from clone 
DKFZp434F0919) 
Affymetrix 
    
MIF Newborn L19686 
      
  
Homo sapiens macrophage migration 
inhibitory factor (MIF) gene, complete 
cds 
Fetal Protein 
    
MLL Elderly NM_005933 
      
  
Homo sapiens myeloid/lymphoid or 
mixed-lineage leukemia (trithorax 
homolog, Drosophila) 
Disease 









Accession      
ID Number 
MMP-13 Elderly NM_002427 
      
  
Homo sapiens matrix 
metallopeptidase 13 (collagenase 3) Bone 
    
MMP-14 Elderly NM_004995 
      
  




    
MMP-9 Elderly NM_004994 
      
  
Homo sapiens matrix 
metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 
Bone 
    
MS4A4A Elderly NM_024021 
      
  
Homo sapiens membrane-spanning 4-
domains, subfamily A, member 4, 
transcript variant 1 
Affymetrix 
    
MS4A4Aa Elderly NM_024021 
      
  
Homo sapiens membrane-spanning 4-
domains, subfamily A, member 4, 
transcript variant 1 
Affymetrix 
    
MS4A4Ab Elderly NM_024021 
      
  
Homo sapiens membrane-spanning 4-
domains, subfamily A, member 4, 
transcript variant 1 
Affymetrix 
    
MT1X Elderly NM_005952 
      
  
Homo sapiens metallothionein 1X Affymetrix 
    
MYC Elderly NM_002467 
      
  
Homo sapiens v-myc 
myelocytomatosis viral oncogene 
homolog (avian) 
Oncogene 
    
NALP14 Juvenile NM_176822 
      
  
Homo sapiens NLR family, pyrin 
domain containing 14 (NLRP14) Affymetrix 
    
NBN Elderly NM_001024688 
      
  
Homo sapiens nibrin, transcript 
variant 2 Disease 
    
NDE1 Juvenile NM_017668 
      
  
Homo sapiens nudE nuclear 
distribution gene E homolog 1 (A. 
nidulans) 
Affymetrix 
    
NMI Elderly NM_004688 
      
  
Homo sapiens N-myc (and STAT) 
interactor Oncogene 
    
NPPB Elderly NM_002521 
      
  
Homo sapiens natriuretic peptide 
precursor B Bone 









Accession      
ID Number 
NRAS Elderly NM_002524 
      
  
Homo sapiens neuroblastoma RAS 
viral (v-ras) oncogene homolog Oncogene 
    
NTS Juvenile NM_006183 
      
  
Homo sapiens neurotensin Hormone 
    
OGG1 Elderly NM_016819 
      
      
  
Homo sapiens 8-oxoguanine DNA 
glycosylase (OGG1), nuclear gene 
encoding mitochondrial protein, 
transcript variant 1b 
Mitochondria 
    
OPG Elderly NM_002546 
TNFRSF11B     
  
Homo sapiens tumor necrosis factor 
receptor superfamily, member 11b 
(osteoprotegerin) 
Bone 
    
OPGL Elderly NM_003701 
RANKL     
TNFSF11 
Homo sapiens tumor necrosis factor 
(ligand) superfamily, member 11, 
transcript variant 1 
Bone 
    
OSGEP Juvenile NM_017807 
      
  
Homo sapiens O-sialoglycoprotein 
endopeptidase Affymetrix 
    
OSM Elderly NM_020530 
      
  
Homo sapiens oncostatin M Growth Factor 
    
OXTR Juvenile NM_000916 
      
  
Homo sapiens oxytocin receptor Hormone 
    
PAQR6 Juvenile NM_024897 
      
  
Homo sapiens progestin and adipoQ 
receptor family member VI, transcript 
variant 1 
Affymetrix 
    
PDCD1 Elderly NM_005018 
      
  
Homo sapiens programmed cell death 1 Programmed Cell Death 
    
PDCD10 Elderly NM_007217 
CCM3     
  
Homo sapiens programmed cell death 
10, transcript variant 1 
Programmed 
Cell Death 
    
PDCD11 Elderly NM_014976 
      
  




    
PDCD1LG2 Elderly NM_025239 
      
  













Accession      
ID Number 
PDCD2L Elderly NM_032346 
      
  




    
PDCD4 Elderly NM_145341 
      
  
Homo sapiens programmed cell death 4 
(neoplastic transformation inhibitor), 
transcript variant 2 
Programmed 
Cell Death 
    
PDCD5 Elderly NM_004708 
      
  
Homo sapiens programmed cell death 5 Programmed Cell Death 
    
PDCD6 Elderly NM_013232 
      
  
Homo sapiens programmed cell death 6 Programmed Cell Death 
    
PDCD6IP Elderly NM_013374 
      
  




    
PDCD7 Elderly NM_005707 
      
  
Homo sapiens programmed cell death 7 Programmed Cell Death 
    
PDE6D Juvenile NM_002601 
      
  
Homo sapiens phosphodiesterase 6D, 
cGMP-specific, rod, delta Affymetrix 
    
PGR Juvenile NM_000926 
      
  
Homo sapiens progesterone receptor Hormone 
    
PIK3CA Elderly NM_006218 
      
  
Homo sapiens phosphoinositide-3-
kinase, catalytic, alpha polypeptide Oncogene 
    
PITPNC1 Newborn AI676095 
      
  
wc05c10.x1 NCI_CGAP_Pr28 Homo 
sapiens cDNA clone IMAGE:2314290 
3- 
Affymetrix 
    
PLEKHA8 Juvenile NM_032639 
      
  
Homo sapiens pleckstrin homology 
domain containing, family A 
(phosphoinositide binding specific) 
member 8 
Affymetrix 
    
POLA1 Elderly NM_016937 
      
  
Homo sapiens polymerase (DNA 
directed), alpha 1 Polymerase 
    
POLA2 Elderly NM_002689 
      
  
Homo sapiens polymerase (DNA 
directed), alpha 2 (70kD subunit) Polymerase 









Accession      
ID Number 
POLB Elderly NM_002690 
      
  
Homo sapiens polymerase (DNA 
directed), beta Polymerase 
    
POLD1 Elderly NM_002691 
      
  
Homo sapiens polymerase (DNA 
directed), delta 1, catalytic subunit 
125kDa 
Polymerase 
    
POLE1 Elderly NM_006231 
      
  
Homo sapiens polymerase (DNA 
directed), epsilon Polymerase 
    
POLE2 Elderly NM_002692 
      
  
Homo sapiens polymerase (DNA 
directed), epsilon 2 (p59 subunit) Polymerase 
    
POLE3 Elderly NM_017443 
      
  
Homo sapiens polymerase (DNA 
directed), epsilon 3 (p17 subunit) Polymerase 
    
POLG Elderly NM_002693 
      
  
Homo sapiens polymerase (DNA 
directed), gamma Polymerase 
    
POLH Elderly NM_006502 
      
  
Homo sapiens polymerase (DNA 
directed), eta Polymerase 
    
POLI Elderly NM_007195 
      
  
Homo sapiens polymerase (DNA 
directed) iota Polymerase 
    
POLK Elderly NM_016218 
      
  
Homo sapiens polymerase (DNA 
directed) kappa Polymerase 
    
POLM Elderly NM_013284 
      
  
Homo sapiens polymerase (DNA 
directed), mu Polymerase 
    
POLN Elderly NM_181808 
      
  
Homo sapiens polymerase (DNA 
directed) nu Polymerase 
    
POLQ Elderly NM_199420 
      
  
Homo sapiens polymerase (DNA 
directed), theta Polymerase 
    
POLR3F Elderly NM_006466 
      
  
Homo sapiens polymerase (RNA) III 
(DNA directed) polypeptide F, 39 kDa Polymerase 










Accession      
ID Number 
POLR3K Elderly NM_016310 
      
  
Homo sapiens polymerase (RNA) III 
(DNA directed) polypeptide K, 12.3 
kDa 
Polymerase 
    
POLS Elderly NM_006999 
      
  
Homo sapiens polymerase (DNA 
directed) sigma Polymerase 
    
POMC Juvenile NM_000939 
      
      
      
  
Homo sapiens proopiomelanocortin 
(adrenocorticotropin/ beta-lipotropin/ 
alpha-melanocyte stimulating 
hormone/ beta-melanocyte stimulating 
hormone/ beta-endorphin), transcript 
variant 2 
Hormone 
    
POT1 Elderly NR_003102 
      
  
Homo sapiens POT1 protection of 
telomeres 1 homolog (S. pombe), 
transcript variant 2 
Telomeres 
    
PPARD Elderly NM_006238 
      
  
Homo sapiens peroxisome proliferator-
activated receptor delta Bone 
    
PPAT Newborn U00238 
      
  
Homo sapiens glutamine PRPP 
amidotransferase (GPAT) Affymetrix 
    
PPOX Juvenile NM_000309 
      
  
Homo sapiens protoporphyrinogen 
oxidase, nuclear gene encoding 
mitochondrial protein 
Mitochondria 
    
PRDX5 Elderly NM_012094 
      
  
Homo sapiens peroxiredoxin 5, nuclear 
gene encoding mitochondrial protein, 
transcript variant 1 
Mitochondria 
    
PRKCA Elderly NM_002737 
      
  
Homo sapiens protein kinase C, alpha Cyclin 
    
PRL Juvenile NM_000948 
      
  
Homo sapiens prolactin Hormone 
    
PTGER4 Elderly NM_000958 
      
  
Homo sapiens prostaglandin E receptor 
4 (subtype EP4) Bone 
    
PTH Juvenile NM_000315 
      
  
Homo sapiens parathyroid hormone Hormone 










Accession      
ID Number 
PTMS Juvenile NM_002824 
      
  
Homo sapiens parathymosin Affymetrix 
    
PTPN18 Elderly NM_014369 
      
  
Homo sapiens protein tyrosine 
phosphatase, non-receptor type 18 
(brain-derived) 
Affymetrix 
    
RAD50 Elderly NM_005732 
      
  
Homo sapiens RAD50 homolog (S. 




Arrest     
RAF1 Elderly NM_002880 
      
  
Homo sapiens v-raf-1 murine leukemia 
viral oncogene homolog 1 Oncogene 
    
RaI Newborn AW003297 
      
  
wq65b01.x1 NCI_CGAP_GC6 Homo 
sapiens cDNA clone IMAGE:2476105 
3- 
Affymetrix 
    
RaIGPS2 Newborn NM_018037 
      
  
Homo sapiens Ral GEF with PH 
domain and SH3 binding motif 2, 
transcript variant 1 
Affymetrix 
    
RANK Elderly AF018253 
      
  
Homo sapiens receptor activator of 
nuclear factor-kappa B 
Growth 
Factor 
    
RAPA-2 Juvenile AJ277276 
TRERF1     
  
Homo sapiens mRNA for rapa-2 (rapa 
gene), transcript variant 3 Hormone 
    
RARA Juvenile NM_000964 
      
  
Homo sapiens retinoic acid receptor, 
alpha, transcript variant 1 Affymetrix 
    
RB1 Elderly NM_000321 
      
  




Genes     
RBL1 Elderly NM_002895 
      
  
Homo sapiens retinoblastoma-like 1 
(p107), transcript variant 1 
Tumor 
Suppressor 
Genes     
RBL2 Elderly NM_005611 
      
  




Genes     
REA Juvenile NM_007273 
      
  
Homo sapiens prohibitin 2 (PHB2) Hormone 









Accession     
ID Number 
RELA Elderly NM_021975 
      
      
  
Homo sapiens v-rel 
reticuloendotheliosis viral oncogene 
homolog A, nuclear factor of kappa 
light polypeptide gene enhancer in B-
cells 3, p65 (avian) 
Oncogene 
    
RUNX2 Elderly NM_004348 
      
  
Homo sapiens runt-related transcription 
factor 2, transcript variant 3 
Transcription 
& Gene 
Regulation     
S15 HSK NM_001018 
      
  




    
SEMA4A Elderly NM_022367 
      
      
  
Homo sapiens sema domain, 
immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A 
Affymetrix 
    
SH3GL1 Juvenile NM_003025 
      
  
Homo sapiens SH3-domain GRB2-like 
1 Affymetrix 
    
SHBG Juvenile NM_001040 
      
  
Homo sapiens sex hormone-binding 
globulin Hormone 
    
SLC20A1 Elderly NM_005415 
      
  
Homo sapiens solute carrier family 20 
(phosphate transporter), member 1 
Immunology 
& Interferons 
    
SLC39A4 Juvenile NM_017767 
      
  
Homo sapiens solute carrier family 39 
(zinc transporter), member 4, transcript 
variant 1 
Affymetrix 
    
SMG5 Elderly NM_015327 
      
  
Homo sapiens Smg-5 homolog, 
nonsense mediated mRNA decay factor 
(C. elegans) 
Telomeres 
    
SMG6 Elderly NM_017575 
      
  
Homo sapiens Smg-6 homolog, 
nonsense mediated mRNA decay factor 
(C. elegans) 
Telomeres 
    
SMG7 Elderly NM_173156 
      
  
Homo sapiens Smg-7 homolog, 
nonsense mediated mRNA decay factor 
(C. elegans), transcript variant 1 
Telomeres 
    
SNCA Elderly NM_000345 
      
  
Homo sapiens synuclein, alpha (non A4 
component of amyloid precursor) 
(SNCA), transcript variant NACP140 
Disease 
    
SPATA1 Juvenile NM_022354 
SP2     
  
Homo sapiens spermatogenesis 
associated 1 Hormone 









Accession      
ID Number 
SPINK5L3 Juvenile XM_376433 
    Replaced by 
  
Homo sapiens serine PI Kazal type 5-
like 3 Affymetrix 
  NM_001040129 
SPINKa Juvenile AK054753 
      
  
Homo sapiens cDNA FLJ30191 fis, 
clone BRACE2001313 Affymetrix 
    
SPINKb Juvenile AK054753 
      
  
Homo sapiens cDNA FLJ30191 fis, 
clone BRACE2001313 Affymetrix 
    
SPP1 Elderly NM_001040058 
      
      
  
Homo sapiens secreted 
phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte 
activation 1), transcript variant 1 
Bone 
    
SPTRX-1 Juvenile NM_032243 
      
  
Homo sapiens thioredoxin domain 
containing 2 (spermatozoa) 
(TXNDC2) 
Hormone 
    
SPTRX-2 Juvenile NM_016616 
      
  
Homo sapiens thioredoxin domain 
containing 3 (spermatozoa) 
(TXNDC3) 
Hormone 
    
SRC Elderly NM_005417 
      
  
Homo sapiens v-src sarcoma 
(Schmidt-Ruppin A-2) viral 
oncogene homolog (avian), transcript 
variant 1 
Oncogene 
    
SRPX Juvenile NM_006307 
      
  
Homo sapiens sushi-repeat-
containing protein, X-linked  Affymetrix 
    
SST Juvenile NM_001048 
      
  
Homo sapiens somatostatin  Hormone 
    
STAF42 Newborn AI760812 
      
  
wi67g12.x1 NCI_CGAP_Kid12 
Homo sapiens cDNA clone 
IMAGE:2398438 3- 
Affymetrix 
    
STK16 Elderly NM_003691 
      
  
Homo sapiens serine/threonine 
kinase 16, transcript variant 1 Affymetrix 
    
TBC1 Juvenile BC028196 
      
      
  
Homo sapiens TBC1 (tre-2/USP6, 
BUB2, cdc16) domain family, 
member 1, mRNA (cDNA clone 
IMAGE:5211948), with apparent 
retained intron 
Affymetrix 










Accession      
ID Number 
TEKT2 Juvenile NM_014466 
      
  
Homo sapiens tektin 2 (testicular) Hormone 
    
TEP1 Elderly NM_007110 
      
  
Homo sapiens telomerase-associated 
protein 1  Telomeres 
    
TERF2 Elderly NM_005652 
      
  
Homo sapiens telomeric repeat binding 
factor 2  Telomeres 
    
TERT Elderly NM_198253 
      
  
Homo sapiens telomerase reverse 
transcriptase, transcript variant 1 Telomeres 
    
TFAP2BL1 Juvenile AL031224 
      
  
Human DNA sequence from clone 
RP3-336H9 on chromosome 6p12.1-
21.1, complete sequence 
Affymetrix 
    
TINF2 Elderly NM_012461 
      
  
Homo sapiens TERF1 (TRF1)-
interacting nuclear factor 2  Telomeres 
    
TNFAIP3 Elderly NM_006290 
      
  
Homo sapiens tumor necrosis factor, 
alpha-induced protein 3  Apoptosis 
    
TNFRSF11A Elderly NM_003839 
      
  
Homo sapiens tumor necrosis factor 
receptor superfamily, member 11a, 
NFKB activator 
Bone 
    
TNFSF10 Elderly NM_003810 
      
  
Homo sapiens tumor necrosis factor 
(ligand) superfamily, member 10  Apoptosis 
    
TNIP1 Elderly NM_006058 
      
  
Homo sapiens TNFAIP3 interacting 
protein 1  Apoptosis 
    
TNKS1BP1 Elderly NM_033396 
      
  
Homo sapiens tankyrase 1 binding 
protein 1, 182kDa  Telomeres 
    
TP53 Elderly NM_000546 
      
  
Homo sapiens tumor protein p53 (Li-
Fraumeni syndrome)  
Tumor 
Suppressor 
Genes     
TP53BP1 Elderly NM_005657 
      
  
Homo sapiens tumor protein p53 
binding protein, 1 
Tumor 
Suppressor 










Accession      
ID Number 
TP53BP2 Elderly NM_005426 
      
  
Homo sapiens tumor protein p53 
binding protein, 2, transcript variant 2 
Tumor 
Suppressor 
Genes     
TP53I3 Elderly NM_004881 
      
  
Homo sapiens tumor protein p53 
inducible protein 3, transcript variant 1 
Tumor 
Suppressor 
Genes     
TP73 Elderly NM_005427 
      
  
Homo sapiens tumor protein p73  Disease 
    
TPST1 Elderly NM_003596 
      
  
Homo sapiens tyrosylprotein 
sulfotransferase 1 Affymetrix 
    
TRPC1 Juvenile NM_003304 
      
  
Homo sapiens transient receptor 
potential cation channel, subfamily C, 
member 1 
Affymetrix 
    
TSLL2 Juvenile NM_145296 
      
  
Homo sapiens cell adhesion molecule 4 
(CADM4) Affymetrix 
    
TUFT1 Juvenile NM_020127 
      
  
Homo sapiens tuftelin 1 Affymetrix 
    
UNQ501 Elderly NM_198536 
      
  
Homo sapiens MBC3205 Affymetrix 
    
VSIG2 Elderly NM_014312 
      
  
Homo sapiens V-set and 
immunoglobulin domain containing 2 
Immunology 
& 
Interferons     
WHSC1L1 Newborn AA741074 
      
ny99e02.s1 NCI_CGAP_GCB1 Homo 
sapiens cDNA clone IMAGE:1286426 
3- 
Affymetrix 
      
WRN Elderly NM_000553 
      
  




Arrest     
XTP3TPA Elderly NM_024096 
      
  
Homo sapiens XTP3-transactivated 
protein A  Affymetrix 
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 Table 26: Candidate Gene Primer Sequences for RT-PCR. 
NEWBORN CANDIDATES 
Candidate Gene Forward Primer Sequence     5' → 3' 
Reverse Primer Sequence      





AFP tcctcagcttgctgtctcag  gctgccatttttctggtgat NM_001134 
APOE (1) ggtcgcttttgggattacct  tccagttccgatttgtaggc M12529 
APOE (2) aggaagatgaaggttctgtg ctcagttcttgggtgacttg NM_000041 
ATF7IP2 ccagtaaatgacctgcgaca aaggcaaggaaagcagaaca AV7169647 
AUF1          
hnRNPD (p37) F1 aacgaggaggatgaaggga R1 ccataaccactctgctggtca NM_001003810 
CHR1orf28 gcctgaatcttgattcccatt gggatggtctagtgcaaagg AA447464 
COL1A2 tggagtccgaggacctaatg gcaagaccagcatgaccttt NM_000089 
DUSP6 ctgtcccagtttttccctga tcacagtgactgagcggcta BC005047 
FACL6 tgtaggcctagccccatgta tgtgcttcatacatttgcacag AV727634 
FKLF tgcagccacacctgaactac tgtgtcggatcacgctagtc AF272830 
FLJ20344a agtggcagcaactggactct tcaacttgccagacttctgc NM_017776 
FLJ20344b ctcccaaagtgctgggatta tgcaaattgccaacatcact NM_017776 
FLJ21901 gacccgctagttgaagcact acgttggcctcagaagaatc NM_024622 
FLJ30658 cctgggaaatgccaaaaata attttgaagccaggtgatgc AW770868 
FLJ35954 tcaatgcaatagcaacttcctc tccaattgtcccagtttgaa R66534 
HBE1 aacatggacaacctcaagcc cacctgcaaactggaagagaa NM_005330 
HBG1 acttccttgggagatgccac aaagcctatccttgaaagctctga NM_000559 
HBG1n1 gaaagctctgaatcatccaggtg gggcaaggtgaatgtggaag N/A 
HBG1n2 agtgagctcagtggcatctc gggcaaggtgaatgtggaag N/A 
HBG2 acttccttgggagatgccat gcctatccttgaaagctctgc NM_000184 
HBG2n2 ctggaggacagggcaaagg gggcaaggtgaatgtggaag N/A 
HBG2n3 ggcagtgagctcagtgcagttc cagctttggcaacctgtcct N/A 
HBZ catgtctctgaccaagactgaga ggatacgaccgataggaacttgt NM_005332 
ITSN2 gggagtgctagcaagtctgg atgactggcaggaaaccatc NM_006277 
KIAA0276 gactttgcacgggaaaagg actggaaaaaggggccag D87466 
KIAA1265 cagggtggacatgatcacag ggcttgagttgaagccagtc AB033091 
KITLG gctttgcttttggagcctta tgtggtctgtcactccagaca NM_000899 
LOC151194 tacctggagatgggagctgt tgctacttttcgatccgtga NM_145280 
LZTFL1 gggctagtgtggccttcag tgcttggcatagttggtttt NM_020347 
MIF ttcatcgtaaacaccaacg ttgctgtaggagcggttc L19686 
PITPNC1 cttcagcagtggcagtggta tgttgggaaattttcagatgc AI676095 
PPAT cagaggcaataccatctcacc cccttcttgtacagatgaaacca U00238 
RaI cgtggtggtttaaacactgg gcagcctgttgatcttttgg AW003297 
RaIGPS2 catgcacttatggcagtggt agggaatgcaaggtgtcatc NM_018037 
STAF42 cccaaaaggtttatttgtca tgcttggtaattctccagtt AI760812 
WHSC1L1 caacagaaacgcttttataagataca gtgattttgccagctggttc AA741074 
 244
 JUVENILE CANDIDATES 
Candidate Gene Forward Primer Sequence     5' → 3' 
Reverse Primer Sequence      





ACTA2 gtggttctggtttgcctgat ctggccctgtaacaccagat AK093340 
ADAM12 gtgcttttggctaccacaca agttcttccccaccgagttt AU145357 
ADAM12a gtgcttttggctaccacaca aattataacagtgaacaagattggtgtt AU145357 
Art3a tgcagccattatgagtgtgc tatttgggtgggttcaagga U47054 
Art3b actttgggggcaaaagaag acttcagccttcacctggaa U47054 
ASL aacatgggacaggctctcag tagtcccacacgcagatcac NM_000048 
BCKDHA cttgagtgccccatcatctt cctcctttgtggcgttgtat NM_000709 
c5229134 acgtcactgtccaactcgtg ctgtgacctggaggttggtt BC037976 
c5286506 ctcacagacacacccagaaac aaaattccaggtgccaacag BC043160 
CABP7 ggctgctctacgacaccttc ccaggtggcgtctacttcat NM_182527 
CABYR gagctgttctcaaaaccaac tgtcctcgtctgtgtctgta NM_012189 
CD28 gaaacacctttgtccaagtc ggggagtcatgttcatgtag NM_006139 
CD200 ggggactgtgaccgacttta tcaggtcctttggagaatgg NM_001004196 
CFIX atgcattctgtggaggctct cagttccagaagggcaatgt NM_000133 
CGI-96 agagagccaccctgtgaaga ctggtcatatgcctccatga AL157851 
COL6A1a ctggccctatcggacctaa aagccctcggtgccattt M20776 
COL6A1b gatgggagaaaggggagaag gggtgcaatgtcgttgttatc M20776 
CXorf22 tgttttcgggggacagttag tagcttcaacgcgtttcctt NM_152632 
CYP17A1 tgatggacgcctttatcctc cataaaggaaggccaggaca NM_000104 
CYP1B1 gtggagaccaccacctctgt gctgaaacccacattctggt NM_000102 
CYP7B1 aggcaagatgtcctggagaa gggtgccgcagaagataata NM_004820 
DHEA ggtttgaccacattcatgg gggccactgtgaagtgattt NM_003167 
DNCL2A-1 atcggtcggaaatggca cgaattcgaaggaaggtgag NM_014183 
DNCL2A-2 ccaggaggtcaaggctacag gatgggaatgccttctgtgt NM_177953 
DNCL2A-3 agggaatcatcgtcgtgaac agagcaagaagtgcccaaaa NM_177954 
DNPEP gtcggtgtggagacctatgg tatttcgctgcagatggatg NM_012100 
E2IG2 tgtacagaggatccccaacc ggtcctcctcctcatcgtct NM_016565 
ERBP ggttgccattgaggaagaaa tgctgctgcttgtcaacttc NM_014597 
ESR1 gtgcctggctagagatcctg agagacttcagggtgctgga NM_000125 
ESR2 tggagtctggtcgtgtgaag gtcggcacttctctgtctcc NM_001437 
FKBP11 cctatggaaaacggggattt catccctaccagaggcaaaa NM_016594 
FLJ11078 tcctcgatgttgtgctgact agtccaggtccagtgtcacc NM_018316 
FLJ22175 acatctgcagtgtcgtctcg aggcttgtcagtgccttgtt NM_025161 
FLJ22672       
PAQR6 cacctgcaccagttctttgt aagaggaagccagtgagcag NM_024897 
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FLJ35982 gccctgaatctcaggcact ggacagggaaggggatttta AK093301 
FLJ35982a tcaggcactggaaggttacc ggacagggaaggggatttta AK093301 
FLJ37440 agccttgtcaaaatggtggt ctgcccgtagagctcacact NM_153214 
FLJ38745 ttgtgtggatgacgtcctgt cagcctccatgaggttgatt AK096064 
FLJ43159 gcctgcattgccttatgaat cagctgctttacccaggaac AI972146 
GAL tcattcagcgacaagaatgg tgcataaattggccgaagat NM_015973 
GFPT2 cagggatgacgtttgctttt gatctcaagccacggatgat NM_005110 
GGT1 gtgttctgccgggatagaaa caggtcctcagctgtcacaa NM_005265 
GHRH aattggagagcatcctggtg ccagttgcattttggctaca NM_021081 
GLO1 atgcgacccagagttaccac ttcaatccagtagccatcagg NM_006708 
GNRH1 ctactgacttcgtgcgtgga cttctggcccaatggattta NM_000825 
GNRH2 gatccccagaatgcccttag  cttcctgtgaagggaccact NM_001501 
GNRHR ctggcctggatcctcagtag ggcagctgaaggtgaaaaag NM_000406 
GPR54 ctcgctggtcatctacgtca actcatggcggtcagagtg NM_032551 
GRIN1 NR1-1 cgggatcttcctgattttca ggatggtactgctgcaggtt NM_000832 
GRIN1 NR1-2 cgggatcttcctgattttca cacccccggtgctctg NM_021569 
GRIN1 NR1-3 cgggatcttcctgattttca tgtctttggaggacctacgc NM_007327 
GRIN2A caagtgggagaaccatacgc cattcatcccctcattggtt NM_000833 
GRIN2B gcatgcctacatgggaaagt tctccaaagagctgcaggat NM_000834 
H17 aaggtccagtccttgggagt ctcggctccacaggtagctt NM_017547 
HOMER3 ccaggaagtgaaggaagcag gtcctgcagtgcgaaaaact NM_004838 
HRG gcccgaaaaaccttgtcata ctagatccatggggcttgaa NM_000412 
HTR1E cctcccaaagtgctggaat tgtagcctcgaaggtttctca NM_000865 
HTR7 ccctccaactacctgatcgt aagccagacggagagaatca NM_000872 
INHA ctctgagcccgaggaagag gagctattggaggctgctgt NM_002191 
ITIH4 ggacctcctgatgttcctga agggtctgagagcaggttca NM_002218 
KIAA0894 ggtgaactcttttcgcaagc agagcacacacagtccaacg NM_014896 
KIAA2022 cagccaacggagaaaacact gctctgcatacagggcttct AB095942 
KISS-1 tggcagctactgcttttcct cagtagcagctggcttcctc NM_002256 
LATS1 gctgtcgatgtggagacaga ggttgtcccaccaacatttc NM_004690 
LEP ggctttggccctatcttttc accggtgactttctgtttgg NM_000230 
LHB gtcaacaccaccatctgtgc ggaagaggaggcctgagagt NM_000894 
LHCGR aggctaattgccacgtcatc gggtgtcttgggtaagcaga NM_000233 
LOC152274 aggaggagagaagggagcag tcaactcctcgggaatgaac AK056398 
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MGC20460 cagcagcccaagaacataca actgttgggaacaggtccag NM_053043 
MGC39650 catctaccctttcgcctctg agatcatctgccccacactc AL137531 
NALP14 gtcttgggtgatggtggagt agatgcgtcaggctcttgtt NM_176822 
NDE1 gagtccaaactcgcttcctg ccagcagtacgaggagaagg NM_017668 
NTS gcatgctactcctggctttc ccaagagggaacatgtgctt NM_006183 
OSGEP attggtgggtgtgaaccact cctggacttgggtcgttaga NM_017807 
OXTR ttcttcgtgcagatgtggag ggacgagttgctctttttgc NM_000916 
PAQR6 ggggctcttctgggaaaata agagcctcccctcaccag NM_024897 
PDE6D gacctgtctgtccctggtgt ggtgctgcctctatcaagga NM_002601 
PGR gtcagtgggcagatgctgta tgtgagctcgacacaactcc NM_000926 
PLEKHA8 ggcatcatgttatgctgtgg gcttcagtcgctgagttcct NM_032639 
POMC aggacctcaccacggaaag gaagtggcccatgacgtact NM_000939 
PPOX tctagccatggacagtctct ctctagacctccacgaagtg NM_000309 
PRL tccataacctctcctcagaaa ataccacgtacttccgtgac NM_000948 
PTH gggtctgcagtccaattcat gcttcttacgcagccattct NM_000315 
PTMS ctgaagagagctgccgaaga aggctggggagaaagaagag NM_002824 
RAPA-2        
TRERF1 ggctcttcagcaatgtcctc cagggcttccataccagtgt AJ277276 
RARA gggagctcattgagaaggtg gtccgagaaggtcatggtgt NM_000964 
REA gagctgagctttagccgaga gggttcttgctcagtgcttc NM_007273 
SH3GL1 ctggcagaggtgaaggactc gactcacctgctcgatgtca NM_003025 
SHBG tcttggctcagtctccacct ctcaagaccaccctggacat NM_001040 
SLC39A4 ttcgtggactttgtgttcca acacactggagctgttgctg NM_017767 
SPATA1        
SP2 caacctgttctttcttcagg ttttgttaaaacctcctcca NM_022354 
SPINK5L3 tttggcacacacacacacac agccttgagaagagctgctg XM_376433 
SPINKa cagaagcagaagcccctatg gccttcctctctgtcagtgg AK054753 
SPINKb tgtgcttgcttccttgtcac atctttgaggtcgtccatgc AK054753 
SPTRX-1 acagagagggaaaaccaact tggtttcttctgaggacttg NM_032243 
SPTRX-2 gagcaatgcaacctttattc tgcaatttttctctcctcat NM_016616 
SRPX tcaagtgcccaagtgtgaag ttctctggggcattgagttt NM_006307 
SST cccagactccgtcagtttct ccatagccgggtttgagtta NM_001048 
TBC1 tcacaacagtcatgacccaag ggccactgggatgaactaga BC028196 
TEKT2 tgacacagatgaaggagtca acagcctctgtcgatctcta NM_014466 
TFAP2BL1 ctagagaccaggctgccatc gcagtgggttcagggagtag AL031224 
TRPC1 tgcttaccaaactgctggtg tggtgagggaatgatgttga NM_003304 
TSLL2 cggataacggcacctacact aaccgacgtctgagcctcta NM_145296 
TUFT1 agaggaacttcggagcaaca gctcttgagcatgtcatcca NM_020127 
 
 247
 ADULT CANDIDATES 
Candidate Gene Forward Primer Sequence     5' → 3' 
Reverse Primer Sequence      





AUF1          
hnRNPD (p45) F2 cccacgacactctgaagcag R2 tccctggttccagttttgac NM_031370 
HBA1 gttaagggccacggcaag ccaaggggcaagaagcat NM_000558 
HBA2 gttaagggccacggcaag cagcgggcaggaggaac NM_000517 
HBB tcctttggggatctgtcca aaggaacctttaatagaaattggacag NM_000518 
HBD ctgaggagaagactgctgtcaa gaattccttgccaaagttgc NM_000519 
HBQ cggctcctcacaagtcaga agttcagcggtactcggaaac NM_005331 
ELDERLY CANDIDATES 
Candidate Gene Forward Primer Sequence     5' → 3' 
Reverse Primer Sequence      





ABL1 gagggcgtgtggaagaaata agtccaggaggttcccgtag NM_007313 
ACD cagctcaatgctgtgcatct ggtaccactttcctcggatg NM_022914 
ACTN3 gattcggctttgctacagga agctggtcaatggtctccag NM_001104 
AGGF1 cacagaacggctgtaccaga agattgaccaaggagcatgg NM_018046 
AIF1 ttggagtccccaagactcac ccttcaaatcagggcaactc NM_001623 
AKT1 atggcaccttcattggctac aaggtgcgttcgatgacagt NM_005163 
AMID ggggatagacctgaagaacca aatctctgctgccatctcca NM_032797 
ANKH ctgtgcctgggctactacaa ggccgactgattctctgtgt NM_054027 
APEX1 caaacctgccacactcaaga gctgttaccagcacaaacga NM_001641 
ARMC7 gagaatgagaccctggtgga agacagcaccgtctcctcat NM_024585 
ATPAF2 gagatcagctcctccaccag actcaatgttgccccacttc NM_145691 
BAX-(all) tgatggacgggtccgg cccctgtcttcatgatctgc NM_138764 
BAX-a/d aactggtgctcaaggccc ggcgtcccaaagtaggaga NM_138761 
BAX-all(e) tctgacggcaacttcaactg ggaggaagtccaatgtccag NM_138764 
BAX-b tctgacggcaacttcaactg cactgtgacctgctccagaa NM_004324 
BAX-d cccttttgcttcagggga ggaggaagtccaatgtccag NM_138763 
BAX-e tctgacggcaacttcaactg aatcgcttgaacccaggag NM_138764 
BAX-s tctgacggcaacttcaactg aaagatggtcacggtccaa NM_138765 
BCL2A1 ggcatcattaactggggaag tccagccagatttaggttcaa NM_004049 
BGLAP ggcagcgaggtagtgaagag agcagagcgacaccctagac NM_199173 
BIRC5 ggaccaccgcatctctacat gtctggctcgttctcagtgg NM_001012271 
CAMK2D actatcaaccctgccaaacg ccccattgttgatagcttcg NM_172127 
CASP2 agactgatcgtggggttgac caggaacctcgtttggtgtt NM_032982 
CBL tctaatgccagctcctcctt ggccatctcgatgttgttct NM_005188 
CCL5 tacaccagtggcaagtgctc tgtactcccgaacccatttc NM_002985 
CCM2 tgtttacacggagtccacca accacccacatccacagat NM_001029835 
CCND1 tcctctccaaaatgccagag tgaggcggtagtaggacagg NM_053056 
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CD28 cggaccttctaagccctttt atagggctggtaatgcttgc NM_006139 
CD86 agacgcggcttttatcttca ttaaaaacacgctgggcttc NM_175862 
CDC2 ccatggggattcagaaattg ccattttgccagaaattcgt NM_001786 
CDC25C ggcacctgattggtgatttt ctggaacttccccgacagta  NM_022809 
CDKN1A ggaagaccatgtggacctgt ggattagggcttcctcttgg NM_078467 
CDKN1B ccggctaactctgaggacac cgagctgtttacgtttgacg NM_004064 
CDKN2C acgtcaatgcacaaaatgga cgaaaccagttcggtctttc NM_001262 
CIITA gatgtggaagacctgggaaa  cacccaggtcagtgatgttg NM_000246 
CLEC2 tgatggctttgattctgctg acaggggctgcatttatgac NM_016509 
CLEC2a agctctcgtctccgttgg cgctttgctaattgttgcag NM_016509 
CLEC2b gcacaggaactctgcaacaa gcctgaagaacccatagcag NM_016509 
COL1A1        
CTx atggctctcctggcaaagat atcaccaggttcgcctttag NM_000088 
CTBP1 ccttcctggtgaacacagc ggctgtcagatggtccttgt NM_001012614 
CTSB ggccgagatctacaaaaacg gccaccacttctgattcgat NM_147780 
CTSK  ccttgaggcttctcttggtg tccacagccatcattctcag NM_000396 
CTSL  acagtggaccaagtggaagg tgggcttacggttttgaaag NM_001912 
CYTBC2 gatggagcggttctggaata ccagacacagggacttcaca D49737 
DDB2 cgatggaaactcagggaaga aaatcaccacctctgcttgc  NM_000107 
DYRK2 gccatgttaaccaggaaacc cgacatgcaggtgatcattc NM_006482 
E2F1 agctggaccacctgatgaat ctcagggcacaggaaaacat NM_005225 
ECGF1 acaaggtcagcctggtcctc ctctgacccacgatacagca NM_001953 
ELAVL1        
HuR acaaaaacgtggcactcctc gccccaggttgtagatgaaa NM_001419 
EMD gccgcctcctcttatagctt tgatgctctggtaggcactg NM_000117 
EREG cgtgtggctcaagtgtcaat  agtgttcacatcggacacca NM_001432 
ERF gggaaacggttcacctacaa agatgaagagcaggctggtg NM_006494 
FLJ20245 gctgctcctggagtcttgg gctcctgggacagatactcg NM_017723 
FLJ20421 gcatttaaagccatggagga ctgaaaccatggggagagaa BF674724 
FLJ35984 accaggggtccatcctctac ggaggtgctgggtttcataa AK093303 
FLJ38628 ctcaaggacagaggccagag cagggccacaaataggaaga NM_152267 
GADD45A ggaggaagtgctcagcaaag atctctgtcgtcgtcctcgt NM_001924 
GADD45B tgctgtgacaacgacatcaa tttgtttgtggcagcaactc NM_015675 
GSTP1 gacctccgctgcaaatacat ggctaggacctcatggatca NM_000852 
HIC2 ctgctgctcacatggtgtct gatgacgtcacacaggaagc  NM_015094 
HIF1A tccatgtgaccatgaggaaa ccaagcaggtcataggtggt NM_001530 
HPCAL4 caactgggcctttgagatgt tggtcgtccttatcctggtc NM_016257 
HRAS gagggcttcctgtgtgtgtt agccaggtcacacttgttcc NM_176795 
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HTATIP catcctccaggcaatgagat  agtagcccacgatgtggaag NM_182710 
IFNG agatgaccagagcatccaaaa cagttcagccatcacttgga  NM_000619 
IGF1 tggatgctcttcagttcgtg cctgcactccctctacttgc NM_000618 
IGF2 acaccctccagttcgtctgt cggaaacagcactcctcaac NM_000612 
IGFBP3 acagccagcgctacaaagtt ggctgcccatacttatccac NM_001013398 
IGFBP5 tgcacctgagatgagacagg gaatcctttgcggtcacaat NM_000599 
IL1A aatgacgccctcaatcaaag ccgtgagtttcccagaagaa NM_000575 
IRF1 ccaggctacatgcaggactt gtaggtaccccttcccatcc NM_002198 
KL aatggctggtttgtctcagg tgtaacctctgtgccactcg NM_153683 
KLF13 gatcctagcggacctcaacc attcccgggtggaagttg NM_015995 
LASS5 aaaatccaatgctggtttcg ccaatagaaggccaattcca NM_147190 
LMNA (norm) ggtggtgacgatctgggct ccagtggagttgatgagagc NM_170707 
LMNA (RT) gtggaaggcacagaacacct gtgaggaggacgcaggaa NM_170707 
LMNA (spec) gcgtcaggagccctgagc gacgcaggaagcctccac NM_170707 
LOH11CR2A ggcaccactccagaacattt tcacccggaaatcacatttt BC001234 
MAD1L1 gagcagatccgttcgaagtc gcatccaagttctgctgaca NM_003550 
MCPH1 agcccagagtgaacatgagc aggtccttaaagccgtcaca NM_024596 
MDM2 ggtgctgtaaccacctcaca tttttgtgcaccaacagacttt NM_002392 
MEPE aactaagcaaagctgtgtgg attctcactggcttcagaaa NM_020203 
MET agcctgattgtgcatttcaa gatgattccctcggtcagaa NM_000245 
MGC14288 gggaagttgcgtagacagtg agctagctgcttgccagttg NM_032901 
MLL taagcccaagtttggtggtc cttctgcaggtaggctttgg NM_005933 
MMP-13 aacatccaaaaacgccagac atgcagcatcaatacggttg NM_002427 
MMP-14 cactgcctacgagaggaagg tcccttcccagactttgatg NM_004995 
MMP-9 gacaagctcttcggcttctg gccattcacgtcgtccttat NM_004994 
MS4A4A ggaatgaaattacgtctttggaa cctgatgcagccagtacaga NM_024021 
MS4A4Aa tctgtactggctgcatcagg gccatgtgagaatgtgatgg NM_024021 
MS4A4Ab aggagagagattcgagcacct ggcagtcagaatctgcacaa NM_024021 
MT1X tcctgcaaatgcaaagagtg acagctgtcctggcatcag NM_005952 
MYC cctaccctctcaacgacagc ctctgaccttttgccagga NM_002467 
NBN gaaaaaggccaaggatggat gccagatggatttctggaag NM_001024688 
NMI cgcgtggactatgacagaca gcccgttgaaagtgaatgtt NM_004688 
NPPB accgcaaaatggtcctctac gttgaggaaaaagccccttg NM_002521 
NRAS gcgaaggcttcctctgtgta agttcgtgggcttgttttgt NM_002524 
OGG1 atggggcatcgtactctagc cgatgttgttgttggaggaa NM_016819 
OPG           
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OPGL          
RANKL         
TNFSF11 
gcttgaagctcagccttttg cgaaagcaaatgttggcata NM_003701 
OSM agctgctcgaaagagtaccg ctgctctaagtcggccagtc NM_020530 
PDCD1 aaggcgcagatcaaagagag aatccagctccccatagtcc NM_005018 
PDCD10        
CCM3 tgaagctgagaccacatcca tgccatacgaagaagggact NM_007217 
PDCD11 gggcaagaagagtgtcaagc gtggcagaaaagctctggtc NM_014976 
PDCD1LG2 atccaacttggctgcttcac aagtgcaaatggcaagctct NM_025239 
PDCD2L ctggtcgtgcaggtgtattg gaaggcccctcctcagtatc NM_032346 
PDCD4 tggattaactgtgccaacca tctcaaatgccctttcatcc NM_145341 
PDCD5 cttgaggcgctgaggagac ccgactgatccagaacttgg NM_004708 
PDCD6 ctccgggatgatcgataaga tccatgttgtgctgctcttc NM_013232 
PDCD6IP ctgttgggaccctcagtctt ttctgctgttttgccaggat NM_013374 
PDCD7 tgaagtgtgtgcaggaggtg gtcgctgaagatgatgcgta NM_005707 
PIK3CA cagacgcatttccacagcta gcaaatggaaaggcaaagtc NM_006218 
POLA1 ccatcacagttttgcattgg cagtgaggagctttgcacac NM_016937 
POLA2 cgaaagccaggcatagtacc ggggctacgagttgacacac NM_002689 
POLB attcggcaggatgatacgag ccaattcgctgatgatggtt NM_002690 
POLD1 ggtgcagagctacgagaagg atgaagagtcccggatgttg NM_002691 
POLE1 tggcatttgacattgagacg gtttggtctcctggacgtgt NM_006231 
POLE2 ttgaacgatctgtggtggaa aaatttggtgcagggtggt NM_002692 
POLE3 agaggcccgaggacctaaa agcacatcactggcattcag NM_017443 
POLG tgaggccaagatggagaact tacgtttatgggcgttcctc NM_002693 
POLH tggactaaacaagcccaacc gttgcctgggtttaactgga NM_006502 
POLI cagttgctcagcgtatccaa aaggaatagggcactgacga NM_007195 
POLK ccatgccaggatttattgct  ggatcgttcatgctcactca NM_016218 
POLM ttccccactttggagaacac gtaccaccggtcagcagtct NM_013284 
POLN ccaagcacccaattcagatt acaccaccttcttggtttgc NM_181808 
POLQ gccttcaggactggactctg agtagaagttgccgccaaga NM_199420 
POLR3F tgcaaaagaaggcacagttg aaaattcgagccactctgtc NM_006466 
POLR3K atcgtggaggagggacaac caccaagcacatcatccact NM_016310 
POLS cccaccacttccagaacact gctttcaaagacgcagttcc NM_006999 
POT1 tgggtattgtacccctccaa ttgatgaagcattccaacca NR_003102 
PPARD aagtggcagaggcagaag ctgcgctcacacttctcgta NM_006238 
PRDX5 cgctcagcgggctatatact aaagatggacaccagcgaat NM_012094 
PRKCA caggatgatgacgtggagtg gttccttgcacatcccaaag NM_002737 
PTGER4 ctggtggtgctcatctgct tcacagaagcaattcggatg NM_000958 
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PTPN18 ccagatgatcccacctgact gaagagggcatcgtcgtaga NM_014369 
RAD50 cttggatatgcgaggacgat ccagaagctggaagttacgc NM_005732 
RAF1 ggctggtagctgactgtgtg ccggttgatcttcggtagag NM_002880 
RANK ctctgatgccttttcctcca agctggcagagaagaactgc AF018253 
RB1 aggaccgagaaggaccaact cagacagaaggcgttcacaa NM_000321 
RBL1 ttgatggcttgttgtttgga tgtttcaccatgtcccttga NM_002895 
RBL2 agaacctggaaagggcagat tggggagctgtacctatcgt NM_005611 
RELA ccacgagcttgtaggaaagg ctgatagcctgctccaggtc NM_021975 
RUNX2 cggaatgcctctgctgttat atgcgccctaaatcactgag NM_004348 
SEMA4A tctgctcctgagtggtgatg aaaccaggacacggatgaag NM_022367 
SLC20A1 ctatgcctgcacagttggaa accagacgataagggcacag NM_005415 
SMG5 ctgcagttcaacccagaggt aggtagggagacatggctga  NM_015327 
SMG6 tgcctccactactgcaaaga ggcatcttccgtgctacact NM_017575 
SMG7 caggagtcttccgtccagag tgagagagaatccggtgagg NM_173156 
SNCA aaaaccaaggagggagtggt cccaactggtcctttttgac NM_000345 
SPP1 gccgaggtgatagtgtggtt attcaactcctcgctttcca NM_001040058 
SRC ggctacatccccagcaacta tgcggatcttgtagtgcttc NM_005417 
STK16 gggttccatgaatcaagcat cccttttggaacaccatgtc NM_003691 
TEP1 gccgcactgtcttggtctat ggagcttgatggcagtcttc NM_007110 
TERF2 gaccttccagcagaagatgc cctgtgcaccagacagagtc NM_005652 
TERT gcaaactctttggggtcttg gggttcttccaaacttgctg NM_198253 
TINF2 tcctgaaagccctgaatcac ctgcatccaactcagcacat NM_012461 
TNFAIP3 atagaaatccccgtccaagg tgggcgtttcacattttaca NM_006290 
TNFRSF11A catgtttacttgcccggttt cctgacagacaccaccttga NM_003839 
TNFSF10 gagtatgaacagcccctgct tccttgatgattcccaggag NM_003810 
TNIP1 tgagcaatggcaacaaagag gctccagcatcttcaccttc NM_006058 
TNKS1BP1 ggaggggccagtaaagtctc ctcttatcaggcgggtgaag NM_033396 
TP53 gcgcacagaggaagagaatc cctcattcagctctcggaa NM_000546 
TP53BP1 cccatacttgggagtggaaa cctcacttcgagcctcattc NM_005657 
TP53BP2 tccttggtcattcaggcttc cggacgcactttcttctctt NM_005426 
TP53I3 gcttcaaatggcagaaaagc aacccatcgaccatcaagag NM_004881 
TP73 gaccgaaaagctgatgagga tcagctccaggctctctttc NM_005427 
TPST1 cccacctaactacggaaaacc aagaggctcctggttctgct NM_003596 
UNQ501 atgcaaatgtgggtgacctt aggctcaggaacagcaggta NM_198536 
VSIG2 tgcgtcttggaacttttcct cccctctctttctggaacct NM_014312 
WRN ggactttggtccacaagcat tctttggtgcccgaagatac NM_000553 
XTP3TPA cctccatgctgagtttgctg atgccaccaggtagatgagg NM_024096 
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Candidates Rejected Candidates 
ABL1 Elderly Literature   Expressed in All Ages 
ACD Elderly Literature   No mRNA Detected 
ACTA2 Juvenile Affymetrix   No mRNA Detected 
ACTN3 Elderly Literature   No mRNA Detected 
ADAM12 Juvenile Affymetrix   Same Size mRNA/DNA 
ADAM12a Juvenile Affymetrix   Same Size mRNA/DNA 
AFP Newborn Literature Fetal Liver   
AGGF1 Elderly Affymetrix Elderly   
AIF1 Elderly Literature   Expressed in All Ages 
AKT1 Elderly Literature   Expressed in All Ages 
AMID Elderly Literature   Expressed Sporadically 
ANKH Elderly Literature   No mRNA Detected 
APEX1 Elderly Literature   Expressed in All Ages 
APOE (1) Newborn Literature   No mRNA Detected 
APOE (2) Newborn Literature   Expressed Sporadically 
ARMC7 Elderly Affymetrix   Expressed Sporadically 
Art3a Juvenile Affymetrix   No mRNA Detected 
Art3b Juvenile Affymetrix   No mRNA Detected 
ASL Juvenile Affymetrix Juvenile   
ATF7IP2 Newborn Affymetrix   Expressed in All Ages 
ATPAF2 Elderly Affymetrix   Expressed Sporadically 
AUF1        
hnRNPD      
p37 
Newborn Literature   Expressed Sporadically 
AUF1    
hnRNPD      
p45 
Adult Literature   Expressed Sporadically 
BAX-(all) Elderly Literature   Expressed in All Ages 
BAX-a/d Elderly Literature   Expressed in All Ages 
BAX-all(e) Elderly Literature   Expressed in All Ages 
BAX-b Elderly Literature   Expressed Sporadically 
BAX-d Elderly Literature   Expressed Sporadically 
BAX-e Elderly Literature   Expressed in All Ages 
BAX-s Elderly Literature   No mRNA Detected 
BCKDHA Juvenile Affymetrix   Expressed in All Ages 
BCL2A1 Elderly Literature   Expressed in All Ages 
BGLAP Elderly Literature   Expressed Sporadically 
BIRC5 Elderly Literature   Expressed in All Ages 










Candidates Rejected Candidates 
c5286506 Juvenile Affymetrix   Same Size mRNA/DNA 
CABP7 Juvenile Affymetrix   No mRNA Detected 
CABYR Juvenile Literature   No mRNA Detected 
CAMK2D Elderly Literature   Expressed in All Ages 
CASP2 Elderly Literature   Expressed in All Ages 
CBL Elderly Literature   Expressed in All Ages 
CCL5 Elderly Affymetrix   Expressed in All Ages 
CCM2 Elderly Literature   Expressed in All Ages 
CCND1 Elderly Literature   Expressed Sporadically 
CD200 Juvenile Literature   Expressed Sporadically 
CD28 Juvenile Affymetrix   Expressed in All Ages 
CD28 Elderly Literature   Expressed in All Ages 
CD86 Elderly Literature   Expressed in All Ages 
CDC2 Elderly Literature Elderly   
CDC25C Elderly Literature   Expressed Sporadically 
CDKN1A Elderly Literature   Expressed in All Ages 
CDKN1B Elderly Literature   Expressed in All Ages 
CDKN2C Elderly Literature   Expressed in All Ages 
CFIX Juvenile Literature   No mRNA Detected 
CGI-96 Juvenile Affymetrix   Expressed in All Ages 
CHR1orf28 Newborn Affymetrix   Same Size mRNA/DNA 
CIITA Elderly Literature   Expressed in All Ages 
CLEC2 Elderly Affymetrix   Expressed in All Ages 
CLEC2a Elderly Affymetrix   Expressed in All Ages 
CLEC2b Elderly Affymetrix   Same Size mRNA/DNA 
COL1A1      
CTx Elderly Literature   Expressed Sporadically 
COL1A2 Newborn Literature Newborns   
COL6A1a Juvenile Affymetrix   Expressed Sporadically 
COL6A1b Juvenile Affymetrix   No mRNA Detected 
CTBP1 Elderly Literature   Expressed in All Ages 
CTSB Elderly Literature   Expressed in All Ages 
CTSK Elderly Literature   Expressed in All Ages 
CTSL Elderly Literature   Expressed Sporadically 
CXorf22 Juvenile Affymetrix   No mRNA Detected 
CYP17A1 Juvenile Literature   Expressed Sporadically 
CYP1B1 Juvenile Literature   No mRNA Detected 
CYP7B1 Juvenile Literature   Expressed Sporadically 
CYTBC2 Elderly Affymetrix   Same Size mRNA/DNA 
DDB2 Elderly Literature   Expressed in All Ages 











Candidates Rejected Candidates 
DNCL2A-1 Juvenile Affymetrix   Expressed in All Ages 
DNCL2A-2 Juvenile Affymetrix   Expressed in All Ages 
DNCL2A-3 Juvenile Affymetrix   Expressed in All Ages 
DNPEP Juvenile Affymetrix   Expressed in All Ages 
DUSP6 Newborn Affymetrix   Expressed in All Ages 
DYRK2 Elderly Literature   Expressed in All Ages 
E2F1 Elderly Literature   Expressed in All Ages 
E2IG2 Juvenile Literature   Expressed Sporadically 
ECGF1 Elderly Literature   No mRNA Detected 
ELAVL1      
HuR Elderly Literature   Expressed in All Ages 
EMD Elderly Literature   Expressed in All Ages 
ERBP Juvenile Literature   Expressed in All Ages 
EREG Elderly Literature   No mRNA Detected 
ERF Elderly Literature   Expressed in All Ages 
ESR1 Juvenile Literature   No mRNA Detected 
ESR2 Juvenile Literature   Expressed Sporadically 
FACL6 Newborn Affymetrix   No mRNA Detected 
FKBP11 Juvenile Affymetrix   Expressed in All Ages 
FKLF Newborn Literature   Expressed in All Ages 
FLJ11078 Juvenile Affymetrix   Expressed in All Ages 
FLJ20245 Elderly Affymetrix   Same Size mRNA/DNA 
FLJ20344a Newborn Affymetrix Newborn   
FLJ20344b Newborn Affymetrix   Same Size mRNA/DNA 
FLJ20421 Elderly Affymetrix   Same Size mRNA/DNA 
FLJ21901 Newborn Affymetrix   Same Size mRNA/DNA 
FLJ22175 Juvenile Affymetrix   Expressed in All Ages 
FLJ22672     
PAQR6 Juvenile Affymetrix   Expressed Sporadically 
FLJ30658 Newborn Affymetrix   Same Size mRNA/DNA 
FLJ35119 Juvenile Affymetrix   Expressed in All Ages 
FLJ35954 Newborn Affymetrix   Same Size mRNA/DNA 
FLJ35982 Juvenile Affymetrix   Same Size mRNA/DNA 
FLJ35982a Juvenile Affymetrix   No mRNA Detected 
FLJ35984 Elderly Affymetrix   Same Size mRNA/DNA 
FLJ37440 Juvenile Affymetrix   No mRNA Detected 
FLJ38628 Elderly Affymetrix   Expressed Sporadically 
FLJ38745 Juvenile Affymetrix   Same Size mRNA/DNA 
FLJ43159 Juvenile Affymetrix   Same Size mRNA/DNA 
GADD45A Elderly Literature   Expressed in All Ages 
GADD45B Elderly Literature   Expressed in All Ages 










Candidates Rejected Candidates 
GFPT2 Juvenile Affymetrix   Expressed Sporadically 
GGT1 Juvenile Affymetrix   Expressed in All Ages 
GHRH Juvenile Literature   Same Size mRNA/DNA 
GLO1 Juvenile Literature   Expressed in All Ages 
GNRH1 Juvenile Literature   Expressed Sporadically 
GNRH2 Juvenile Literature   Same Size mRNA/DNA 
GNRHR Juvenile Literature   No mRNA Detected 
GPR54 Juvenile Literature   Expressed Sporadically 
GRIN1        
NR1-1 Juvenile Literature   Expressed Sporadically 
GRIN1        
NR1-2 Juvenile Literature   No mRNA Detected 
GRIN1        
NR1-3 Juvenile Literature   No mRNA Detected 
GRIN2A Juvenile Literature   No mRNA Detected 
GRIN2B Juvenile Literature   No mRNA Detected 
GSTP1 Elderly Affymetrix   Expressed in All Ages 
H17 Juvenile Affymetrix   Expressed in All Ages 
HBA1 Adult Literature   Expressed in All Ages 
HBA2 Adult Literature   Expressed in All Ages 
HBB Adult Literature   Expressed in All Ages 
HBD Adult Literature   Expressed in All Ages 
HBE1 Newborn Literature Newborn   
HBG1 Newborn Literature   Expressed in All Ages 
HBG1n1 Newborn Literature Newborn   
HBG1n2 Newborn Literature Newborn   
HBG2 Newborn Literature   Expressed in All Ages 
HBG2n2 Newborn Literature Newborn   
HBG2n3 Newborn Literature Newborn   
HBZ Newborn Literature   No mRNA Detected 
HBQ Adult Literature   Expressed Sporadically 
HIC2 Elderly Affymetrix   No mRNA Detected 
HIF1A Elderly Literature   Expressed in All Ages 
HOMER3 Juvenile Affymetrix   Expressed Sporadically 
HPCAL4 Elderly Affymetrix   Expressed Sporadically 
HRAS Elderly Literature   No mRNA Detected 
HRG Juvenile Affymetrix   Expressed Sporadically 
HTATIP Elderly Literature   Expressed in All Ages 
HTR1E Juvenile Affymetrix   No mRNA Detected 
HTR7 Juvenile Affymetrix   Expressed Sporadically 
IFNG Elderly Literature   Expressed Sporadically 










Candidates Rejected Candidates 
IGF2 Elderly Literature   No mRNA Detected 
IGFBP3 Elderly Literature Elderly   
IGFBP5 Elderly Literature   No mRNA Detected 
IL1A Elderly Literature   Expressed Sporadically 
INHA Juvenile Literature   No mRNA Detected 
IRF1 Elderly Literature   Expressed in All Ages 
ITIH4 Juvenile Affymetrix   Expressed Sporadically 
ITSN2 Newborn Affymetrix   Expressed in All Ages 
KIAA0276 Newborn Affymetrix   Expressed in All Ages 
KIAA0894 Juvenile Affymetrix   No mRNA Detected 
KIAA1265 Newborn Affymetrix   Expressed in All Ages 
KIAA2022 Juvenile Affymetrix   Expressed Sporadically 
KISS-1 Juvenile Literature   Expressed Sporadically 
KITLG Newborn Literature   Expressed Sporadically 
KL Elderly Literature   Expressed Sporadically 
KLF13 Elderly Literature   No mRNA Detected 
LASS5 Elderly Affymetrix   Expressed Sporadically 
LATS1 Juvenile Affymetrix   Expressed in All Ages 
LEP Juvenile Literature   Expressed Sporadically 
LHB Juvenile Literature   No mRNA Detected 
LHCGR Juvenile Literature   No mRNA Detected 
LMNA 
(norm) Elderly Literature   Expressed in All Ages 
LMNA (RT) Elderly Literature   Expressed Sporadically 
LMNA 
(spec) Elderly Literature   No mRNA Detected 
LOC151194 Newborn Affymetrix Newborn   
LOC152274 Juvenile Affymetrix   No mRNA Detected 
LOC284242 Juvenile Affymetrix   No mRNA Detected 
LOH11CR2A Elderly Affymetrix Elderly   
LZTFL1 Newborn Affymetrix   Same Size mRNA/DNA 
MAD1L1 Elderly Literature Elderly   
MCPH1 Elderly Literature   Expressed in All Ages 
MDM2 Elderly Literature   Expressed in All Ages 
MEPE Elderly Literature   No mRNA Detected 
MET Elderly Literature   Expressed Sporadically 
MGC14288 Elderly Affymetrix   Expressed in All Ages 
MGC20460 Juvenile Affymetrix   Expressed in All Ages 
MGC39650 Juvenile Affymetrix   Expressed Sporadically 
MIF Newborn Literature   No mRNA Detected 
MLL Elderly Literature   No mRNA Detected 










Candidates Rejected Candidates 
MMP-14 Elderly Literature   Expressed Sporadically 
MMP-9 Elderly Literature   Expressed Sporadically 
MS4A4A Elderly Affymetrix   Expressed Sporadically 
MS4A4Aa Elderly Affymetrix   Expressed in All Ages 
MS4A4Ab Elderly Affymetrix   Expressed Sporadically 
MT1X Elderly Affymetrix   Expressed in All Ages 
MYC Elderly Literature   Expressed in All Ages 
NALP14 Juvenile Affymetrix   Expressed Sporadically 
NBN Elderly Literature   No mRNA Detected 
NDE1 Juvenile Affymetrix   Expressed in All Ages 
NMI Elderly Literature   Expressed in All Ages 
NPPB Elderly Literature   No mRNA Detected 
NRAS Elderly Literature   Expressed in All Ages 
NTS Juvenile Literature   No mRNA Detected 
OGG1 Elderly Literature   Expressed Sporadically 
OPG       
TNFRSF11B Elderly Literature   No mRNA Detected 
OPGL        
RANKL       
TNFSF11 
Elderly Literature   Expressed Sporadically 
OSGEP Juvenile Affymetrix   Expressed in All Ages 
OSM Elderly Literature   Expressed Sporadically 
OXTR Juvenile Literature   Expressed Sporadically 
PAQR6 Juvenile Affymetrix   No mRNA Detected 
PDCD1 Elderly Literature   Expressed Sporadically 
PDCD10      
CCM3 Elderly Literature   Expressed in All Ages 
PDCD11 Elderly Literature   Expressed in All Ages 
PDCD1LG2 Elderly Literature   Expressed Sporadically 
PDCD2L Elderly Literature   Expressed Sporadically 
PDCD4 Elderly Literature   Expressed in All Ages 
PDCD5 Elderly Literature   Expressed in All Ages 
PDCD6 Elderly Literature Elderly   
PDCD6IP Elderly Literature   Expressed in All Ages 
PDCD7 Elderly Literature   Expressed in All Ages 
PDE6D Juvenile Affymetrix   Expressed in All Ages 
PGR Juvenile Literature   No mRNA Detected 
PIK3CA Elderly Literature   Expressed in All Ages 
PITPNC1 Newborn Affymetrix   Same Size mRNA/DNA 











Candidates Rejected Candidates 
POLA1 Elderly Literature   Expressed in All Ages 
POLA2 Elderly Literature   Expressed in All Ages 
POLB Elderly Literature   Expressed in All Ages 
POLD1 Elderly Literature   Expressed in All Ages 
POLE1 Elderly Literature   Expressed in All Ages 
POLE2 Elderly Literature   Expressed in All Ages 
POLE3 Elderly Literature   Expressed in All Ages 
POLG Elderly Literature   Expressed in All Ages 
POLH Elderly Literature   Expressed in All Ages 
POLI Elderly Literature   Expressed in All Ages 
POLK Elderly Literature   Expressed in All Ages 
POLM Elderly Literature Elderly   
POLN Elderly Literature   No mRNA Detected 
POLQ Elderly Literature Elderly   
POLR3F Elderly Literature   Expressed in All Ages 
POLR3K Elderly Literature   Expressed in All Ages 
POLS Elderly Literature   Expressed in All Ages 
POMC Juvenile Literature   No mRNA Detected 
POT1 Elderly Literature   Expressed in All Ages 
PPARD Elderly Literature Elderly   
PPAT Newborn Affymetrix   Same Size mRNA/DNA 
PPOX Juvenile Literature Juvenile   
PRDX5 Elderly Literature   Expressed in All Ages 
PRKCA Elderly Literature   Expressed in All Ages 
PRL Juvenile Literature Juvenile   
PTGER4 Elderly Literature   Expressed in All Ages 
PTH Juvenile Literature   No mRNA Detected 
PTMS Juvenile Affymetrix   Same Size mRNA/DNA 
PTPN18 Elderly Affymetrix   Expressed Sporadically 
RAD50 Elderly Literature   Expressed in All Ages 
RAF1 Elderly Literature   No mRNA Detected 
RaI Newborn Affymetrix   Same Size mRNA/DNA 
RaIGPS2 Newborn Affymetrix   Expressed in All Ages 
RANK Elderly Literature   Expressed Sporadically 
RAPA-2      
TRERF1 Juvenile Literature   Expressed in All Ages 
RARA Juvenile Affymetrix   Expressed in All Ages 
RB1 Elderly Literature   Expressed in All Ages 
RBL1 Elderly Literature   Expressed in All Ages 











Candidates Rejected Candidates 
REA Juvenile Literature   Same Size mRNA/DNA 
RELA Elderly Literature   Expressed in All Ages 
RUNX2 Elderly Literature   Expressed in All Ages 
SEMA4A Elderly Affymetrix   Expressed in All Ages 
SH3GL1 Juvenile Affymetrix   Expressed in All Ages 
SHBG Juvenile Literature   No mRNA Detected 
SLC20A1 Elderly Literature   Expressed in All Ages 
SLC39A4 Juvenile Affymetrix   Same Size mRNA/DNA 
SMG5 Elderly Literature   Expressed in All Ages 
SMG6 Elderly Literature   Expressed in All Ages 
SMG7 Elderly Literature   Expressed in All Ages 
SNCA Elderly Literature   Expressed in All Ages 
SPATA1      
SP2 Juvenile Literature   Expressed Sporadically 
SPINK5L3 Juvenile Affymetrix   Same Size mRNA/DNA 
SPINKa Juvenile Affymetrix   Same Size mRNA/DNA 
SPINKb Juvenile Affymetrix   No mRNA Detected 
SPP1 Elderly Literature   Expressed Sporadically 
SPTRX-1 Juvenile Literature Juvenile   
SPTRX-2 Juvenile Literature Juvenile   
SRC Elderly Literature Elderly   
SRPX Juvenile Affymetrix   No mRNA Detected 
SST Juvenile Literature   No mRNA Detected 
STAF42 Newborn Affymetrix   Same Size mRNA/DNA 
STK16 Elderly Affymetrix   Expressed Sporadically 
TBC1 Juvenile Affymetrix Juvenile   
TEKT2 Juvenile Literature Juvenile   
TEP1 Elderly Literature   No mRNA Detected 
TERF2 Elderly Literature   No mRNA Detected 
TERT Elderly Literature   No mRNA Detected 
TFAP2BL1 Juvenile Affymetrix   No mRNA Detected 
TINF2 Elderly Literature   Expressed in All Ages 
TNFAIP3 Elderly Literature   Expressed in All Ages 
TNFRSF11A Elderly Literature   Expressed Sporadically 
TNFSF10 Elderly Literature   Expressed in All Ages 
TNIP1 Elderly Literature   Expressed in All Ages 













Candidates Rejected Candidates 
TP53 Elderly Literature   Expressed in All Ages 
TP53BP1 Elderly Literature   No mRNA Detected 
TP53BP2 Elderly Literature   No mRNA Detected 
TP53I3 Elderly Literature   No mRNA Detected 
TP73 Elderly Literature   No mRNA Detected 
TPST1 Elderly Affymetrix   Expressed Sporadically 
TRPC1 Juvenile Affymetrix   Expressed Sporadically 
TSLL2 Juvenile Affymetrix   Expressed in All Ages 
TUFT1 Juvenile Affymetrix   Expressed in All Ages 
UNQ501 Elderly Affymetrix   Expressed in All Ages 
VSIG2 Elderly Literature   Expressed Sporadically 
WHSC1L1 Newborn Affymetrix   Same Size mRNA/DNA 
WRN Elderly Literature   Expressed Sporadically 
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AGGF1 Elderly 502F aagctgctgcatcacacagaac NM_018046 
    568T 6FAMcaggtggaagaacMGBNFQ   
    604R tcccacgttggagtattttactga   
ASL Juvenile 594F ctgcagtgacagctggttgag NM_001024943 
    676T 6FAMaatggcatccctttgcMGBNFQ   
    727R acatgctggccactgacctt   
CDC2 Elderly 881F acctggaatcctgcataagca NM_001786 
    904T 6FAMtcctgaagactgactatatMGBNFQ   
    948R tctattaaaggaacttcgtcatccaa   
COL1A2 Newborn 1383F gcatccttggttagggtcaatc NM_000089 
    1406T 6FAMagtagtaaccactgctccMGBNFQ   
    1456R catgccgtgacttgagactca   
FLJ20344a Newborn 318F gcgaagcctgatgtgatcttc NM_017776 
    395T 6FAMctgtgcagaagtctggMGBNFQ   
    455R tttgtcttggctttccttgtagtg   
HBE1 Newborn 671F attgccctggcccataagta NM_005330 
    697T 6FAMagttctcttccagtttgcagMGBNFQ   
    743R aggagggtgtcagggtcaca   
HBG1n1 Newborn 61F gaaagctctgaatcatccaggtg N/A 
    85T 6FAMtttgtggcatctcccaaggaagtcagcMGBNFQ   
    134R agtcaaggcacatggcaagaag   
HBG2n3 Newborn 78F gcagtgagctcagtgcagttc N/A 
    110T 6FAMcaaaggtgcccttgagatcatccaggMGBNFQ   
    159R ttccttgggagatgccataaa   
IGFBP3 Elderly 743F agaacttctcctccgagtccaa NM_001013398 
    772T 6FAMacagaatatggtccctgccMGBNFQ   
    822R caggtgattcagtgtgtcttcca   
LOC151194 Newborn 400F gggctggtgggcatagtg NM_145280 
    423T 6FAMcctgctgggtgctcaMGBNFQ   
    461R acttttcgatccgtgatagtcaca   
LOH11CR2A Elderly 1178F cttggcaccactccagaaca BC001234 
    1227T 6FAMcccctacagcttttMGBNFQ   
    1277R actaaacgtgtctgtaacttctccatct   
MAD1L1 Elderly 696F caggcagtgtcagcagaacttg NM_003550 
    767T 6FAMctggcgagaccatcaaMGBNFQ   












PDCD6 Elderly 429F tcgataagaacgagctgaagca  NM_013232 
    459T 6FAMcaggtttcggctaccgMGBNFQ    
    498R atgtcgtggaactggtcagaga    
POLM Elderly 1095F ggcccaggtgtctgaagatg  NM_013284 
    1140T 6FAMatgtcttctgctccgggtMGBNFQ    
    1176R aacagccatgggctgtttg    
POLQ Elderly 6374F cagcccagacggttggaa  NM_199420 
    6403T 6FAMcatccctgcataaacMGBNFQ    
    6459R tgcaatcgtgggcagattc    
PPARD Elderly 906F catcctcaccggcaaagc  NM_006238 
    929T 6FAMacacggcgcccttMGBNFQ    
    963R tgtctcgatgtcgtggatcac   
PPOX Juvenile 791F aaacccatcgttccatattactgg NM_000309 
    826T 6FAMtccgccctgccccMGBNFQ   
    869R tggcgaatgagtgctgagtc   
PRL Juvenile 983F ttctagagggcatggagctgat NM_000948 
    1007T 6FAMtcagccaggttcatcMGBNFQ   
    1049R gggtagatctcattttctttggtttc   
SPTRX-1 Juvenile 244F gagggaaaaccaactgtaacgtg NM_032243 
    268T 6FAMcacccaaataaagctcaMGBNFQ   
    308R cacgttgctggacaggactagt   
SPTRX-2 Juvenile 531F aaatgaactgaacgaagacgaaatt NM_016616 
    564T 6FAMtgctgtcgcagaagcMGBNFQ   
    607R taaatggctgcaaagtcacaatg   
SRC Elderly 893F tgaggagtggtattttggcaaga  NM_005417 
    995T 6FAMcacgaaaggtgcctactMGBNFQ    
    1040R ggcgttgtcgaagtcagaca    
TBC1 Juvenile 729F gctatgtgttcaaagccgatga BC028196 
    752T 6FAMcaaacaaaatgctcatcatcMGBNFQ   
    803R ctccggcagctctttcaaag   
TEKT2 Juvenile 700F tctcaacctcagatccccaaa NM_014466 
    752T 6FAMcctgatggctccaccaMGBNFQ   
















GNAS All Ages 1653F ggacaaagtcaacttccacatgttt NM_016592 
    1690T NEDcagcgcgatgaacgccgcaaMGBNFQ   
    1749R gaagatgatggcagtcacatcgt   
S15 All Ages 16F ccaaagcgatctcttctgaggat NM_001018 
    40T VICcggcaagatggcagaagtagagcagaaMGBNFQ   
    105R acgccgcggtaggtgaa   
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 Figure 48: UCF IRB Form. 
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